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SUMMARY 
 
Expression of a limited set of genes (COX-2, HAT1, USP28, HSP90ß, OPN, DDX6, eIF4E, DEFA 1, 
DEFA 3, DEFA 6, PKM2 and PLK1) was studied by quantitative Real Time-PCR (qRT-PCR) in 
colon tissues derived from individual patients who underwent colon surgery. The selected genes, 
with known tumor marker properties, code for proteins involved in cellular processes such as 
apoptosis, proliferation, mitosis, glycolysis, innate host defence, cellular homeostasis and 
translational initiation. In addition to paired-normal and tumor tissue, also pre-malignant tissues such 
as normal near tumor and adenoma were examined. For computation of the relative expression, ß-
actin was used as a reliable normalization control, because of its stable expression which was found 
to be independent of the age, gender or the type of the investigated colon tissue. 
As known direct targets of the Wnt signaling pathway, activation mutations of which are the earliest 
events occurring during the cancer development, a few of the molecules, namely OPN, COX-2, 
DEFA 6 and eIF4E were analyzed to find out whether they can be used as markers of early stages of 
colon cancer development and not solely, as already stated in the literature, markers of fully blown 
cancer. A massive expression burst of the DEFA 6 gene in benign colon adenoma was discovered 
(85 fold), which immediately suggests its potential to be applied as a marker for early premalignant 
stages of colorectal cancer detection. Among the investigated 18 patients, the ratios in adenoma as 
well as in carcinoma as compared to normal tissue vary more than 1000 fold indicating the 
pronounced individuality of each patient’s cancer. However, in 68% of the cases the overexpression 
in an adenoma was more than 60 fold, whereas in fully blown tumor, this elevation was much less. 
In almost 71% of the tumor cases the expression alteration of DEFA 6 was less than 20 fold. 
Furthermore, using an empirical approach, as well as Principal Component Analysis (PCA), 4 out of 
12 tested genes, namely OPN, COX-2, HSP90ß and PKM2 were determined as the most prominent 
ones able to distinguish non-malignant from malignant colon tissues. This finding was confirmed by 
a blind study where 36 tissues, obtained from 18 donors were tested. The outcome was very 
promising since 78% of the samples were predicted correctly and no false negatives were found. 
In order to make use of the enormous information contained in NIH’s data base dbEST, its 
predictions were directly compared with the gene expression data derived from colon tissues and 
generated by qRT-PCR. The analysis showed that the agreement between dbEST and qRT-PCR data 
is quite precise as for almost all genes the expression tendency in tumor compared to normal tissue 
remained the same, independent of the applied data source. 
With the intention to check whether the gene expression patterns of in vitro models reflect the 
corresponding patterns of the in vivo counterparts, comparative analysis of gene expression data 
derived from adenoma and tumor tissues and cell lines (LT97, HT29 and SW480) was performed. 
The analysis revealed that the expression levels of OPN, DEFA 1-3 and DEFA 6 genes in cultured 
cells differ drastically from those observed in colon tissue samples, which should be considered to 
prevent any misinterpretation, when in vitro data is translated to in vivo situation. 
In addition to gene expression data, quantitative Western blots were used to check as to what extent 
protein expression reflects the mRNA expression. HSP90ß, PKM2, eIF4E and DDX6 were under 
investigation. Among all 12 patients analyzed, the HSP90ß and PKM2 genes showed relatively low, 
but significant amplification in tumor tissues. On the protein side, however, no changes in the 
expression were found. Furthermore, when the data were evaluated in a patient-wise manner, the 
HSP90ß-mRNA and protein expression ratio between normal and tumor tissues showed to be 
relatively stable among the donors. In contrast, eIF4E disclosed higher inter-individual variability on 
the mRNA level, which is smoothed down on the protein level. All these observations can be a 
consequence of either posttranscriptional or posttranslational modifications or can be due to a 
smaller sensitivity of the protein assay to detect slight expression differences. 
In conclusion, qRT-PCR shows that safe discrimination between normal, early and fully blown 
cancer is possible on the basis of approximately low number of genes and no Mega Chip is required. 
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Die Expression ausgewählter Gene (COX-2, HAT1, USP28, HSP90ß, OPN, DDX6, eIF4E, 
DEFA1-3, DEFA 6, PKM2 und PLK1) in Kolongewebe von individuellen Patienten, die 
sich einer Kolonresektion unterzogen haben, wurde mit Hilfe quantitativer Real Time-PCR 
(qRT-PCR) charakterisiert. Die ausgewählten Gene mit bekannten Tumormarker-
Eigenschaften kodieren Proteine, welche in zellulären Prozessen wie Apoptose, 
Proliferation, Mitose, Glykolyse, angeborener Immunabwehr, zelluläre Homöostase und in 
der Initiation der Translation involviert sind. Neben dem gepaarten Normal- und 
Tumorgewebe wurden ebenso prämaligne Vorstufen, wie tumornahes Normalgewebe und 
Adenomgewebe, untersucht. Für die Berechnung der relativen Expression wurde ß-Aktin, 
wegen seiner stabilen Expression, als verlässliches Referenzgen verwendet, was sich als 
unabhängig von Alter, Geschlecht oder Gewebetyp erwiesen hatte. 
Einige der direkten Zielgene des Wnt-Signalweges (OPN, COX-2, DEFA 6 und eIF4E), 
dessen Aktivierung durch Mutationen zu den frühesten Ereignissen in der 
Kolonkarzinogenese zählt, wurden analysiert, um herauszufinden, ob diese nicht nur als 
Marker von malignen Tumoren genutzt werden können, wie bereits in der Literatur 
postuliert, sondern auch als Marker für frühe Tumorstadien. Ein massiver 
Expressionsanstieg konnte für das DEFA 6-Gen in gutartigen Adenomgewebeproben 
detektiert werden (85fach), was das unmittelbare Potential als Marker früher, prämaligner 
Tumorstadien in der Entwicklung von Kolonkrebs erkennen lässt. Unter den 18 in die 
Untersuchungen einbezogenen Patienten, variierte die Expression im Adenom als auch im 
Karzinom im Vergleich zum Normalgewebe um mehr als ein 1000faches, was ein Hinweis 
auf die Individualität jeder Krebserkrankung ist. In 67 % der Fälle war die Expression im 
Adenomgewebe dennoch mehr als 60fach erhöht, wohingegen die Überexpression im 
malignen Tumorgewebe viel geringer war. In 71% der Proben mit Tumorgewebe war die  
Expression von DEFA6 weniger als 20fach verändert. 
Sowohl eine empirische Erhebung als auch die Hauptkomponentenanalyse (PCA) stellten 4 
der 12 untersuchten Gene (OPN, COX-2, HSP90ß und PKM2), als die Bedeutendsten dar, 
die eine Differenzierung von nicht-malignem und malignem Kolongewebe ermöglichen. 
Dieses Ergebnis konnte durch eine Blindstudie mit 36 untersuchten Geweben von 18 
Spendern verifiziert werden. Die korrekte Vorhersage von 78% der Proben, ohne falsch-
negative Ergebnisse verdeutlicht die Relevanz des Ergebnisses.  
Um sich das umfangreiche Informationspotential der NIH Datenbank dbEST zu Nutze zu 
machen, wurden dessen Prognosen direkt mit den Real time-PCR Genexpressionsdaten der 
Kolongewebeproben verglichen. Die Analyse ergab eine recht genaue Übereinstimmung der 
dbEST mit den qRT-PCR Daten. Die Tendenz der Expression für nahezu alle Gene im 
Tumorgewebe blieb, im Vergleich zum Normalgewebe, dieselbe, unabhängig von der 
zugrunde gelegten Datenquelle. 
Zur Überprüfung, ob das Genexpressionsmuster von in vitro-Modellen die entsprechenden 
Muster der in vivo-Gegenstücke wiederspiegelt, wurden die Genexpressionsdaten der 
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Adenom- und Tumorgewebe mit denen von Zelllinien (LT97, HT29 und SW480) 
verglichen. Die Analyse zeigte, dass sich die Expression der Gene OPN, DEFA 1-3 und 
DEFA 6 erheblich von der, welche in den Kolongewebeproben festgestellt wurde, 
unterschied. Diese Tatsache sollte bei der Übertragung von in vitro Daten auf die in vivo 
Situation berücksichtigt werden, um Fehlinterpretationen zu vermeiden. 
Als Ergänzung zu den Genexpressionsexperimenten wurden quantitative Western Blot 
Analysen durchgeführt, um zu untersuchen, in welchem Ausmaß die Proteinexpression die 
mRNA-Expression reflektiert. In die Untersuchungen wurden HSP90ß, PKM2, eIF4E und 
DDX6 einbezogen. Unter den insgesamt 12 Patienten zeigten die Gene, welche für HSP90ß 
und PKM2 kodieren, eine relativ niedrige, aber signifikante Amplifikation in den malignen 
Geweben. Auf Proteinebene wurden hingegen keine Expressionsveränderungen detektiert. 
Bei der patienten-spezifischen Datenauswertung, zeigte sich ein relativ stabiler HSP90ß 
mRNA- und Proteinexpressionsquotient zwischen Normal- und Tumorgewebe bei den 
Probanden. Im Gegensatz dazu konnte eine höhere interindividuelle Variabilität auf 
Genexpressionsebene für eIF4E festgestellt werden, die auf Proteinebene allerdings nicht 
mehr so deutlich sichtbar war. Es ist möglich, dass die Beobachtungen entweder durch 
posttranskriptionelle oder posttranslationale Modifikationen hervorgerufen wurden, bzw. 
durch eine geringe Empfindlichkeit der Proteinanalyse-Methode geringe 
Expressionsunterschiede zu detektieren.  
Zusammenfassend lässt sich feststellen, dass unter Verwendung von qRT-PCR eine 
zuverlässige Differenzierung zwischen normalem Gewebe sowie frühen und späten 
Tumorstadien auf Grundlage einer nahezu geringen Anzahl von Genen möglich ist und die 
Anwendung von Mega Chips nicht erforderlich macht. 
 
 
 
 
 
INTRODUCTION 
1 
 
1. INTRODUCTION 
Colorectal cancer is one of the most common type of cancer with one million new cases 
diagnosed per year worldwide, where the developed countries account for over 65% of all 
cases (1).  
As a prevalent disease in the ageing population, colorectal cancer develops as a multistep 
process from a premalignant stage via in situ carcinoma to invasive and metastatic cancer. 
Such a malignant transformation process requires years and possibly decades and it is 
accompanied by a number of genetic alterations such as activation of oncogenes and/or 
inactivation of tumor suppressor genes, see Figure 1-1, page 4. As a consequence, during 
the carcinogenesis many different cellular processes and signaling cascades appear to be 
affected, which in turn can alter the expression of various genes involved in basic processes 
such as apoptosis, proliferation, mitosis, glycolysis, innate host defence, cellular 
homeostasis, translational initiation.  
 
1.1. Diagnostic approaches to prove the detection or treatment of 
colorectal cancer (CRC) 
 
The early detection is an important factor in decreasing colon cancer deaths, therefore 
efficient diagnostic and therapeutic approaches are important for the success of cancer 
prevention. The current cancer diagnosis and classification relies on clinical and 
histopathological information. However, some cases bring diagnostic confusion because of 
incomplete clinical information or unusual histopathological features. An additional 
drawback of this diagnostic approach is that the histopathological information is based on 
criteria which are quite subjective. For that reason, the use of gene markers in addition to 
conventional approaches offers the opportunities for safer and improved diagnosis. The 
necessity to use gene expression analysis in combination with other diagnostic approaches is 
supported by the fact that often malignancies with the same clinical features possess 
different genetic alterations, which occur in different host backgrounds. Therefore the 
tumors can follow quite different development (2). Thus, the additional application of gene 
expression analysis may lead to more precise diagnosis due to the ability to identify inter-
individual genetic background of tumors with the same clinical presentation and thus 
allowing patients to receive more adequate further treatment.  
DNA microarray/chip technology is a powerful tool to investigate the complexity of cancer 
by measuring the mRNA expression level of thousands of genes simultaneously (2; 3). Such 
gene expression studies may aim to identify novel markers, reflecting the process of tumor 
initiation, which is desirable not only for diagnostic purposes, but for better understanding 
of the biological processes leading to neoplastic transformation. In addition, the assay can 
also be applied for testing the predictive response or resistance to treatment, especially to 
neoadjuvant chemotherapy (3). However, for diagnostic purposes, such a global 
measurement has several disadvantages. Apart from the fact that it is expensive and 
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therefore would be difficult to be applied in the clinical practice, this application usually 
possesses excessive noise generated by the often exceeding large gene set that masks the 
distinction of clinical outcome governed by a smaller set. In addition, due to the possible 
cross-hybridization between the sample and the spotted probe, the specificity of DNA mega 
chips can be lower compared to that when a small set of targets is analyzed in parallel. 
Therefore, the selection and usage of a limited set of genes with known tumor marker 
properties, can be a useful strategy for the development of a precise diagnostic approach. If 
this panel of genes safely discriminates malignant from non-malignant tissue, a small, 
simple, highly-specific chip can be designed for routine diagnosis, not only on gene, but on 
protein expression level as well. 
 
Access to tissues of different stages of colon carcinogenesis 
For performance of all diagnostic analyses, a matched pair-wise comparison of normal and 
cancer tissue is required. The surgical technique of resection of this tumor type results in the 
ability to obtain an appropriate amount of colon tissue samples for analytical studies. 
However, the fully blown carcinoma does not account for the expression alterations that are 
critical for the initiation and the development of cancer. Thus, apart from the classical 
combination of paired normal and tumor tissue, also tissue from intermediate, premalignant 
stage, namely matched normal near tumor and adenoma tissue samples should be examined. 
The analysis of such pre-cancerous tissues possibly would allow the discovery of markers 
for diagnosis of early, premalignant stages of colon cancer development, with higher 
sensitivity and specificity. Such an early detection is a key determinant in the survival rate 
of the cancer patients, since it is curable to large extent. Due to the huge variety of the 
human population and the high degree of heterogeneity present in the tumor, markers with 
high sensitivity and specificity are missing so far.  
With this background knowledge, in the present work, a set of selected colon cancer 
markers was studied for their predictive power with respect to malignant, but also to 
precancerous adenoma colon tissues. Apart from the fact that all of them were detected to 
have enhanced expression in CRC, the chosen molecules possess different cellular 
functions. For a brief description of their functional properties in the cell refer to section 1.4, 
page 7. 
Moreover, a few of the molecules investigated in the present work namely OPN, COX-2, 
DEFA 6, eIF4E (4-8), are known or suggested to be direct targets of the Wnt signaling 
pathway, activation mutations of which are the earliest events occurring during the cancer 
development. Therefore, it was interesting to determine (and/or confirm for some of them) 
whether they can be used as markers of early stages of colon cancer development and not 
solely, as already described, as markers for fully blown colorectal cancer. In section 1.3, 
page 5, short description of the Wnt pathway is given. However, the signaling cascade is not 
introduced in details, since it is not a goal of the present work. 
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1.2. Colorectal cancer development 
The etiology of colorectal cancer is heterogeneous, with both environmental and hereditary 
factors playing roles to varying degrees. Thus, three different types of colorectal cancer with 
some overlapping of clinical features occur, namely sporadic, familial and hereditary 
cancer. Sporadic cancer is a result of the interaction between somatic mutations and 
environmental factors and arises stochastically and at older age. In contrast, familial cancer 
is clustered in families and possibly occurs due to the exposure to the some environmental 
risk factors or to the presence of low-penetrance mutations in susceptibility genes. On the 
other hand, high-penetrance germ line mutations are found in hereditary cancer (9). Thus, 
approximately 20% of all patients with CRC have a family history of the disease, and 
roughly 5-10% of the total annual burden is inherited in an autosomal-dominant fashion 
(10). 
Hereditary cancer syndromes are divided into two categories based on the presence of 
polyposis, such as familial adenomatous polyposis (FAP) or hereditary nonpolyposis 
colorectal cancer (HNPCC). The latter one is the most common form of hereditary CRC (1).  
FAP is diagnosed through the presence of numerous florid colonic adenomas (the most 
frequent precursors of CRC carcinomas). In addition, these forms of CRC display 
chromosomal instability (CIN), an aneuploid karyotype, and they harbor mutations in 
important tumor suppressor genes and oncogenes such as APC (11; 12), K-ras and p53 (1). 
On the other hand, the microsatellite instability (MIN) is the hallmark of HNPCC, (13). 
Usually these abnormalities are repaired by mismatch-repair proteins (MMR), but their 
deficiency in tumors makes the repair inefficient. Mutations, caused by MIN have been 
found in ß-catenin, proapoptotic Bax (14) and adenomatous polyposis coli (APC), (15).  
However, the hereditary CRC cases are only small percentage of all CRCs and they are 
often detected in young age. The highest percentage of colorectal cancer cases is sporadic 
(non-hereditary) as they are rarely detected before the age of 40, (16). 
The molecular genetics of CRC is the one of the best understood among the various human 
neoplasias. In Figure 1-1, page 4 the current model of carcinogenesis is illustrated (12; 17; 
18).  
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The smallest detectable lesion in the adenoma-carcinoma sequence is an aberrant crypt foci 
(ACF). ACFs are putative preneoplastic lesions and so far two types of ACF are 
distinguished (20). The most widespread type is associated with hypercellular or 
hyperplastic crypts that rarely turn into malignant carcinomas. The non-malignant 
hyperplastic forms may arise from activation mutations in K-RAS (20). The hyperplastic 
ACFs do not posses ß-catenin mutations (21). In contrast, the second type of lesions, termed 
dysplastic ACF occurs often in carcinoma-associated colon mucosa and the majority of 
them bear mutations in APC and ß-catenin molecules (21). The expansion of these 
dysplastic ACFs give rise to large adenomas of several centimeters. The latter one carries 
activating mutations in the RAS oncogene or complementary mutations in the upstream 
component B-RAF. Further, mutations in the TGF-beta signaling pathway (mainly in 
SMAD-4) confer additional malignant features to adenoma cells. Adenoma progresses into 
carcinoma in situ and in around 50% of the these carcinoma cases, inactivation of TP53 is 
detected (22). This TP53 inactivation causes additional genetic alterations as a consequence 
of DNA damage and genetic instability (CIN and MIN), (1).  
Figure 1-1  Correlation between CRC progression and the accumulation of genetic alterations according to 
Fearon and Vogelstein (1990). The genetic alterations frequently found in CIN tumors are depicted in black, 
while those depicted in red corresponds to mutations more common in MIN tumors. Such process is believed 
to develop over the course of 20-40 years. (modified according to (1) and (19)). 
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In addition to alterations detected in oncogenes and tumor suppressor genes, another 
characteristic feature occurring during the carcinogenesis is the mutation in a majority of the 
miss-match repair (MMR) genes (23). Apart from the entire set of genetic alterations, clear 
evidences revealed that the cancer is a disease driven also by epigenetic changes, such as 
loss or gain of DNA methylation as well as altered patterns of histone modifications (24). 
 
1.3. Wnt signalling pathway 
The Wnt pathway controls cell’s fate during embryonic development. In addition, it also 
persists as a key regulator of homeostasis in adult-renewing tissues, where the mutational 
deregulation of the Wnt cascade was shown to be tightly associated with their malignant 
transformation (25).  
Figure 1-2, page 6 gives a schematic illustration of how the Wnt pathway works in normal 
and cancer epithelial cells. For more detailed description, see the figure’s legend. 
 
Briefly: essential for this signaling pathway is the stabilization of ß-catenin and its 
interaction with Tcf/Lef transcription factor within the nucleus. ß-catenin cytosolic levels 
are tightly regulated as in the absence of Wnt signals, ß-catenin is associated with APC, 
Axin and some kinases (so called APC complex), which results in its ubiquitylation and 
degradation by the proteosome (26; 27). Signaling by Wnt factors inhibits the APC 
complex. The same effect can be accomplished by mutational deactivation of APC or ß-
catenin, events occurring during tumorigenesis. As a consequence, ß-catenin is stabilized, 
translocated into the nucleus, where it interacts with transcription factors driving the 
transcription of various target genes. List of the target genes of Wnt/ß-catenin signalling can 
be seen on following link: 
http://www.stanford.edu/~rnusse/pathways/targets.html 
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Figure 1-2  The Wnt - signaling pathway. Panel A depicts the down-regulation of ß-catenin transactivation 
activity in epithelial cells of healthy colon. ß-catenin remains in a complex of Axin/Axil/conductin, APC, 
GSK3ß kinase and the casein kinase 1 or 2 (CK1 or 2). In the absence of Wnt stimulation, the kinases 
(GSK3ß and CK 1 or 2) become active and phosphorylate ß-catenin at serine and threonine residues in the N-
terminal domain. This phosphorylation is supported by APC and Axin, which acts as a scaffol protein, 
bringing together enzyme(s) and substrate(s). As a consequence of the phosphorylation, ß-catein binds with 
F-box protein ß-TrCP of the Skp I-Cullin-F-box (SCF) complex of ubiquitin ligases and thus undergoes 
proteasomal degradation. However, Tcf-Lef transcription factor can bind to DNA, without the presence of ß-
catenin molecule. Nonetheless, repressors and co-repressors, namely CtBP (carboxy-terminal binding 
protein), CBP (CREB-binding protein) associate TcF-Lef and suppress the transcription of cell cycle 
regulator molecules such as c-myc and cyclin D1. Panel B shows the role of the APC- and ß-catenin-
mutations in regard to regulation of the ß-catenin level and its transactivation property in malignant colon 
cells. The mutant ß-catenin escapes its proteosomal degradation and becomes stabilized in the cytoplasm. 
The same effect can be accomplished by mutational APC-deacivation. As a result, the stabilized ß-catenin 
heterodimerizes with Tcf-Lef transcription factor and localized into the nucleus, where actively transcribes 
cell cycle related genes cause proliferation, survival and motility. The binding of ß-catenin to TCF-Lef 
inhibits the binding of CtBt, CBt repressors. Figure from (28) 
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1.4. Basic knowledge about the genes under investigation and the 
encoding by them proteins  
 
Osteopontin (OPN) 
Osteopontin (OPN) is a glyco-phosphoprotein, extensively modified at both 
posttranscriptional and posttranslational level. As a consequence of an alternative splicing, 
at least three human OPN isoforms exist (29). OPN was originally isolated from bone 
matrix but subsequently was found in many other tissues and cell types. It is a constitutively 
expressed protein, but induced expression of OPN in response to various cytokines or 
inflammatory mediators has been detected in many cell types, including cancer cells. OPN 
is associated with many different cellular processes, such as cell migration and proliferation, 
tissue repair and angiogenesis. OPN also appears to play an important role in promoting cell 
survival and protecting cells from apoptosis (29-31). 
Most of the cellular activities of the OPN have been assigned to the extracellular effects that 
occur after its secretion, where the binding of OPN to the specific receptor leads to 
activation of certain intracellular signaling pathways. However, an intracellular form of 
OPN has been previously described. It is localized in the perimembranous region of the cell 
and may have a specific role in the cell migration and proliferation. A recent study has 
shown the novel nuclear location of the intracellular OPN and its functional tandem with 
PLK1, also localized in the nucleus (32). Furthermore, Jain et al. have reported that OPN 
stimulates the activation of protein kinase C α/nuclear factor-inducing kinase/nuclear factor-
κB-dependent signaling cascades that induces Cyclooxygenase-2 (COX-2) expression 
(another selected target under present investigation), which in turn regulates the 
prostaglandin E2 (PGE2) production, matrix metalloproteinase-2 activation, tumor 
progression and angiogenesis (33). All these processes where OPN was implicated, 
determine its prominent role in the promotion of different types of cancers. Elevated OPN 
expression was detected in breast, stomach, lung, prostate, ovarian cancers and liver.(29; 
31). Particularly, in numerous of studies the prominent role for OPN in the promotion of 
colon malignancy and metastasis has been described (34-36).   
 
Cyclooxygenase-2 (COX-2) 
There are many lines of evidence showing that PGE2 might contribute to cancer 
development through various mechanisms including increased endothelial cell motility and 
invasion, inhibition of apoptosis, modulation of inflammation and immune response as well 
as promotion of angiogenesis. Elevated prostaglandin levels are also found in colon cancers 
and their precursor lesions, adenomatous polyps. Two forms of enzymes, Cyclooxygenase-1 
(COX-1) and COX-2 are responsible for the prostaglandin’s synthesis. COX-1 is 
constitutively expressed in most tissues and has been proposed to generate prostaglandins 
for normal physiological functions. The second isoform, COX-2 is widely excepted as an 
inducible form of an enzyme that is usually not expressed in normal tissue, but rapidly 
induced by tumor promoters, growth factors, cytokines, viruses and other stimuli (37; 38). 
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However, it was shown that in the colonic wall, COX-2 molecule is also constitutively 
expressed (39). So far, many studies have reported that COX-2 promotes tumor cell 
proliferation, survival and angiogenesis by the PGE2 mediated pathway (40; 41). 
Significant increases in COX-2 expression has been found in many types of cancer as 
gastric, lung, pancreatic, head and neck, breast, ovari and in other cancers (33). COX-2 
expression markedly increases in 80% to almost 100% of the human colorectal carcinomas, 
predominantly within the neoplastic epithelial cells (38; 40; 42; 43). Enhanced expression of 
COX-2 in those cells is linked to alterations in the cellular adhesion and to inhibition of 
apoptosis (44). In addition, the constitutive COX-2 expression modulates tumor 
angiogenesis (45) and increases the metastatic potential of the cells (46). In contrast, COX-1 
levels remain unchanged.  
 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 (DDX6) 
DDX6 (also named as RCK or p54) is a member of the DEAD box protein/RNA helicase 
family. The RNA helicase activity assigned to DEAD box proteins is thought to modulate 
the mRNA secondary and tertiary structure (47). These proteins have been implicated in a 
diversity of cellular functions such as ribosome assembly, pre–mRNA splicing and 
translation initiation (48). It was shown that the expression of DDX6 is very poor or 
undetectable in brain, skeletal muscle and lung tissues, but significant amounts of this 
protein was found in tumors that originate from these tissues (48). Several lines of evidence 
presume the role of DDX6 in cell proliferation and malignant transformation by facilitating 
the translation of mRNA(s) for some oncogenes or growth-related genes. In this respect 
Hashimoto et al. have been reported that in more than 65% of colorectal tumors, DDX6 is 
over-expressed and that in the majority of these cases the overexpression of c-myc was also 
observed (49). Further, in vitro investigations showed that DDX6 contributes to the 
elevation of c-myc translation efficiency by exhibiting unwinding activity towards c-myc 
mRNA (50). This co–overexpression of c-myc and DDX6 is in coordination with 
inactivation of anti-oncogene, such as APC. The inactivation of APC gene leads to 
activation of c-myc transcript (51). In addition it was reported that in the early stage of 
colon tumorogenesis, c-myc protein elevates the expression of eukaryotic translation 
initiation factor (eIF4E) transcript, also one of the targets we are interested in. Thus, the 
raising of the eIF4E mRNA level will increase the synthesis of proteins involved in cell 
proliferation (8; 52). Successively, eIF4E increases the level of c-myc protein. 
Consequently, DDX6 which stabilizes and elevates the c–myc protein synthesis by 
unwinding the c-myc mRNA may enhance the eIF4E protein level. Thus, eIF4E, together 
with other translation initiation factors, may increase the protein synthesis mostly of 
proteins involved in cell cycle-promoting and thus leading to decrease of the cell death. As a 
concequence, the inability of cells to undergo apoptosis may promote cancer development. 
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Eukaryotic initiation factor 4E (eIF4E)  
The control of mRNA translation plays a critical role in the regulation of cell growth, 
proliferation and differentiation. The dysregulation of this process may contribute to 
neoplastic transformation of the cells and consequent exhibition of malignant phenotype. 
eIF4E is a translation factor, the activity of which regulates the level of translation initiation. 
eIF4E is a cap-binding phosphoprotein, rate-limiting subunit of the eIF4F complex. eIF4E is 
responsible to bring the cellular mRNAs to the eIF4F complex through specific binding of 
cap-structure present on virtually all mature cellular mRNAs. Once engaged, the eIF4F 
complex can be able to scan the mRNA in 5’-3’ direction from the cap, unwinding any 
secondary structure within the 5’untranslated region (UTR) to uncover the translation 
initiation codon and to facilitate ribosome loading on the mRNA (53). 
In normal living cells, the accessibility of eIF4E is limited and as a consequence the 
translation is restricted. Under these conditions, where the molar concentration of mRNA 
exceeds that of eIF4E, the mature mRNAs have to compete for eIF4E in order to win access 
to ribosome machinery. There are two types of mRNA, namely highly and weakly 
competitive mRNA. The highly competitive mRNAs have a short, unstructured 5’UTR and 
therefore their scanning proceeds easily from 5’ cap through the short leader sequence in 
order to reveal the initiation codon and thus to facilitate the translation process. Such a well 
translated mRNAs are the majority of the cellular mRNAs (e.g. ß-actin). In contrast, the less 
competitive mRNAs have highly-structured 5’UTR, which make them poorly translated in 
normal cells. These mRNAs encode proteins that stimulate processes; well know to be 
deregulated in cancer; such as growth and angiogenesis (e.g., fibroblast growth factor 2 
(FGF-2), vascular endothelial growth factor (VEGF), cyclin D1 and c -myc) as well as cell 
survival (e.g Bcl-2) and invasion (e.g. MMPs). However, the translation efficiency of the 
poorly translated mRNAs can grow only under condition where eIF4E activity is elevated 
(53; 54). 
Increased expression of eIF4E has been found in broad spectrum of human cancers and 
cancer cell lines, including bladder, breast, cervical, head and neck, and prostate (53-55). 
Additionally, numerous reports described that the initiation factor eIF4E is strongly 
involved in colon tumorogenesis (8; 54). Elevated eIF4E expression and activity may 
contribute to increase in both, general protein synthesis and preferential synthesis of specific 
growth–promoting proteins. Therefore, it is hypotesised its major potential role in tumor 
progression. Due to this fact, it might be a useful intermediate biomarker for use in 
chemoprevention intervention studies in patients with colorectal polyps.  
 
Histone Acetyl Transferase 1 (HAT1) 
In the intact cell, DNA is closely associated with histones and other nuclear proteins to form 
chromatin. By posttranscriptional modification of the nucleosomal histones, the regulation 
of the gene expression in the eukaryotic organism can be performed. One such covalent 
modification is the acetylation of the lysine residues in the amino terminal tail domain of 
highly conserved histones. This alteration leads to conversion of the chromosomes’s regions 
into transcriptionally active chromatin since the accessibility of transcription factors to the 
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DNA template has been increased. The process is catalyzed by histone acetyltransferases, 
which are separated in two types, type A and B, depending on their subcellular localization 
and function.  
Type A HATs are located in the nucleus. Many of them play a role as transcription co 
factors, to be able to regulate the gene expression. 
HAT1 is type B enzyme. Type B HATs are thought to be located in the cytoplasm and 
acetylate newly synthesized histones, but not nucleosomal histones, prior to chromatin 
assembly (56). The acetylation of the nascent histones would be expected to promote 
transcription by facilitating the binding of transcription factors to nucleosomal DNA (57). 
Interestingly, there are few reports revealing the nuclear localization of HAT1 in S-phase 
cells too (56; 58). HAT1 may play role in the telomeric silencing (59).  
Substantial increase in the expression of HAT1 was detected in primary and metastatic 
colon tumors, in liver tumors as well as in a variety of other cancers (60-62).  
 
Ubiquitin Specific Protease 28 (USP28) 
MYC as a key regulator of cell growth, proliferation and apoptosis is implicated in the 
genesis of many human tumors. Increase in its gene- and protein-expression has been 
observed in a majority of the colorectal adenomas compared to their adjacent, normal 
mucosa (63). Stabilization of MYC proto-oncogene can be achieved by USP28, which is 
antagonizing the activity of SCF-FBW7 complex. The latter is responsible for MYC 
degradation through the proteasome pathway (64). 
Consistent with the necessity for high level of MYC for proliferation of some human cancer 
cells, Popov et al. have reported that the expression of USP28 was elevated in colon and 
breast carcinomas to enhance the stability of MYC protein. In contrast, they have shown 
that the reduction in the USP28 expression can strongly inhibit the growth of the cancer 
cells (64). 
 
Polo-like kinase 1 (PLK1) 
PLK1 is a member of the serine/threonine protein kinase family, cdc5/polo subfamily. It has 
been shown that constitutively expressed PLK1 is a mitotic regulator, responsible for 
phosphorylation of Cdc25C and cyclin B1 molecules, which leads to their activation and 
nuclear translocation. The nuclear accumulation of Cdc25C may promote the activation of 
cdc2/cyclin B1 complex in the nucleus by counteracting the inhibitory activity of Wee1, 
which is constitutively nuclear. This event is thought to be important for driving the cells 
into mitosis (65; 66). PLK1 is also involved in centrosome maturation and assembly, spindle 
function, mitotic exit and cytokinesis and therefore its inactivation may contribute to mitotic 
arrest, induction of the pro-apoptotic pathway and suppression of tumor growth in response 
to stress (67). In contrast, PLK1 expression positively correlates with the expression of 
markers for cell proliferation, such as Ki-67 (68). PLK1 overexpression may lead to 
elevated proliferation and cellular transformation. Smith et al. have shown that the 
overexpression of PLK1 in murine fibroblasts increased the number of the cells with 
fragmented or multiple nuclei. When these cells, with typical phenotype of transformed 
 
INTRODUCTION 
11 
 
cells in culture were injected into mice, tumor could be caused (69). Moreover, recent study 
has shown the interaction of OPN with PLK1, which is limited in the nucleus, presumably 
during mitosis. As PLK1, elevated expression of OPN also can promote the multinucleation 
in different cell types. This common biological role, together with the founded physical 
interaction between OPN and PLK1 supports the speculation that these two targets function 
together by taking a part in the process of cell duplication (32).  
Furthermore, enhanced expression of PLK1 has been reported in various types of cancer as 
lung, skin, breast, prostate, stomach, head and neck, brain, ovary as well as colon cancer and 
often it is correlated with poor patient prognosis (68; 70). Many lines of evidence defined 
the PLK1 expression as a suitable marker of metastasis (71). It was also reported that by 
phosphorilation of p53 tumor suppressor protein, PLK1 inhibits the pro-apoptotic functions 
of p53 (72).  
 
Pyruvate kinase type M2 (PKM2)  
One common feature during the development of cancer is the alteration in the expression of 
enzymes involved in the glycolytic pathway. The protein encoded by PKM2 gene is a 
pyruvate kinase, a glycolytic enzyme which plays a key role in this pathway. The pyruvate 
kinase catalyzes the dephosphorylation of phosphoenolpyruvate (PEP) to pyruvate and it is 
responsible for the ATP-production. Several different isoenzymes from this kinase are 
identified (L, R; M1; M2, tumor M2). They are tissue-specifically expressed in different 
organisms. L type is the major isoezyme in the liver, R is found in red cells (erythrocytes), 
M1 is the main form in muscle, heart and brain, and M2 is predominant in lung tissue as 
well as in cells with increased nucleic acid synthesis, as for example proliferating cells like 
those from the fetal tissues, adult stem cells and tumor cells (73; 74). All these isoforms 
occur as a homotetramers in their active state with high affinity to their substrate PEP. 
During the tumorogenesis the tissue specific isoenzyme, such as PKM1 in brain or PKL in 
the liver, generally disappears and the level of PKM2 strongly increases. As a consequence 
PKM2 releases into the blood and in the case of gastrointestinal tumors also into the stool of 
tumor patients possibly because of tumor necrosis and cell turnover (74; 75). Interestingly, 
in contrast to the normal proliferating cells, where PKM2 is mainly found as tetramer (74), 
the isoform of PKM2 found in tumors is in dimeric state, and it is termed tumor PKM2. This 
isoform has lower PEP affinity and therefore all glycolytic intermediates above pyruvate 
kinase are accumulated and channelled into synthetic processes as for example nuclei acid 
synthesis, amino- acid and phospholipids synthesis (76).  
The increased expression of PKM2 can be caused by mutation in the ras gene (in more than 
40 to 60 % of the colon cancer patients ras has been shown to be mutated) (76) and up-
regulation of transcription factors like HIF1, SP1 and SP3 (74). Furthermore, the 
dissociation of the tetrameric form to dimeric form in cancer cells mainly is caused by the 
interaction of PKM2 with oncoproteins as pp60 v-src kinase and HPV-16 E7 (77).  
It was reported that the level of tumor PKM2 correlates with the staging and the ability of 
the tumor cells to metastasise. Immunohistological analysis has shown the heterogeneous 
distribution of tumor PKM2 in various primary tumors while their metastases are 
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characterized with homogeneously large amount of tumor PKM2 (78; 79). In agreement 
with this data, elevated expression of tumor PKM2 has been found in EDTA-plasma 
samples of patients with pancreatic, lung, renal, breast and gastrointestinal carcinoma as 
well as in stool samples of patients with colorectal and stomach cancer. Moreover, the 
PKM2 expression is not organ specific and reflects the metabolic activity of the tumor (74). 
 
Heat Shock Proteins 90 beta (HSP90ß) 
HSP90ß is a member of one of the most evolutionary conserved classes of molecules called 
Heat Shock Proteins (HSPs) or Stress Proteins. They play a fundamental role in the 
maintenance of cellular homeostasis. Under normal physiological conditions, HSPs act as 
"molecular chaperones". As such, they are critical to maintaining the normal protein-folding 
environment and therefore are able to modulate the protein activity. In addition, these 
chaperones can affect assemble/disassemble of the protein complexes, the protein 
translocation or degradation through the proteosome pathway and thus regulate the 
apoptosis (80). Their elevated expression increase the ability of the cell to survive in tissues 
harmed by different types of stress such as heat, heavy metals, hypoxia, or acidosis. These 
conditions are commonly occurring during tumorogenesis. Therefore their altered usage 
during oncogenesis is critical to the development of human cancers by reflecting the ability 
of malignant cells to maintain homeostasis in a hostile environment, but also allows the 
tumor cells to tolerate alterations from within, including mutation of critical signaling 
molecules that would otherwise be lethal (80; 81). HSP90 can promotes the initiation of 
angiogenesis (82). Additionally, HSP90 inhibits apoptosis (83). 
HSP90 family members are HSP90α and HSP90ß, but the functional differences between 
these two isoforms are still poorly understood as in most expression studies, differentiation 
between α and ß isoforms of HSP90 was not performed. However, several reports described 
that the abundant HSP90 protein overexpressed in Mantle-cell Lymphoma (MCL), 
leukemias, Hodkin’s disease, as well as in breast and lung cancers (84). In addition, Hui Cen 
et al. showed that the expression of HSP90 was increased in colon cancer tissue in 
comparison with normal colon tissue by using PathwayFinder GEArray (85). 
 
Defensin alpha (DEFA 1-3 and DEFA 6) 
Human defensins are a family of naturally occurring cationic short peptides of 29 to 42 
amino acids in length, which have shown, in addition to their well known diverse functional 
activities in innate antimicrobial immunity (86-88), elevated expression in various tumor 
types, including colon cancer. In contrast to DEFA 1-3 which has been shown to be an 
unspecific colon cancer marker, DEFA 6 is more tissue specific due to its high expression in 
colon cancer as compared to other tumors (89-93). 
In humans, two subfamilies, namely alpha- and beta-defensins exist. The known six alpha-
defensins include the neutrophil defensin alpha 1 to 4 (DEFA 1-4) and the enteric DEFA 5 
and 6. DEFA 1–4 are major components of the dense azurophilic granules of neutrophils, 
while DEFA 5 and 6 are primarily expressed in the lysozyme-rich granules of the Paneth 
cells of the small intestine, but also found in intermediate cells (94; 95). 
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In contrast to DEFA 1 and 3 peptides which differ only by the first amino acid and are 
encoded by different genes, so far no gene for DEFA 2 was discovered. Therefore, it is 
thought that DEFA 2 is a proteolytic product of one or both of DEFA 1 and DEFA 3 
peptides (96). 
Independent of the origin of the defensin molecules, it is essential to reveal the function they 
have in the tumor microenvironment, in vivo. Depending on the amount of defensin in the 
tumor tissue, in vitro analyses illustrated that different modulations of the cancer growth can 
be promoted. At physiological concentration, defensins can assist the cancer survival via 
exhibiting mitogenic effects (97). It was also shown that defensins can endogenously bind to 
HLA-DR, a MHC II molecule on hematopoietic progenitor cells and renal carcinoma cells, 
and therefore can restrict the recognition of the cancer cells by T-cells (91; 98). In addition, 
defensin may negatively regulate NK cells and CD4+ T cells, which can help the cancer 
cells to avoid the local immune recognition (99). This activity, together with the mitogenic 
effect can favor malignant growth and progression (97). 
In contrast, at high concentration, addition of defensins can exert cytotoxic effects (91; 97). 
In this respect, it was already reported that tumor cells located at regions with extended 
defensin patches tended to display morphological signs of necrosis (93). Müller et al. also 
revealed that the strong labeling of DEFA 1-3 in some parts of the tumor seemed to be 
correlated with large areas of cellular necrosis (97). 
Recent publication showed that DEFA 1 molecule was expressed by the tumor cell and as a 
consequence this intracellular localization can directly results in tumor cells-apoptosis with 
considerable inhibition of tumor growth in vivo. In addition,  the potential antitumor effect 
of DEFA 1 was supported by the observed inhibition of tumor angiogenesis (100). In 
contrast to these observations, another report revealed that apart from the verified alpha-
defensin expression in bladder cancer cells exposure to this molecule increased the 
motility/invasiveness and proliferation of tumor cells in vitro (101). 
Taking into consideration all above described observations it can be suggested that alpha 
defensin molecules potentially can modulate colorectal cancer progression. However, the 
question whether they pro- or demote this process remains unclear. 
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2. AIMS OF THE WORK 
 
To find out: 
 
• the most informative combination of selected genes able to distinguish normal from 
tumor colon tissues derived from patients having colon surgery. 
 
• whether some of the molecules, known as targets of the Wnt pathway, mutational 
activation of which is the earliest event occurring during colon cancer development, can be 
used as a markers for early detection of colorectal cancer. 
 
• whether the gene expression patterns of in vitro models, such as LT97, HT29 and 
SW480 colon cancer cell lines, reflect the corresponding patterns of the in vivo 
counterparts, namely different types of colon tissues. 
 
• whether the wealth of information contained in NIH’s data base dbEST reflects the 
data derived from human individuals by quantitative Real-Time PCR. 
 
• to what extent the protein expression pattern of the analyzed molecules reflects the 
corresponding gene expression pattern. 
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3. MATERIALS AND METHODS 
3.1. Materials 
3.1.1. Chemicals and Kits 
Acetone Roth, Karlsruhe, GER 
Acryl-Bisacrylamid (29:1) Roth, Karlsruhe, GER 
Agarose Broad Range Roth, Karlsruhe, GER 
Ammonium persulphate Sigma-Aldrich, Munich, GER 
B-glycerolphosphate Sigma-Aldrich, Munich, GER 
Bovine Serum Albumine (Fraction V) Sigma-Aldrich, Munich, GER 
Bromphenol Blue Sigma-Aldrich, Munich, GER 
Butanol Roth, Karlsruhe, GER 
DEPC Roth, Karlsruhe, GER 
DMEM Promocell GmbH, GER 
DNase I, Amplification Grade Invitrogen GmbH, Karlsruhe, GER 
dNTRs mix Promega, GER 
DTT Sigma-Aldrich, Munich, GER 
ECL Pierce Western Blotting Substrate Perbio Science, Bonn, GER 
ECL Plus Amersham Western Blotting Detection System GE Healthcare, Buckinghamshire, GBR 
EDTA Roth, Karlsruhe, GER 
EGF (epidermal growth factor) Calbiochem-Novabiochem 
Ethanol Roth, Karlsruhe, GER 
Ethidium Bromide SERVA, Heidelberg, GER 
Fetal calf serum PAA Laboratories, Pasching, AUT 
Formaldehyde 37% Sigma-Aldrich, Munich, GER 
Formamide Sigma-Aldrich, Munich, GER 
Gentamicyn Invitrogen GmbH, Karlsruhe, GER 
Glycerol/ glycerine Roth, Karlsruhe, GER 
Go Tag DNA Polymerase Promega, GER 
Hybond-ECL Nitrocellulose Membrane GE Healthcare, Buckinghamshire, GBR 
Hyperfilm ECL Amersham GE Healthcare, Buckinghamshire, GBR 
Hydrocortisone Sigma-Aldrich, Munich, GER 
Isopropanol Roth, Karlsruhe, GER 
iQ™ SYBR® Green Supermix Bio-Rad, GER 
Insulin Sigma-Aldrich, Munich, GER 
KCl Sigma-Aldrich, Munich, GER 
KH2PO4 Merck, Darmstadt, GER 
L-15 Medium (Leibovitz) Sigma-Aldrich, Munich, GER 
Methanol Roth, Karlsruhe, GER 
2-mercaptoethanol Merck, Darmstadt, GER 
MCDB 302 Biochrom AG, GER 
MgCl2 Sigma-Aldrich, Munich, GER 
MOPS Roth, Karlsruhe, GER 
Na Acetate Sigma-Aldrich, Munich, GER 
NaCl Roth, Karlsruhe, GER 
NaF Roth, Karlsruhe, GER 
Na2HPO4 Merck, Darmstadt, GER 
NaH2PO4 Roth, Karlsruhe, GER 
NaOH Roth, Karlsruhe, GER 
Na3VO4 Sigma-Aldrich, Munich, GER 
NEA-non essential amino acids Biochrome AG, GER 
Nonfat dried milk powder AppliChem, Darmstadt, GER 
NP40 Sigma-Aldrich, Munich, GER 
Oligo(dT)12-18 primers Invitrogen GmbH, Karlsruhe, GER 
PageRuler Prestainded Protein Ladder Plus Fermentas, St. Leon-Rot, GER 
Penicillin/Streptomycin Solution Sigma-Aldrich, Munich, GER 
PCR mycoplasma test kit AppliChem GmbH, GER 
PMSF Sigma-Aldrich, Munich, GER 
PonceauS Concentrate Roth, Karlsruhe, GER 
Protease Inhibitor Cocktail Roche, Mannheim, GER 
Pefabloc Roth, Karlsruhe, GER 
QIAquick Gel Extraction Kit QIAGEN, Hilden, GER 
RNAse H New England Biolabs 
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RNAlater Qiagen, Hilden, GER 
Rneasy® Mini Kit QIAGEN, Hilden, GER 
Rotiphorese blauR brilliant blue concentrate Roth, Karlsruhe, GER 
Roti®-Quant (concentrate) Roth, Karlsruhe, GER 
Rotiphorese Gel 40 (19:1) Roth, Karlsruhe, GER 
RPMI 1640 Medium Biochrom AG, Berlin, GER 
SDS SERVA, Heidelberg, GER 
Smart Ladder (Dann Standard) Eurogentec, Köln, GER 
Smart Ladder Small Fragment Eurogentec, Köln, GER 
Sodium Azide Sigma-Aldrich, Munich, GER 
Sodium selenite Sigma-Aldrich, Munich, GER 
SuperScript II Reverse Transcriptase Invitrogen GmbH, Karlsruhe, GER 
TEMED Roth, Karlsruhe, GER 
Tris Base Sigma-Aldrich, Munich, GER 
Transferrin  (Esther) Invitrogen GmbH, Karlsruhe, GER 
Tris HCl Roth, Karlsruhe, GER 
Trypsin/ EDTA Solution Biochrom AG, Berlin, GER 
Tween 20 Roth, Karlsruhe, GER 
Trijodo-L-Thyronine ICN 
Xylene cyanol Sigma-Aldrich, Munich, GER 
 
3.1.2. Cell lines for gene expression analysis 
Six cell lines were examined in the present study. Table 3-1 provides general information 
about the all cell lines. Five of them (HT29, Caco 2, HCT116, SW480 and SW620) were 
established from primary colonic adenocarcinomas. These cell lines differ greatly in their 
degree of differentiation, their proliferation rate, and their metastatic potential. One cell line 
(LT97) was isolated from colonic microadenomas. 
 
Cell line Description 
LT97 LT97 are early adenoma cells isolated from microadenomas of a patient suffering from hereditary 
familiar polyposis. They possess genetic alteration characteristics of early adenoma in vivo. LT97 cells 
have lost both alleles of the APC tumor suppressor gene (102). 
 
HT29 HT29 is a moderately well differentiated human colon cancer cell line which was established from a 
grade II tumor. When injected into nude mice, it produces well-differentiated tumors consistent with 
grade I tumors (103). HT29 contain mutant APC protein (104). 
 
Caco 2 Forms moderately well differentiated adenocarcinomas consistent with colonic primary grade II, in nude 
mice (105). Caco 2 contain mutant APC protein (104). 
 
HCT116 HCT116 is reported to have the microsatellite instable (MSI) phenotype and it is highly tumorogenetic 
(106).  HCT116 contain wild type APC protein (104). 
 
SW480 SW480 is a poorly differentiated cell line which was established from a grade III/IV primary tumor. A 
lymph node metastasis arising from this tumor was isolated and used to generate the SW620 cell line 
(103). SW480 contain mutant APC protein (104). 
 
SW620 See SW480. They contain mutant APC protein (104). 
 
3.1.3. Medium and reagents for cultivation of cell lines  
HT29, SW480 and SH-SY5Y cells were routinely grown in RPMI 1640 Medium, with 
stable glutamine, supplemented with 10% Fetal Calf Serum (FCS), 10mM ß-
mercaptoethanol and 1% penicillin/streptomycin solution. 
Table 3-1 Description of tumor cell lines 
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LT97 cell line was maintained in a culture medium (MCDB 302), containing 20% of L15 
Leibovitz medium (supplemented with L-Glutamin) ; 2% FCS, 0.2nM triiodo-L-thyronine; 
2 μg/ml transferrin; 1 μg/ml hydrocortisone; 10 μg/ml insulin; 5nM sodium selenite and 30 
ng/ml EGF (epidermal growth factor) and 1% penicillin/streptomycin solution. 
Caco 2, HCT116 and SW620 were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) with stable glutamine and 1% penicillin/streptomycin solution. For Caco 2 and 
HCT116, DMEM was supplemented with 20% FCS and 0.5% ß-mercaptoethanol. In the 
case of SW620, 1% v/v non-essential amino acid solution and 20% v/v of FCS were added 
to the medium.  
The cells were usually grown in 25 cm2 or 75 cm2 tissue culture flasks to 75-85% 
confluence. The cultivation was carried out in a humidified incubator (5% CO2; 95% 
humidity, at 37°C). Cells were washed twice with PBS, trypsinised (Trypsin/EDTA) and 
after centrifugation at 80 g for 5 min the cell pellets were collected and resuspended in 
appropriate lysis buffer either for further RNA or protein extraction. 
 
3.1.4. Antibodies and recombinant proteins 
The antibodies and recombinant proteins, used in this work are listed in Table 3-2 and Table 
3-3, respectively. 
Antibody name Ig Type Company Used dilution 
Anti – COX-2 Goat monoclonal,  R&D systems 1.5 μg/m 
Anti – eIF4E Mouse monoclonal BD Transduction Lab 1: 500 
Anti – PKM2 Rabbit policlonal ABGENT 1: 500 
Anti – DDX6 Rabbit policlonal Bethyl Laboratories 1: 10 000 
Anti – ß Actin Mouse monoclonal SIGMA 1:10 000 
Anti – HSP90ß Mouse monoclonal Zymed Laboratories 1.5 μg/ml 
Anti – Rat Goat peroxidase conjugate Santa Cruz 1: 500 
Anti – Rabbit Goat peroxidase conjugate Dako Cytomation 1: 10 000 
Anti – Mouse  Goat peroxidase conjugate SIGMA 1:10 000 or  20 000 
Anti – Goat Donkey peroxidase conjugate Santa Cruz 1:5 000 or  10 000 
 
Protein name Molecular Weight Company 
Recombinant human eIF4E 28 kDa GloboZymes 
Recombinant human COX-2 70-74 kDa Bizol 
Recombinant human COX-2 70-74 kDa Oxford Biomedical Research 
Recombinant human HSP90 90 kDa Alexis 
 
 
3.2. Methods 
3.2.1. Tissue sample preparation for gene and protein expression analysis 
All patients have given their informed consent and the study was institutionally approved by 
the ethics committee of the Friedrich Schiller University of Jena. Altogether, tissue samples 
Table 3-2 List of antibodies 
Table 3-3 List of recombinant proteins 
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from 36 patients were included in the study as 6 of them are examined by Frantziska Jahns 
(Department of Nutritional Toxicology, Institute for Nutrition, Friedrich-Schiller-University 
Jena), in respect to the early phase of her PhD work. 
The donors of the colon tissue were admitted to the University Hospital of Jena, Germany to 
undergo surgery for removal of colon tumors or colon polyps. The normal colon samples 
from each patient with colon cancer were taken at a distance of 20 to 50 cm from the tumor 
site. Confirmation of the tumor stage of the patients was provided by pathological 
examination after the surgery (Table 3-4). In addition to the adenoma samples, 
macroscopically normal tissues, removed at location 1 to 5 mm near by the tumor were 
collected. All adenoma samples were benign. 
The tissue samples were stored in Hank’s balanced salt solution (HBSS) and transported to 
the laboratory on ice within 1 h after the surgery. The human colon epithelium was 
separated from the tissue by perfusion-supported mechanical disaggregation (107). The 
epithelial stripes were either immediately submerged in RNAlater, stored at -80°C until 
further use for RNA extraction or were placed in 1.5 ml plastic tubes, put in liquid nitrogen 
and stored at -80°C for subsequent protein extraction. 
Total RNA from leukocytes (peripheral blood mononuclear cells (PBMCs)), derived from 
eight healthy donors was kindly provided by Thomas Hofmann (Department of Nutritional 
Toxicology, Institute for Nutrition, Friedrich-Schiller-University Jena). 
 
Buffers: 
Hank’s balanced salt solution (HBSS) – 0.8 g/L NaCl, 0.4 g/L KCl, 0.06 g/L Na2HPO4 x 2 H2O, 
0.06 g/L K2HPO4, 1 g/L glucose, 0.35 g/L NaHCO3 and 4.8 g/L HEPES, pH 7.2) 
 
* One of the 
analyzed patients 
had two types of 
benign adenoma 
 
** One of the 
donors did not 
possess cancer 
colon tissue 
 
*** Information on 
tumor grade was not 
available 
 
Table 3-4  Clinicopathological characteristics of 36 patients. Four different types of tissues were examined 
for expression analysis of 12 genes implicated in various cellular processes as well as 2 reference genes. 
Patient and tumor characteristics Number of cases 
Type of analyzed tissue 
Normal 
Normal near Tumor 
Adenoma 
Tumor 
 
36 
18 
19* 
33** 
Gender 
Male 
Female 
 
24 
12 
 
Age (years) 
 
Mean age 71 ± 9.4 
Tumor grade 
GX 
G1 
G2 
G3 
G4 
 
1*** 
3 
14 
14 
1 
Tumor stage (according to TNM system) 
UICC I 
UICC II 
UICC III 
UICC IV 
33 patients in total 
8 
8 
11 
6 
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3.2.2. Agarose gel electrophoresis  
Ethidium bromine gel electrophoresis 
In order to confirm the specificity of the designed primer pairs, size verification of the 
amplified PCR products was performed. The PCR mixtures were combined with DNA 
loading buffer and separated using 1.2-2% ethidium bromide stained agarose gels. The 
agarose was dissolved in TAE buffer. Gels were run at 100 V and the products were 
visualized under UV light and documented with Argus X1 software (Biostep GmbH, 
Germany). The length of the DNA fragments was determined by comparing their 
electrophoretic mobility with ready-to-use DNA marker sample of known lengths (range of 
the size 100-1000 bp).  
 
Buffers: 
DNA loading buffer – 50 mM Tris-HCl, pH 7.6, 30% Glycerin, Xylene cyanol, Bromophenol blue 
TAE buffer – 40 mM Tris, 20 mM acetic acid, 1 mM EDTA, pH 8.0 
 
Formaldehyde agarose gel electrophoresis 
To determine the integrity of the isolated total RNA, sharp bands of the respective 
ribosomal RNAs should appear after running the samples on formaldehyde agarose gel (FA 
gel). Prior to be loaded on a gel, the samples were mixed with 1x RNA loading buffer and 
boiled at 65°C for 5 min. The apparent ratio of 28S rRNA to 18S rRNA should be 
approximately 2:1. If the observed ribosomal bands are smear, it is likely that the samples 
are degraded before or during the RNA purification.  
 
Buffers: 
10x FA gel buffer – 200 mM MOPS, 50 mM Sodium Acetate, 10 mM EDTA, pH 7 (with NaOH) 
1x FA gel running buffer – 100 ml, 10x FA gel buffer, 20 ml, 37% formaldehyde, 880 ml RNase-free 
water 
1x RNA loading buffer – 16 μl saturated bromophenol blue solution; 80 μl, 500 mM EDTA, pH 8; 720 
μl 37% formaldehyde; 2% glycerol; 3.084 μl formamide, 4 ml 10x FA gel buffer; RNase-free water to 10 ml 
 
3.2.3. Gene expression analysis 
Total RNA extraction from tissue samples and cell lines 
Total cellular RNA was isolated either from epithelium colon stripes or from cell pellets 
derived from different cell lines using RNAeasy Mini Kit where genomic DNA 
contaminations were effectively removed by using genomic DNA Eliminator spin column. 
Proper volume of RLT Plus lysis buffer was added to the fresh prepared cell pellets and/or 
tissue samples. The cells were homogenized using a syringe and needle, while for the deep 
frozen colon stripes Polytron PT 2100 homogenizer (Kinematica AG, Littau-Luzern, 
Switzerland) was used. Next steps of the RNA isolation were performed according to the 
manufacture’s instructions. The RNA yield was determined by measuring the absorbance at 
260 nm (A260) in a NanoDrop®ND-1000 Spectrophotometer (NanoDrop Technologies, 
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Montchanin, DE, USA). An absorbance of 1 unit at 260 nm corresponds to 44 μg of RNA 
per ml. Prior measurement, calibration of the instrument with suitable buffer used for RNA 
elution was applied. The ratio of absorbance at 260 nm to 280 nm (A260/A280 ratio) gives an 
estimate of RNA purity with respect to protein contaminations. Pure RNA has an A260/A280 
ratio of 1.9-2.1.  
 
RNA integrity  
Prior performance of  the in vitro reverse transcription steps, the integrity of the isolated 
total RNA was tested by agarose-formaldehyde denaturing gel electrophoresis or for more 
rapid and precise characterization of the isolated total RNA, Agilent 2100 bioanalyzer 
(Agilent Technologies, Palo Alto, CA, USA) was used. According to the bioanalyzer, the 
eukaryotic total RNA is classified based on a numbering system from 1 to 10 as 1 
corresponds to the most degraded RNA and 10 to the most intact RNA. The RNA integrity 
number (RIN) of the analyzed samples, determined by this technique was between 6.4 and 
9.6. 
 
Complementary DNA (cDNA) synthesis  
First strand cDNA was synthesized from total RNA using oligo (dT) 12-18 primers and 
SuperScript II Reverse Transcriptase according to the provider. cDNA was diluted with 
appropriate volume of RNase-free water and stored at -20°C till further processing. 
 
Genomic DNA (gDNA) extraction 
The cells or tissues were resuspended in 500 μl of lysis buffer. After addition of 25 μl, 
Proteinase K (10 mg/ml), the mixture was incubated overnight at 55°C. The proteins were 
precipitated by adding 300 μl, 5M NaCl followed by vigorously mixing of the suspension. 
After centrifugation at 15 800 g, 400 μl isopropanol was added to the supernatant and DNA 
was precipitated. The DNA pellet was washed with 70% ethanol, dried at room temperature 
and than eluted in appropriate volume of TE buffer for 30 min at 65°C.  
The gDNA concentration was determined by measuring the absorbtion at 260 nm (A260 = 50 
ng/μl), while the DNA purity was verified by calculating the ratio A260/A280. Pure DNA has 
an A260/A280 ratio of 1.7-1.9. 
 
Buffers: 
Lysis buffer – 50 mM tris-HCl, pH 8, 100 mM EDTA, 100 mM NaCl, 1% SDS 
TE buffer – 10 mM Tris-HCl, pH 8, 1 mM EDTA, pH 8  
 
Design of primers 
Altogether, 12 gene of interest (GOI) and 2 reference genes were analyzed. However, it 
should be considered the fact that besides the lack of DEFA 2 gene, the sequence of the 
genes encoding the neutrophilic defensins, i.e. DEFA 1 and DEFA 3, differ by only 2 
nucleotide substitutions (1 leading to a coding difference and 1 in the 3’UTR) (108). 
Therefore only one primer pair was used for detection of DEFA 1 and DEFA 3 genes. 
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All primer pairs were designed, using freely available Primer3 software, version 0.4.0, 
(http://frodo.wi.mit.edu/). To assess the primer specificity, basic local aligment search tools 
(BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi) were applied. Notably, the primers were 
designed to amplify across an intron/exon boundary or in two different exons, separated by 
a very big intron, thereby preventing amplification of residual genomic DNA. Information 
about the mRNA reference sequences of the protein-coding genes, their exon boundaries 
and the size of the introns in between was accessible at: http://genome.ucsc.edu/cgi-
bin/hgGateway. The amplicon size varied within the range 94 bp to 202 bp. The sequences 
of the used primer pairs are shown in Table 3-5, page 22. For further verification of the 
primer specificity, the products amplified by defensin’s primer pairs were sequenced. 
 
Verification of the primer specificity 
To verify the primer specificity and to ensure that the designed primer pairs were not 
amplifying additional products in the presence of genomic DNA (gDNA), in-silico PCR was 
implemented (http://genome.ucsc.edu/cgi-bin/hgPcr?command=start or 
http://www.ncbi.nlm.nih.gov/sutils/e-pcr/). In addition to this computational procedure, an 
experimental approach, such as standard polymerase chain reaction (PCR), was carried out. 
For generation of the amplicon, reflecting the relative abundance of certain target gene, the 
gene specific primers were tested in a presence of various templates, i.e gDNA and 
complementary DNA (cDNA). PCR reactions were carried out using Go Tag DNA 
Polymerase. In addition, to the reaction mixture were added: 5x Go Tag Reaction buffer, 
200 μM dNTRs mix (equimolar, dGTP, dCTP, dATP and dTTP), gene specific primers (10 
μM) and DNA template (either gDNA or cDNA). 
Control reaction (NTC) that contains all essential components of the amplification reaction 
except the template enables detection of contaminations. Reactions were run on 
Mastercycler gradient (Eppendorf) with the following thermal conditions: 95°C for 2 min 
followed by 40 cycles of 95°C for 30 sec, 60°C for 30 sec and 72°C for 30 sec and as a last 
step, final extension was run at 72°C for 10 min. On Figure 3-1, representative examples are 
shown. If the primers are specific, amplicon with correct size should be observed only in 
case where cDNA was used as a DNA template. 
 
Buffers: 
5x Go Tag Reaction buffer – 50 mM Tris-HCl, pH 9; 50 mM NaCl and 5 mM MgCl2 
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Figure 3-1 Verification of primer 
specificity for (A.) Defensin, alpha 6 
gene (DEFA 6) and (B.) Defensin alpha 
1-3 genes (DEFA 1-3). The expected 
amplicon size is 198 bp and 222 bp, 
respectively. In order to verify the lack 
of contaminations, non-template control 
reaction (NTC) was run in parallel. 
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Table 3-5 Sequence of oligonucleotide primers used for PCR amplification and product size predicted for 
sample cDNA. All primers are listed as 5’ to 3’. 
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Quantitative Real - Time PCR (qRT-PCR) conditions  
Aliquots of 2 µL cDNA was mixed with PCR master mix iQ™ SYBR® Green Supermix (2 
x SYBR Green I, iTaq DNA polymerase, reaction buffer, deoxynucleotide triphosphate mix, 
10 mM MgCl2, 20 nM fluorescein, and stabilizers), and the gene-specific primers in a final 
volume of 25 µL. For one specific sample the assay was performed in duplicate or triplicate. 
The enzyme was activated after an initial two minutes denaturation step at 95°C and 40 
cycles of 30 sec at 94°C, 30 sec at 60°C and 30 sec at 72°C. Amplification was performed in 
an iCycler thermal cycling instrument (iCycler iQ
® 
Real-Time PCR Detection System; 
BioRad) in 96-well microtiter plates. For each experimental run, a control reaction that 
contains all essential components of the amplification reaction except template was 
included. This enables detection of contaminations and presence of primer-dimer formation. 
 
PCR reaction efficiency 
The slope of a standard curve provides an indication of the efficiency of the qRT- PCR. 
Upon analysis, its slope should be –3.322 for 100% PCR efficiency. The standard curve was 
generated using a dilution series of five different concentrations of cDNA, measured in 
triplicate. The standards were giving a slope between - 3.1 and - 3.4 which was acceptable 
for accurate quantification. The fluorescent signal from each PCR reaction was collected as 
the peak-normalized values plotted versus the cycle numbers.  
Reactions were characterized by comparing Ct values. The Ct value is a unitless value 
defined as the fractional cycle number at which the target fluorescent signal passes a fixed 
threshold above the baseline, when it is always located within the linear phase of 
amplification. The higher the initial copy number of cDNA for a certain gene target is the 
lower Ct value this gene has. 
 
3.2.4. Protein expression analysis. 
3.2.4.1. Protein extraction 
 
Preparation of lysates from tissue samples 
The frozen colon stripes, stored at -80°C and ready to be used were thawed in prechilled 
homogenization RIPA buffer. In addition to 1 mM Na3VO4 and 1 mM PMSF, protease 
inhibitor cocktail (Roche) was added to the buffer in order to protect the lysate from the 
action of proteases. Cellular debris were removed by centrifugation at 15 800 g for 7 min, at 
4°C. The supernatant was carefully removed to a fresh, ice-cold tube.  
The protein concentration was determined by applying the standard Bradford protein assay 
(Roti®- Quant), where calf serum albumin was used for calibration protein. The sample was 
ready to be applied for further analysis. 
 
Buffers: 
RIPA buffer – 150 mM NaCl, 1.0 % NP-40, 0.5 % Na deoxycholate, 0.1 % SDS, 50 mM Tris, pH 8 
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3.2.4.2. SDS PAGE and Western blot, quantification by ECL 
In order to analyze the protein content, the tissue and/or cell extracts were subjected to SDS 
PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) and thus separated. The 
percentage of the gel casted was dependent on the size of the analyzed protein. The smaller 
the size of the protein of interest, the higher the percentage of the gel is and vise versa. The 
protein extracts, corresponding to 15 to 80 μg of the total protein amount were boiled in 1 x 
Laemmili buffer for 5 min at 95°C. Briefly, by 2 min centrifugation step at 15 800 g, the 
denatured protein extracts were clarified. Once prepared, the samples were ready to be 
loaded into the wells of the gel (ranged from 10% to 12%). Each gel was run in running 
buffer with constant voltage of 40 V until the protein went out from the stacking gel, then 
the voltage was increased to 60 or 80 V for the separating gel. Electrophoresis time 
depended on the protein size and it was carried on for at least 90 min. Pre-stained, high-
range (10-250 kDa) molecular weight standard (PageRuler Prestained Protein Ladder) was 
used to determine the molecular weight of the proteins. Semi-dry transfer (transblot, Bio 
Rad) was applied to transfer the separated by SDS PAGE proteins onto polyvinylidene 
difluoride (PVDF) or nitrocellulose membrane using transfer buffer. Constant voltage of 
14V was applied as the transfer time depended on the size of the protein under investigation, 
which range from 60 to 90 min. The bound proteins were visualized by Ponceau S solution. 
To block the unspecific binding sites, the membrane was soaked in 5% non fat dried milk, 
dissolved in PBS-Tween 0.05%  for 1 hour at RT and then was probed with primary 
antibody (determined dilution, refer to Table 3-2, page 17). Incubation, preferably overnight 
at 4°C was applied. Next, followed by 3x washing with PBS-Tween 0.05% or 0.1% 
solution, the membrane was incubated with the respective horseradish peroxidase-labeled 
secondary antibody for 1 hour at RT. Finally, after the last triple rinsing of the membrane, 
the proteins were visualized by using chemiluminiscent ECL or ECL Plus™ reagents and 
exposed to Amersham ECL-Hyperfilm.  
If necessary to be re-probed with another antibody, the membranes were first washed twice 
with PBS-Tween 0.1% and then submerged in stripping buffer, thereafter incubated at 50°C 
for 30 min with occasional agitation. Followed by extensive washing with PBS-Tween 
0.1%, and blocking (blocking buffer), the membrane was ready to be used for 
immunodetection with different antibodies as described above. 
 
Buffers: 
1x Laemmili buffer – 10% Glycerol, 62.5 mM Tris HCl, pH 7.5, 2% SDS, 50 mM DTT and Bromphenol 
blue 
Separating gel – 1.5 M Tris, pH 8.8, 0.4% SDS 
Stacking gel – 0.5 M Tris, pH 6.8, 0.4% SDS 
10x Running buffer – 0.25 M Tris; 14.4% Glycine (w/v) 
1x Running buffer – 100 ml 10 X Running buffer, 5 ml, 20% SDS. Fill up to 1000 ml with Millipore-Q 
Water 
10x Transfer buffer – 250 mM Tris (Base); 1.92 M Glycine 
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1x Transfer buffer – 100 ml, 10x Transfer buffer and 200 ml , 100% Methanol. Fill up to 1000ml with 
Millipore-Q Water 
10x Phosphate-buffered Saline (PBS) – 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM 
KH2PO4, pH 7.4. 
Stripping buffer – 100mM ß-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl pH 6.7 
Blocking buffer – 5% non-fat dried milk in PBS – Tween 0.05% 
 
3.2.4.3. Quantification of the chemiluminescent signal by densitometry and 
evaluation of the Western blot data 
Densitometric estimation of the blots was performed using Quantity One quantification 
software, version 4.5 (Bio Rad). It measures the signal intensity derived from the digital 
data object. To be visible and quantifiable, the intensity of the clustered pixels from the data 
object should be higher than the intensity of the pixels that make up the background of the 
image. The densitometric value used for evaluation is called “Volume” and it is equal to the 
sum of the intensities of the pixels within the determined volume boundary multiply by the 
pixel area. Further correction of the value was performed by the followed background 
subtraction.  
The intensity of the target protein was normalized to the signal intensity of the reference 
protein, i.e ß-actin. The last functioned as an internal, loading control.  
 
3.2.5. Data mining, evaluation techniques and statistical methods  
3.2.5.1. Data mining 
Expression data for the genes of interest as well as the classification of tissues have been 
obtained via the "Virtual Northern" function of NIH's database dbEST (109-111). Recent 
short descriptions are available in references (112-114). This database searches in literature 
for data from DNA or oligonucleotide chip experiments, normalizes them and lists the 
results gene by gene for a set of tissues. The data can be obtained for each gene via 
http://cgap.nci.nih.gov/Genes/GeneFinder. Presently, the database contains information on 
some 4 million genes or EST expression data.  
 
3.2.5.2. Principal Component Analysis (PCA)-the idea behind it 
In the present work a combination of 12 genes of interest (GOI) as well as 2 reference genes 
was analyzed in normal and tumor colon tissues. In order to find out which of these selected 
genes have a high diagnostic power and which ones are of less importance for 
distinguishing normal from tumor tissue, the statistical technique “Principal Component 
Analysis” (PCA) was used. PCA is a mathematical procedure that transforms a number of 
(possibly) correlated variables into a smaller number of essential variables called Principal 
Components (PC). The description of the algorithm and the applied terminology can be seen 
below. 
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To demonstrate how PCA works, an artificial example will be described. Assume that a set 
of four genes (variables) was used to distinguish tumor from normal tissue obtained from 
three patients. The putative expression measured by qRT-PCR for each gene (variable) 
across the two types of tissues was presented as threshold cycle (Ct) values. These 
expression values were not further normalized and raw data was used for evaluation (Table 
3-6). The resulting data showed that Gene C and Gene D had very stable expression values 
among the analyzed tissue samples, which lead to the assumption, that these two genes 
would not have any impact in the discrimination between the analyzed normal and tumor 
tissues. 
 
Type of tissue Gene A Gene B Gene C Gene D 
N1 26 25 26 21 
N2 27 25 25 23 
N3 25 27 27 22 
T1 29 28 26 21 
T2 30 28 25 23 
T3 28 30 27 22 
 
 
Next, the obtained qRT-PCR data were applied to the PCA software and the outcome of the 
analysis is shown in Figure 3-2, page 27. It should be noted that due to the PCA 
performance the scale of the scatter presentation was changed. 
The assay disclosed that discrimination between “normal” and “tumor” tissue population 
can be achieved and for this positive outcome, the first principal component (PC1) had the 
most prominent impact since it showed the largest variance in the analyzed data. PC1 
accounted for more than 63% of the variance in the data and this was proved by the 
eigenvalue (detailed description, below), which had the highest value (5.5), compared to the 
eigenvalues of the rest of the principal components (Figure 3-2, B). Next, in order to verify 
the most important variables (genes), responsible for the prominent role of PC1, its 
“component loading“ was evaluated (Figure 3-2, C). The observation revealed that Gene A 
and Gene B were the genes with the heaviest impact that enable discrimination between the 
two types of tissues. They both had almost equal loadings in this component. In contrast, 
Gene C and Gene D did not show any discrimination impact. 
The finding that the discrimination power of the analyzed genes was not equal could also be 
clearly observed and verified when the expressions of two different genes were plotted in 
combination. Figure 3-3, page 28 summarized the assembled 4 different combinations of 
genes. While the combinations of genes, where the most prominent targets, such as Gene A 
and Gene B were implicated, can distinguish normal from tumor tissue (Figure 3-3, A, B 
and C), the combination of genes, which did not show any alterations in the expression 
Table 3-6 Expression of Gene A, B, C and D (columns) measured by qRT-PCR in normal (N) and tumor (T) 
tissue for three patients (rows). The numbers indicate the different patients. Raw expression data are 
presented as a number of threshold cycles (Ct). No additional normalization of the expression was 
performed. 
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between the different types of tissues, as Gene C and Gene D, was unable to discriminate 
between normal and tumor tissue (Figure 3-3, D, page 28). 
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Figure 3-2 (A.) Scatter of the first 2 Principal Components (PC) computed after performance of PCA with 
four variables, e.g. Gene A, Gene B, Gene C and Gene D. The raw data were transformed to four Principal 
Components (PCs) where the first one has the biggest impact for the separation between the normal (green) 
and tumor (red) tissue populations. In addition; (B.) presents a table where the percentage variance for each 
of the 4 computed PCs is listed together with the corresponding eigenvalue; (C.) A schematic diagram 
showing the “component loading”of PC1, which in fact facilitates the user to determine to what degree the 
different original variables (genes) enter into the most prominent component. 
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Background of PCA. Description and terminology. 
As described above, PCA is a statistical technique that transforms a number of (possibly) 
correlated variables into a smaller number of essential variables called PCs. For further 
understanding of the way how this analysis works, here is given an example with actual 
experimental data, namely gene expression data obtained from paired normal and tumor 
colon tissue. In this case a single variable is the measured expression of a defined gene 
across different colon tissue types. In a qRT-PCR experiment, the gene expression is 
represented by Ct values. As it was mentioned above, these measures were not normalized 
and raw data were applied to the software. It should be taken into account that when 
multivariate data are evaluated (parallel evaluation of many genes (variables)) not all, but at 
least some of the variables can often be correlated with each other. Such an example is 
shown in Figure 3-4, page 29, where two highly correlated variables were plotted, i.e COX-
2 and OPN gene expressions across normal and tumor colon tissue. These two variables 
Figure 3-3  Scatter of the pairwise expression of 4 genes examined. (A), (B) and (C) show cases where 
distinction between normal (N) and tumor (T) tissue is possible; (D) presents the combination of Gene C and 
Gene D. Their expressions did not differ when N and T tissues were compared (Table 3-6, page 26). 
Therefore, the combination of these 2 genes is not able to discriminate between the two different tissue types 
analyzed. 
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were correlated with each other, since if in one sample the gene expression value of COX-2 
was high, the value of OPN variable was high as well and/or vise versa. This presentation 
closely resembles Figure 3-3 A, page 28. Thus, after performance of PCA, the data of these 
two variables were transformed into PCs. These PCs are a linear combination of the original 
variables and they are equal to the number of the original variables.  
The PCs are always orthogonal/perpendicular to each other and therefore they are 
uncorrelated. By definition, the first principal component (PC1) accounts for as much of the 
variability in the data as possible and every succeeding component accounts for as much of 
the remaining variability as possible. In the present example, two PCs were calculated, 
termed PC1 and PC2 where the first one (PC1) possessed the main variance in the analyzed 
data. Principal component 2 (PC2) was the second component accounted for the remaining 
variability (115; 116).  
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In addition, Figure 3-4 highlights samples S1 and S2, which represent the largest variance in 
this data set. Every sample point (♦) indicates the non-normalized, raw expression of OPN 
and COX-2 in one tissue donor as the colored in red points represent the tumor samples and 
the green one, the normal samples. Thus, S1 and S2 symbolize the donors with the highest 
and the lowest OPN and COX-2 expression levels among the entire set of investigated 
variables. Obviously, PC1 was closely passing by S1 and S2, symbolizing the highest 
Figure 3-4  Scatter plot of two variables. The romb symbol “♦” represents the measured, non-normalized 
expression of two genes, e.g. OPN and COX-2 in one sample, presented as number of threshold cycles (Ct). 
The PCA transformed the analyzed variables into two PCs where PC1 gives the major variance in the data. 
S1 and S2 illustrate respectively the samples with the highest and the lowest relative expression among the 
different samples and hence, represent the major variance in this data set. 
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variance in the data, while PC2 was covering the second main variance presented in that 
data set. When 3 additional variables, for example the expression of PLK1, PKM2 and 
USP28 genes were added to the already assessed OPN and COX-2 data, five variables 
(expression patterns) in total were analyzed. Interestingly, the 3 new variables were highly 
correlated within each other, but they were not correlated with the first 2 variables (OPN 
and COX-2). Therefore, among the data, one can suggest that 2 different groups were 
differentiated, each consisting of highly correlated variables. After evaluation of an entire 
set of 5 variables, PCA projected the data onto new variables (PCs) as the first two PCs 
were those with the most prominent function. Probably these two PCs demonstrate the 
relationship between the 2 newly determined groups, OPN and COX-2 genes on one hand 
and PLK1, PKM2 and USP28 genes on the other. Indeed, via applying PCA some of the 
components with lesser significance among the investigated data set can be ignored, while 
the most informative will remain. As a result, in the present example the number of 
variables can be decreased from 5 to 2, as the latter were those with the most prominent 
role.  
The measure of variance in the data associated with a PC is called eigenvalue. This value 
can be used to asses the relative importance of the PC. If the PC has a low eigenvalue, then 
it is contributing little to the explanation of variances in the variables and may be ignored as 
redundant with more important PCs. As it was mentioned above, the first PC posses the 
highest eigenvalue and gives the direction of maximal variance. The second PC gives the 
direction of the second highest variance orthogonal to the first PC and etc. Thus, the final 
result of applying PCA is a data compression, which reduces the high dimensionality of the 
experimentally obtained data to fewer dimensions, with a minimum loss of information. In 
this way, the most relevant components, or patterns, across the gene expression data which 
are responsible for the group’s similarity or differences will be identified. 
For more detailed description, the reader can refer to: 
http://www.chem.agilent.com/cag/bsp/products/gsgx/Downloads/pdf/pca.pdf 
 
Description of the software used for PCA analysis 
The software used for the PCA of the gene expression data is available at: 
http://folk.uio.no/ohammer/past/. The outcome from the PCA can be displayed as a 2D 
picture, viewed from its most informative viewpoint when representing the first two most 
prominent PCs. In addition to that, the data analysis package reports the list of all computed 
PCs as well as the corresponding eigenvalues, which indicate the most significant PCs. The 
software enables the researchers to verify the “component loadings”, which in fact means to 
test to what degree the different original variables (given in the original order along the x 
axis) enter into different components. These “component loadings” are important when the 
user tries to interpret the “meaning” of the components.  
To implement the PCA, raw Ct data obtained by qRT-PCR was utilized. For a detailed 
description of the Ct value refer to page 23, “PCR Reaction Efficiency”. In order to perform 
the PCA approach, it should also be considered that the applied raw Ct data must be 
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acquired using the same starting cDNA concentration. However, this requirement was not 
fulfilled for each of the analyzed patient’s materials. Therefore, prior to application of the 
software, the raw Ct data from those exceptional cases was undergoing additional 
adjustment as described below: 
 
Ct is the number of cycles when the fluorescence intensity of the target gene in qRT-PCR 
reaction passes a fixed threshold value Vt   (equation 1) 
Vt = C0 * 2 Ct     (1) 
where C0 is an initial cDNA concentration.  
 
Therefore, according to equation 1, the initial concentration is: 
C0 = Vt / 2 Ct     or   C0 = Vt * 2 –Ct   (2) 
 
From equation 2 follows that: 
log2 (C0) = log2 (Vt) – Ct or – Ct = log2 (C0) – log2 (Vt)  (3) 
 
Under identical PCR conditions – Ct represents a measure for the logarithmic initial 
concentration of the amount of cDNA in the reaction (equation 3). 
In order to compare the qRT-PCR reactions with different starting cDNA concentrations, a 
correction factor λ was used for the adjustment.  The corrected values are given as: 
C1 = C0 *λ.    (4) 
 
According to the equation 3, the outcome of the qRT-PCR analysis will be: 
log2 (C1) = log2 (Vt) – Ct1 or log2 (C0) + log2 (λ) = log2 (Vt) – Ct1     (5) 
or 
log2 (C0) = log2 (Vt) – Ct1 – log2 (λ) or – Ct = – Ct1 – log2 (λ)        (6) 
 
Thus, if a reaction on the basis of C1 = C0 *λ is used instead of C0 for the determination of 
the initial concentration, the measured value of – Ct1 has to be corrected to – Ct1 – log2 (λ).  
 
3.2.5.3. Relative expression software tool (REST) 
REST is a program, available as a free download at http://rest.gene-quantification.info/. The 
software was used for relative quantification of a gene expression data, generated by qRT-
PCR. REST compares two groups, with up to 16 data points (genes) in the sample group 
versus 16 data points (genes) in the control group, which allows the use of more than just 
one house keeping gene (HKG) for evaluation of data. In this particular study, the cohort of 
normal tissue samples was always regarded as “control group”. The rest of the examined 
tissue-populations, e.g. normal near tumor, adenoma and/or tumor were considered as 
“sample groups”. 
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The data presented to the software was the mean Ct value obtained from samples amplified 
in duplicate or triplicate by the PCR approach. For a detailed description of Ct, refer to 
section “PCR Reaction Efficiency”, page 23. 
Equation 7 shows the mathematical model used for computation of the expression ratio (R) 
between the relative expression of the gene of interest (GOI) in the control and the sample 
groups obtained by qRT-PCR. 
 
( )( ) )(
)(
samplecontrolCtref
ref
samplecontrolCtGOI
GOI
E
ER −Δ
−Δ
=    (7) 
 
where E is the PCR efficiency and Ct represents the mean of Ct, provided by the iCycler, for 
the GOI and for the reference (ref) gene.  
 
In this work, the PCR efficiency of all applied primer pairs was comparatively similar, and 
also was high enough to be considered as 100% (which means that with each PCR cycle, 2 
copies of mRNA are amplified). Therefore, an optimal primer efficiency of 2 (E=2.0) was 
assumed. By REST, comparison between the relative expressions in the control and sample 
groups can be achieved (117). In order to test whether the expression alterations between 
two analyzed groups are significant, a nonparametric test was automatically carried out by 
the software. For comprehensive description refer to (117). 
 
To compute the relative expression of a single gene of interest, its mRNA expression was 
normalized to that of the reference mRNA (equation 8): 
 
 2 (Ct reference - Ct gene of interest)    (8) 
 
3.2.5.4. Statistical methods  
In order to perform the appropriate statistical tests, the data was exported to Prism Software, 
version 4 (Graph Pad, San Diego, USA). 
If the data followed Gaussian bell-shaped distribution, parametric tests were applied. 
However, often a mix of Gaussian and non-Gaussian distributed data set was compared and 
therefore, the use of parametric test was not appropriate. Thus, non parametric tests were 
applied. These tests make no assumption about the data-distribution, but rather rank the 
values from low to high and therefore assess the distribution of the ranks.  
The following tests were applied: 
To compare two paired, matched groups, Wilcoxon paired test was performed. 
Mann-Whitney test was used in order to evaluate the means of the relative mRNA 
expression in response to gender of the patients.  
To compare the means among three or more unpaired groups, Kruskal-Wallis test followed 
by Dunn’s post test was applied. 
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Pearson (for Gaussian distributed data) or Spearman (for non-Gaussian distributed data) 
correlation analyses were used to examine how well two variables vary together. 
To explore whether the age of the patients has any effect on the expression level of the 
analyzed gene, linear regression analysis was applied. 
Comparisons among three or more different cell lines were performed using One-way 
ANOVA (analysis of variances) for normal distributed values. It was not appropriate to 
apply the non parametric Kruskal-Wallis test due to the small sample size (three values per 
group).  
 
Non-paired, Mann-Whitney and Kruskal-Wallis test 
These are non parametric tests that compare two unpaired groups. The whole set of applied 
values are ranked from low to high, without paying attention to which of the analyzed group 
each value belong. The smallest number gets rank of 1, while the largest one gets a rank of 
N, where N is the total number of values in the examined groups. Next, the ranks from each 
group are summed up and if the sums are very different, than the p-value will be very small. 
The latter answer the question: If the populations really have the same median, what is the 
chance that random sampling would result in a sum of ranks as far apart as observed in this 
experiment? 
If the p-value is small, the idea that the difference is due to random sampling can be 
rejected, rather can be concluded that the populations have different medians (detailed 
description “Statistics Guide” provided by Prism SOFTWARE, page: 53-54 and page: 71-
73). 
 
Paired, matched Wilcoxon test 
It is nonparametric test that compares two paired groups. The test calculates the difference 
between paired measurements for each analyzed subject. For example, this test was used to 
compare the differeneces in the relative gene expression between paired tissue samples, 
derived from one single patient. Basically, the absolute values corresponding to the 
computed differences between each set of pairs are ranked from low to high. The ranks from 
each analyzed group are summed up and the sums are compared. If the sums of the ranks 
are very different, the p-value will be small. (page: 54-56, Statistical guide, Prism). 
 
One-way ANOVA 
In brief, One-way ANOVA works by comparing the differences in the means among three 
or more unmatched groups (variables) when the data is categorized in a one–way. For more 
information about how this is accomplished, refer to:  
http://www.analystsoft.com/en/products/statplus/content/help/src/analysis_analysis_of_vari
ance_one_way_anova.html 
When the p-value is small, than the null hypothesis of no differences between the means is 
rejected and the alternative hypothesis that the means are different from each other is 
accepted. 
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Furthermore, in order to compare all pairs of group means, Tukey’s post test was selected. 
Thus, one can evaluate whether the differences between two paired groups are significant. 
 
Linear regression and Pearson/Spearman correlation tests 
While the linear regression finds the line that best predicts Y from X, the correlation 
quantifies how well X and Y vary together. Moreover, the correlation analysis only makes 
sense when both X and Y variables are measurable outcomes. If one of the variables is 
controlled, than linear regression should be applied. 
For extensive description one can refer to “Statistics Guide”, page 92 and “Regression 
book”, provided by Prism SOFTWARE. 
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4. Results 
4.1. Quantitation of the housekeeping gene (HKG) expression in 
normal, normal near tumor, adenoma and tumor colon tissue across 
patients with colorectal cancer (CRC) 
 
The quantitative Real-Time PCR (qRT-PCR) analysis is a commonly used method to 
measure and compare the messenger RNA (mRNA) expression levels (transcript 
abundance) among different tissues and/or disease states. For accurate performance of the 
assay, several parameters such as RNA integrity, efficiency of cDNA synthesis, initial 
sample amount need to be considered. It is essentially impossible to obtain the same starting 
amount of the material under investigation. Therefore, for accurate quantitation of mRNA 
levels in any tissue samples, it is necessary to apply normalization with endogenous 
standards, mainly housekeeping genes (HKGs). The proper choice of HKGs highly depends 
on the tissue and the cell types under investigation. In theory these HKGs, which are 
responsible for the basic cell survival, should be constitutively expressed in all cell types, 
without being affected by any human diseases. One of the commonly used endogenous 
standards, also employed in our investigation, is the ß-actin gene. It is ubiquitously 
expressed in all cell types and additionally it was showing stable expression in colon 
carcinoma (118). However, many studies have shown differences in the expression profiles 
of endogenous reference genes between different tissues, pathological states and/or different 
experimental conditions (118-121). Apart from these observations, previous studies have 
already reported the relatively stable expression of the gene encoding the lysosomal enzyme 
ß-Glucuronidase (GUS) in normal tissue compared to tumor colorectal tissue (118). 
Therefore, for more accurate and reliable normalization of our experimental data, the 
expression of GUS was selected as a standard, in addition to the expression of the widely 
used ß-actin gene.  
The selected reference genes belong to different functional classes. While the ß-actin is a 
cytoskeletal protein, essential for the structure and kinetics of the cytoskeleton, the GUS is a 
glycoprotein which functions as an exoglycosidase in the lysosomes. This functional 
independence is important, because selection of genes that share common biochemical 
pathways can have influence on the assay, due to the fact that their expression patterns can 
be co-regulated. 
Prior to the performance of the comparative qRT-PCR analysis, the PCR efficiency of each 
primer pair designed to amplify certain HKG as well as the quality of each RNA sample 
was determined to ensure the correctness of the assay. Furthermore, in order to validate the 
expression stability of the HKG across different tissue types, raw (non-normalized) 
expression data obtained from qRT-PCR assay were plotted in Figure 4-1, page 36. This 
figure presents the cycle number at which the threshold fluorescence was obtained for the 
both calibration genes in paired normal and tumor tissues, across 26 donors. 
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The left part of the graph presents the threshold cycles in normal (N) tissue samples and the 
right- in the tumor (T) tissue samples. This way of representation revealed that the both 
calibration genes need relatively the same number of PCR amplification cycles in order to 
become detectable, in normal and in tumor colon tissue.  
It was also shown distinction between the abundance levels of both HKGs in the cell. The 
differences (Δ(GUS - ß-actin)) in the expression between GUS and ß-actin were 
approximately 5 - 6 cycles (5.18 cycles ± 0.79 for normal tissue and 5.86 cycles ± 1.08 for 
cancer tissue), i.e. the absolute expression level of ß-actin was 32 to 64 times higher than 
the expression level of GUS. In addition to this verification, another way to test the 
expression stability of the respective normalization gene was to build-up the ratio of ß-actin 
and/or GUS in paired colon tissue samples. Thus, Figure 4-2 exhibits ß-actin and GUS ratio 
in matched normal and tumor tissue across 26 individual donors.  
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If the computed expression ratio is equal to 1 then the reference expression is quite stable 
(constant) and not affected by any disease statement. In contrast, any fluctuations of the 
ratio values (different from 1) will correspond to decrease in the HKG’s expression stability. 
One might expect that, since the cancer is a disease with up-regulated cell proliferation on 
the one hand and on the other – the cytoskeleton plays a role in the cell migration that ß-
actin expression would change with increasing disease stages. However, this was not the 
case, since the obtained result revealed minimal variances in the reference genes expression 
independent of the type of colon tissue which was investigated. 
Figure 4-2  Comparative HKG expressions as determined by qRT-PCR across 26 donors. Every single bar 
represents the ratio computed between the expressions of defined HKG in paired non-malignant and 
malignant colon tissues, derived from single patient, see the legend above the figure. In this ratio, the 
expression in non- malignant tissue was always dominator. Ratio above or under 1 indicates variation in the 
HKG expression in colon cancer tissue compared to normal colon tissue. The patients (Ps) are listed 
according to their age, the small letter discriminate among patients with the same age. 
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Thus, the analysis of the present study showed that the average fold change in the ß-actin 
expression, in malignant colon tissue, when compared to the corresponding expression in 
non-malignant (normal) tissue was 0.95 fold ± 0.05 and 0.99 fold ± 0.05 for GUS, 
respectively. Furthermore, the HKGs mRNA transcriptional levels were also stable in the 
rest of the examined tissues, namely normal near tumor (NnrT) and adenoma (A) tissues, 
when their expression levels were compared to the respective expression in normal tissue. 
The averaged data is summarized in Table 4-1.  
 
 
 
 
Next, the similarity of the HKG-expression pattern across the entire set of different tissue 
samples was measured. A metric analysis (Pearson correlation test) was applied. 
Interestingly, the analysis revealed statistically significant correlation in the expression of ß-
actin and GUS in normal, normal near tumor and tumor colon tissue, while no correlation 
was found in adenoma colon tissues, see Figure 4-3, page 39. In fact, one reasonable 
explanation for the lost of correlation between the expression patterns of ß- actin and GUS 
in adenoma colon tissue, could be the low number of donors analyzed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4-1  Averaged fold changes in the HKG expression related to the expression in normal colon. Fold 
change equal to 1 denotes that there is no change in the HKG expression in certain type of tissue compared to 
the expression in normal colon tissue. 
Type of tissue Fold changes in ß-actin expression Fold changes in GUS expression 
Normal near Tumor vs Normal tissue 0.97  ±  0.05 0.98  ±  0.03 
Adenoma vs Normal tissue 1  ±  0.054 0.98  ±  0.045 
Tumor vs Normal tissue 0.95  ±  0.05 0.99  ±  0.05 
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Housekeeping genes are stably expressed at age from 57 to 88 years 
The linear regression analysis of the HKGs expressions in normal tissue samples illustrates 
that there is no dependence on the age (Figure 4-4, page 40). This leads to the conclusion 
that, at least in the case of ß-actin and GUS the expression is constant up to high age.  
As a further verification of the relatively stable HKG expression, the expression data was 
categorized according to gender of the patients. No significant differences between the 
groups were found when Mann-Whitney test was applied (data not shown). The same was 
found when the HKGs expression in malignant colon tissue was compared with grade and 
stage of cancer (using Kruskal-Wallis test), data not shown.  
 
 
 
Figure 4-3  Pearson‘s correlation analysis of the relative HKG expression. The x- and y-axis represent the Ct 
values of ß-actin and GUS expression, respectively obtained in Normal (A.), Normal near Tumor (B.), 
Adenoma (C.) and Tumor (D.) colon tissues. The Pearson correlation (r) coefficient represents the similarity 
in the expression pattern between the two HKGs. r equal to 1 reflects perfect correlation between two 
expression patterns. Statistical significance is denoted by the p-values. 
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Concluding remarks: 
Apart from the diverse functional activity, the analyzed HKGs revealed high expression 
stability. ß-actin and GUS showed a minimal variance in their expression patterns, 
independent of the tissue type investigated as well as independent of the difference in their 
abundance in the cell. Moreover, the Pearson correlation analysis demonstrated that their 
expression patterns were significantly correlated among the normal, normal near tumor and 
tumor tissues, derived from patients having colon surgery. In contrast, no correlation was 
found in adenoma colon tissue. The analysis also showed that the HKG expression is not 
influenced by age, gender or type of tissue. As a consequence, these observations verify the 
capability of the selected HKGs to be used for further normalization of the experimental 
gene expression data. 
 
Figure 4-4  Linear regression analysis of age of the patients versus the expression of ß-actin (A.) and GUS 
(B.); (C.) and (D.) present the same data as in (A.) and (B.), but with highly suppressed zero point on the y-
axis. The correlation coefficient (r2) and the significance level (p) were calculated. The r2 values close to zero 
indicate that there is absolutely not age dependence. 
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4.2. No significant differences between single or multi-housekeeping 
gene normalization, using Relative Expression Software Tool (REST)! 
 
Usually, the outcomes of many expression studies are relying on data, normalized on a 
single control gene. However, numerous studies reported that HKG expression can vary 
considerably as a result of different treatments and/or disease stages (121; 122). Due to such 
expression variability, the normalization to single HKG can lead to relatively large errors in 
a significant proportion of the tested sample (123). Therefore, multiple HKG normalization 
can be applied. In the present work, normalization on one (single) and on combination of 
two HKGs was performed. 
In section 4.1, page 35 already showed that ß-actin and GUS were similarly well suited to 
be used as standard, calibration genes. Moreover, they both are representative of different 
biochemical pathways, which are not co-regulated and therefore can be speculated that the 
parallel calibration with both of them can cover better the molecular changes occurring 
during the colon cancer development. 
In order to find out whether the data evaluation will be similarly accurate if the gene 
expression is calibrated on a single HKG or on a combination of two HKGs, the 
experimental gene expression data was normalized once to a single HKG and in addition, it 
was also calibrated to a combination of two HKGs. The test was performed using Relative 
Expression Software Tool (REST) for group-wise comparison of the relative expression of 
12 target genes across paired normal and tumor colon tissue. The data was provided by 
randomly selected 8 patients from the cohort of 27 analyzed patients in total. For more 
detailed description of the REST, refer to 3.2.5.3, page 31.  
In short, the software performs normalization of the expression for each GOI to single or 
combination of two HKGs. At the same time the software estimates the alteration of the 
normalized expression in the “sample group” by comparing it to the respective expressions 
in the “control group”. Hence, in our experimental data, the expressions of all 12 genes in 
normal tissue, which represents the “control group” were compared with the corresponding 
gene expressions in tumor tissue or the so called “sample groups”. The expression ratio, the 
corresponding fold changes in the expression as well as the outcomes from the 
automatically performed non-parametric test are listed in Table 4-2, page 42. 
The analysis demonstrated that when the same expression data was normalized to a single or 
to a combination of two reference genes, not considerable differences, in the final outcomes 
appeared. For instance, in respect to DDX6, HAT1 and eIF4E genes, insignificant 
differences within the range of 1 fold down- or up-regulation in cancer were computed 
when single and multi-normalization was performed, respectively. In addition, although the 
same tendency of increased expression in cancer for all analyzed alpha-defensins (DEFA 1-
3 and DEFA 6) was detected, only slight deviations in the p-value of the final outcome were 
observed.  
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This uncertainty in the results can not be considered as significant error, because any 
changes in the expression within 1 fold and even more can be related to some deviation in 
the technical procedure, such as a pipetting variation for example. 
 
Normalized on ß actin Normalized on ß-actin and GUS  
Name of target Ratio 
Sample vs 
Control   
Fold changes p-value Ratio 
Sample vs 
Control   
Fold changes p-value 
DDX6 0.86 - 1.16* 0.58 1.09  1.09  0.78 
HAT1 0.93 - 1.1* 0.74,  1.19  1.19  0.5 
HSP90ß 2.6 2.6 0.001 3.33 3.33 0.001 
COX-2 15.1 15.1 0.009 19.2  19.2  0.008 
OPN 49.32 49.32 0.001 62.62 62.62 0.001 
PKM2 1.79 1.79 0.015 2.28 2.28 0.006 
PLK1 1.92 1.92 0.18 2.45  2.45  0.07 
USP28 1.37 1.37 0.29 1.74 1.74 0.14 
eIF4E 0.97  -1.03* 0.89 1.23 1.23 0.2 
DEFA 1-3** 7.69 7.69 0.059 9.75 9.75 0.034 
DEFA 6 13.93  13.93  0.063 17.69 17.69 0.05 
 
* the value listed as negative corresponds to fold change down-regulation 
** DEFA 1-3 accounts for 2 genes, namely DEFA 1 and DEFA 3. So far no gene has been found for DEFA 2. 
 
Concluding remarks: 
In addition to the finding that ß-actin and GUS were similarly well suited to be used for 
calibration, the comparative analysis revealed that no considerable changes occurred when 
the expression data was evaluated to single or to combination of the two reference genes. 
Based on these observations as well as on the fact that ß-actin was also used as a loading 
(normalization) control for the protein assay, all gene experimental data were solely 
calibrated to one reference gene, namely ß–actin.  
 
 
 
 
 
 
 
 
 
 
 
Table 4-2   Summary of evaluated gene expression data for 12 ** targets using REST software. The raw data 
was normalized once on the single reference gene (ß-actin) and subsequently on combination of two reference 
genes (ß-actin and GUS). Moreover, the relative expressions in the “sample group” were compared with the 
expressions in the “control group”. Listed is the ratio, the corresponding fold change in the gene expression as 
well as the p-value derived from the performed statistical analysis. Marked in grey are the significant ones. 
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4.3. Individuality of the gene expression and changes in cancer 
The entire set of targets investigated in this work consists of genes encoding proteins 
involved in a broad spectrum of cellular processes such as translation initiation, cellular 
proliferation, mitosis and/or apoptosis (section 1.4, page 7). Moreover, all of them revealed 
altered expression in a wide variety of cancers, including colon cancer. However, gene 
expression analysis of fully blown carcinoma does not account for the expression alterations 
that are critical for the initiation and the development of the cancer. Therefore, qRT-PCR 
gene expression analysis of all 12 GOI in a patient-resolved manner was performed. Besides 
the classical combination of paired-normal and tumor tissue, also the matched normal near 
tumor and adenoma tissue samples were examined.  
For most of the investigated genes, the expression data was collected from 29 patients (two 
of the donors had only non-malignant colon tissues). The exception is the expression data of 
the alpha defensin molecules (DEFA 1-3 and DEFA 6), which were accumulated from 36 
patients in total, as 7 of them have been analyzed in the context of the early PhD work of 
Franziska Jahns (Department of Nutritional Toxicology, Institute for Nutrition, Friedrich-
Schiller-University Jena). 
For each of the selected genes, the fold changes in the mRNA expression when two paired 
groups of tissue were compared, the outcome of the performed Wilcoxon nonparametric test 
as well as the number of analyzed tissue pairs, were summarized in Table 4-3, page 44. Due 
to the fact that not all of the investigated objects had the entire set of tissues tested, the 
number of tissue’s pairs differs for any single combination assessed. The proportional 
changes in the expression for each gene between normal near tumor, adenoma and tumor 
colon tissue on one hand and normal tissue on another are presented in Figure 4-5, page 46. 
Each separate graph corresponds to one selected gene, where a single, colored bar displays 
the fold changes in the mRNA expression in different tissue’s types versus the expression in 
normal tissue. 
The analysis revealed that in regard to the expression alterations in tumor, OPN was the 
gene showing the highest and significant up-regulation in tumor compared to its expression 
in normal colon tissue. The OPN overexpression in cancer was of around 13 fold. The OPN 
elevation in tumor still remained high when compared with its expression in normal near 
tumor tissue (8 fold), see Table 4-3, page 44. The second most prominent group of genes in 
this study was the alpha defensins, namely DEFA 1-3 and DEFA 6, as well as COX-2. All of 
them showed moderate expression increase in fully blown tumors (ranged from 4 to 6 fold). 
The rest of the analyzed targets revealed relatively low gene expression alterations in 
malignant colon tissues. Thus, comparatively low (in the range of 2 fold), but significant 
increase in the expression of the affected, malignant colon tissues was detected for HSP90ß, 
PKM2 and PLK1 genes (Table 4-3, page 44). Although not considerable, such constitutively 
higher expression in tumor cells as compared to their normal counterparts, suggests that 
they are may be critical for tumor cell growth and/or survival, which has been speculated for 
the case of HSP90 by Isaacs et al. (124). 
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(denominator) 
Normal near Tumor
(denominator) 
Adenoma 
(denominator) 
Tumor 
(denominator) 
PKM2     
Normal 
(numerator) 
X    
 
Normal near Tumor 
(numerator) 
Fold changes, 1.11 
p= 0.22 
n=18 
X 
 
 
  
 
Adenoma 
(numerator) 
Fold changes, 2.96 
p= 0.0005 
n=12 
Fold changes, 2.4 
p= 0.002 
n=10 
X 
 
 
 
 
Tumor 
(numerator) 
Fold changes, 1.62 
p<0.0001 
n=27 
Fold changes, 1.57 
p= 0.0003 
n=17 
Fold changes, -1.54 
p= 0.001 
n=11 
X 
 
 
DDX6  
Normal 
(numerator) 
X    
 
Normal near Tumor 
(numerator) 
Fold changes, -1.4 
p= 0.035 
n=18 
X 
 
 
  
 
Adenoma 
(numerator) 
Fold changes, 1.14 
p= 0.8 
n=12 
Fold changes, 1.7 
p= 0.2 
n=10 
X 
 
 
 
 
Tumor 
(numerator) 
Fold changes, -1.15 
p= 0.2 
n=27 
Fold changes, 1.1 
p= 0.73 
n=17 
Fold changes, -1.06 
p= 0.52 
n=11 
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HAT1  
Normal 
(numerator) 
X    
 
Normal near Tumor 
(numerator) 
Fold changes, -1.13 
p= 0.13 
n=18 
X 
 
 
  
 
Adenoma 
(numerator) 
Fold changes, 1.64 
p= 0.014 
n=12 
Fold changes, 1.9 
p= 0.04 
n=10 
X 
 
 
 
 
Tumor 
(numerator) 
Fold changes, -1.08 
p= 0.8 
n=27 
Fold changes, 1.3 
p= 0.4 
n=17 
Fold changes, -1.8 
p= 0.08 
n=11 
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USP28     
Normal 
(numerator) 
X    
 
Normal near Tumor 
(numerator) 
Fold changes, 1.3 
p= 0.4 
n=18 
X 
 
 
  
 
Adenoma 
(numerator) 
Fold changes, 2.8 
p= 0.034 
n=12 
Fold changes, 1.71 
p= 0.06 
n=10 
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Tumor 
(numerator) 
Fold changes, 1.08 
p= 0.96 
n=27 
Fold changes, 1.05 
p= 0.92 
n=17 
Fold changes, -1.4 
p= 0.12 
n=11 
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HSP90ß   
Normal 
(numerator) 
 
X 
   
 
Normal near Tumor 
(numerator) 
Fold changes, 1.06 
p= 0.69 
n=18 
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Adenoma 
(numerator) 
Fold changes, 1.7 
p= 0.002 
n=12 
Fold changes, 2.7 
p= 0.006 
n=10 
X 
 
 
 
 
Tumor 
(numerator) 
Fold changes, 2.13 
p= 0.0009 
n=27 
Fold changes, 1.97 
p= 0.02 
n=17 
Fold changes, -1.34 
p= 0.64 
n=11 
X 
 
 
 
 
Table 4-3  Summary of the mRNA expression alterations when 2 paired groups of tissue are compared. The 
respective fold changes in the expression are indicated as well as the p-value (Wilcoxon test) which 
represents the significance in the mRNA expression differences of defined gene when two paired groups are 
compared. The negative value represents fold down-regulation compared to the group which is denominator 
in the ratio created; n denotes the number of pairs included in the computation analysis. 
 
RESULTS 
45 
 
 
 
 
 
Normal 
(denominator) 
Normal near Tumor
(denominator) 
Adenoma 
(denominator) 
Tumor 
(denominator) 
DEFA 6     
Normal 
(numerator) 
X    
 
Normal near Tumor 
(numerator) 
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p= 0.0073 
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p= 0.0007 
n=18 
Fold changes- 1.33 
p= 0.83 
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Tumor 
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Fold changes, 6.4 
p= 0.021 
n=33 
Fold changes, 1.15 
p= 0.78 
n=18 
Fold changes,  - 1.4 
p= 0.71 
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Normal 
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Normal near Tumor 
(numerator) 
Fold changes, -1.13 
p= 0.62 
n=18 
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(numerator) 
Fold changes, 1.88 
p= 0.03 
n= 12 
Fold changes, 1.94 
p= 0.02 
n= 10 
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(numerator) 
Fold changes, 1.04 
p= 0.95 
n=27 
Fold changes, 1.02 
p= 0.56 
n=17 
Fold changes, -1.65 
p= 0.01 
n=11 
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Normal 
(numerator) 
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Normal near Tumor 
(numerator) 
Fold changes, 1.83 
P= 0.0023 
N=18 
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(numerator) 
Fold changes, 3.2 
P= 0.04 
N=12 
Fold changes, 1.34 
P= 0.73 
N=10 
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Tumor 
(numerator) 
Fold changes, 12.94 
P<0.0001 
N=27 
Fold changes, 7.9 
P= 0.0003 
N=17 
Fold changes, 11.15 
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p= 0.16 
n=18 
X 
 
 
  
 
Adenoma 
(numerator) 
Fold changes, 4.05 
p= 0.03 
n=12 
Fold changes, 3.17 
p= 0.08 
n=10 
X 
 
 
 
 
Tumor 
(numerator) 
Fold changes, 4.11 
p<0.0001 
n=27 
Fold changes, 3.3 
p= 0.0003 
n=17 
Fold changes, -1.4 
p= 0.7 
n=11 
X 
 
 
PLK1  
Normal 
(numerator) 
X    
 
Normal near Tumor 
(numerator) 
Fold changes, -1.6 
p= 0.08 
n=18 
X 
 
 
  
 
Adenoma 
(numerator) 
Fold changes, 2.4 
p= 0.005 
n=12 
Fold changes, 5.6 
p= 0.006 
n=10 
X 
 
 
 
 
Tumor 
(numerator) 
Fold changes, 2.01 
p= 0.02 
n=27 
Fold changes, 2.8 
p= 0.03 
n=17 
Fold changes, -1.4 
p= 0.06 
n=11 
X 
 
 
 
RESULTS 
46 
 
 
 
DEFA 1-3
0
2
4
6
DEFA 6
0
30
60
90
eIF4E
-2
-1
0
1
2
OPN
0
5
10
15
COX-2
0.0
1.5
3.0
4.5
PKM2
0
1
2
3
PLK1
-2
-1
0
1
2
DDX6
-1.5
-1.0
-0.5
0.0
0.5
1.0
1.5
HAT1
-2
-1
0
1
2
HAT1
-2
-1
0
1
2
USP28
0
1
2
3
HSP90ß
0
1
2
Tumor vs NormalAdenoma vs NormalNormal near Tumor vs Normal
Fo
ld
 c
ha
ng
e
Fo
ld
 c
ha
ng
e
Fo
ld
 c
ha
ng
e
Fo
ld
 c
ha
ng
e
Fo
ld
 c
ha
ng
e
Fo
ld
 c
ha
ng
e
Fo
ld
 c
ha
ng
e
Fo
ld
 c
ha
ng
e
 
 
Figure 4-5  mRNA expression alteration in normal near tumor, adenoma and tumor tissues, respectively 
versus the normal tissue. Each separate graph represents the expression alterations for one single gene and 
every single bar depicts the fold changes of expression in defined tissue type, in respect to the expression in 
normal tissue. The fold changes are calculated as medians of the computed ratios between the relative 
expressions in the both tissue groups which are compared. The expression in normal tissue is always 
denominator. The outcome of the statistical analysis is presented in Table 4-3, page 44. 
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Furthermore, more surprising was the dramatic expression burst of DEFA 6, with 85 fold in 
benign adenoma over the expression in normal colon tissue. When compared with normal 
near tumor tissue, this expression remained very high as well, i.e. 61 fold. Such an increase 
in one single stage of colon cancer development makes the molecule comparatively strong 
genetic marker. However, the full potential of these data becomes only evident when it is 
presented in a patient resolved manner. Thus, Figure 4-6 summarizes the computed DEFA 6 
mRNA expression ratio between adenoma and normal as well as between tumor and normal 
colon tissue, obtained from each single individual with adenoma tissue. The patient’s 
characteristic such as age, gender, grade and stage of cancer are denoted below the figure.  
No consistent dependence of DEFA 6 expression ratios as a function of tumor grade and 
stage, age or gender has been detected. The ratios in adenoma as well as in carcinoma as 
compared to normal tissue vary more than 1000 fold indicating the individuality of each 
patient’s cancer.  
 
* One of the donors (67b) had two adenomas, therefore the figure shows 19 tissues. 
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Figure 4-6 Gene expression regulation of DEFA 6 mRNA in 18 individuals*. The patients are characterized 
for their age, gender, grade and stage of cancer. N.D. means that the stage/grade was not determined. The 
scale of the y axis is logarithmic. None of the patients has simultaneously down-regulated DEFA 6 in both, 
adenoma as well as cancer tissue. The dotted horizontal line at 1 indicates that DEFA 6 would be un-effected. 
For the first patient on the left, no comparison of adenoma with carcinoma was possible, since the donor had 
developed only adenoma. Of the 17 other samples, 13 revealed a higher expression in adenoma than in 
carcinoma, two cases (encircled) showed essentially no change and three objects (in rectangular boxes) had 
the highest expression in carcinoma. 
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In addition, in 12/18 cases (67%) DEFA 6 was overexpressed with more than 60 fold in 
adenoma (see Figure 4-6, page 47, the black horizontal line is empirical and separates all 
samples with overexpression of 60 or more fold from the rest of the samples). Most of the 
tumor tissues showed overexpression with less than 60 fold. 
In contrast to DEFA 6, rather low were the transcriptional levels of the rest of the analyzed 
antimicrobial alpha defensins (DEFA 1-3) along the normal-andeno-carcinoma axis. These 
observations were in agreement with the data derived from culture cell lines (section 4.8, 
page 69). Although low abundant, according to the performed nonparametric test, DEFA 1-3 
mRNA was significantly up-regulated, with 4 and 6.4 fold in adenoma and tumor colon 
tissue, respectively, when compared to the normal samples. Thus, independent of the 
common functional activity DEFA 1-3 appeared to not show expression effects, similar to 
this which DEFA 6 disclosed. This data indirectly confirm the fact that the transcription 
activation of the enteric and neutrophilic defensin-genes is regulated by diverse signaling 
pathways. 
In contrast to the alpha-defensins, the rest of the tested molecules showed gene expression 
alterations in adenoma tissue, compared to the paired normal colon tissue, in the range from 
“1.14” fold (for DDX6) to “4.1” fold (for COX-2), as most of them were significant. 
In addition, the analysis revealed that macroscopically normal colon tissue, adjacent to the 
tumor site has showed though not very substantial, some alterations in the mRNA levels of 
the genes analyzed, when compared to normal colon tissue. Exception is the significant 
moderate up-regulation of DEFA 6 (5.4 fold) in normal near tumor, compared to normal 
tissues. Those observations confirm that tissues, morphologically similar to normal tissue 
already have altered gene expression profile (125). 
 
Concluding remarks  
Gene expression alterations have been observed in normal near tumor tissues when 
compared to the respective normal colon tissues. This result indicates that tissue, 
morphologically appearing as normal, removed not so far away from the tumor site, 
possesses already modifications on gene expression level. Therefore, their analysis could be 
of high interest, in order to find molecules critical for the initiation and the development of 
cancer. 
To our knowledge this is the first study demonstrating the burst of DEFA 6 gene in human 
benign adenoma tissue samples, which immediately indicates its potential to be used as a 
marker for early premalignant stages of colorectal cancer and not solely as a marker for 
colon cancer detection. 
The analysis also disclosed that in comparison to the expression of DEFA 6, the 
transcription levels of DEFA 1-3 mRNA were relatively low across all the investigated 
tissues. Moreover, DEFA 1-3 do not show an expression effect, similar to that of DEFA 6 
gene. This data indirectly confirmed the fact that the transcription activation of the both, 
enteric and neurtophilic defensins is regulated by diverse signaling pathways.  
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In addition, the gene with the most prominent elevation in colon cancer is OPN with almost 
13 fold followed by DEFA 1-3, DEFA 6 and COX 2, which exhibited moderate increase in 
cancer. 
 
4.3.1. Extremely high expression levels of DEFA 1-3 mRNAs and 
undetectable DEFA 6 mRNA transcription in peripheral blood mononuclear 
cells (PBMCs). 
In the present work, several members of the alpha defensin family were analyzed, namely 
DEFA 1-3 and DEFA 6. Apart from their common functions in innate antimicrobial 
immunity, they are produced by different cell sources. While DEFA 1-3 are major 
component of the azurophilic granules of neutrophils, DEFA 6 is mainly produced by the 
Paneth cell of the small intestine. Thus, in order to confirm that the main sources of DEFA 
1-3- and DEFA 6-production are different, besides the analysis of colon tissues with 
different degree of cancer progression, total RNA isolated from leukocytes (peripheral 
blood mononuclear cells (PBMCs)) of healthy individuals was tested for transcription of 
alpha defensins.  
The expression levels of DEFA 1-3 and DEFA 6 mRNAs were examined in PBMCs derived 
from eight healthy patients by qRT-PCR. The analysis showed that in contrast to DEFA 6 
mRNA, which was not found to be expressed in the leukocytes, DEFA 1-3 genes were 
highly expressed in these samples. Moreover, it was observed that DEFA 1-3 expression 
varies drastically among the donors analyzed, (Figure 4-7). From extremely high as it was 
detected in patients (P) P1, P2, P3 and P5, DEFA 1-3 expression was converting to very low 
(P4, P6, P7, P8).  
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The observed high inter-individual variation in the DEFA 1-3 mRNA expression levels 
among all analyzed PBMC extractions is a consequence of the already reported high copy 
number variability (CNV) affecting the alpha- and beta-defensins genes clustered on human 
Figure 4-7  Inter-individual variability of 
DEFA 1-3 mRNA expression in PMBCs
derived from eight healthy patients (P). For 
better visualization, the scale was 
segmented. 
 
RESULTS 
50 
 
chromosome 8p23.1 (96; 126). An additional reason for the disclosed variability could be 
the demonstrated frequent absence of the DEFA 3 allele, which has been found missing in 
significant proportions of the individuals tested (127). However, when compared with the 
median of the relative expression in colon tissue, the median of DEFA 1-3 mRNA 
expressions in PBMCs were tremendously higher (with 7 to 8 orders of magnitude higher), 
(Figure 4-8). Notice that due to the lack of DEFA 6 expression in PMBCs, comparative 
analysis between the expression in leukocytes and colon tissues can not be performed. 
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4.3.2. Gene expression dependency on the age 
In the further investigation, it was analyzed whether and how the mRNA expression levels 
of the investigated genes correlate with clinicopathological characteristics of the colorectal 
cancer patients such as age, gender, grade and stage of tumor. 
Ageing is the main risk factor associated with cancer development (128). In order to analyze 
whether the GOI have an expression pattern dependent on the age of the analyzed subjects, 
Spearman correlation analysis was performed. The expression in normal as well as in cancer 
colon tissues was evaluated. The analysis showed that none of the investigated genes 
appeared to be altered in an age-dependent manner. However, slight positive but not 
significant correlation with the age was found for the expression of DEFA 6 in normal and 
tumor colon tissue, see Table 4-4, page 51.  
 
 
 
 
 
 
 
 
Figure 4-8  Median DEFA 1-3 mRNA 
expression in PMBCs from healthy 
donors as well as in non-, pre-malignant 
and malignant colon tissues derived from 
patients who underwent colorectal cancer 
surgery. On the top of each bar, the 
medians of the relative expression values 
are denoted. Due to the high variability in 
the expression levels, for better 
visualization the scale was segmented. 
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4.3.3. Analysis of expression levels in carcinomas according to the tumor 
grading  
The gene expression pattern was examined for dependency on the grade and the stage of the 
tumor. 
Tumor grade and stage are two different tumor classification systems. While the tumor 
grade categorize the cells in terms of how abnormal they look under the microscope and 
how quickly the tumor is likely to grow and spread, the determination of staging is based on 
complex of factors such as location of primary tumor, tumor size, number of tumors and 
lymph involvement. 
In this study, the grade of the entire set of samples derived from colorectal cancer patients 
was classified according the scale from 1 to 4, namely from Grade 1 (G1) to Grade 4 (G4). 
The cells of G1 tumors resemble normal cells, which tend to grow and multiply slowly. G1 
tumors are generally considered as the least aggressive in behavior, while G3 or G4 tumors 
do not look like normal cells of the same type and tend to grow rapidly and spread faster 
than tumors with lower grade.  
As mentioned above, the investigated defensin genes were analyzed in 36 patients in total 
(in 2 subjects no tumor tissue have been found, 1 patient had cancer, but the information 
about the grade on the tumor was missing and 1 subject was source of adenoma, but not of 
tumor tissue). From the 32 donors left, 3 were categorized as G1 tumor, 14 as G2, other 14 
as G3 and only one sample was classified as G4. Apart from them, for the rest of the 
investigated targets (genes), the data used for evaluation was derived from 29 patients. Two 
donors had no tumor tissue. From the remained 27 samples, 3 patients were diagnosed as G1 
tumor, 13 as G2 and 10 as G3, see Table 3-4, page 18. Further, by using the data from each 
Table 4-4  Spearman correlation analysis exploring the relationship between mRNA expression levels of 
defined gene of interest and the age of the donors. Spearman correlation coefficients and the respective p-
values are listed. None of the investigated genes showed significant correlation in their expression patterns 
with the age in non-malignant and malignant colon tissue. r range from -1 to +1 as r equal to 1 corresponds to 
perfect positive correlation. 
Expression in Normal tissue Expression in Tumor tissue  
Gene Spearman correlation 
analysis, p-value 
Correlation  
coefficient, r 
Spearman correlation 
analysis, p-value 
Correlation 
coefficient, r 
OPN 0.4  0.16 0.77  0.06 
COX-2 0.34  0.19 0.57 -0.12 
DDX6 0.84  0.04 0.68 -0.09 
DEFA 1-3 0.23  0.21 0.79  0.05 
DEFA 6 0.11  0.28 0.15  0.28 
eIF4E 0.68 -0.08 0.3 -0.21 
HAT1 0.60 -0.10 0.37 -0.18 
HSP90ß 0.43  0.15 0.33 -0.2 
PKM2 0.42  0.15 0.8 -0.05 
PLK1 0.57  0.11 0.44 -0.18 
USP28 0.32  0.19 0.61 -0.10 
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grading-group, linear regression analysis was performed. No significant deviation from zero 
was observed when mRNA expression of the investigated genes was compared with the 
grade of the tumor (data not shown). In addition to the linear regression analysis, Kruskal-
Wallis analysis was performed, to test whether the mRNA expression variations among the 
different grade-groups are significant. No significance was found (data not shown).  
Nevertheless, a tendency of increased OPN expression in patients with moderately (G2) and 
poorly differentiated (G3) tumors compared to those with well differentiated tumors (G1) 
was detected (Figure 4-9). This observation was in contradiction with the reported 
significantly lower OPN expression in poorly differentiated (G3) tumors compared to those 
with well (G1) or moderately (G2) differentiated carcinomas, which was explained by 
considering that in highly undifferentiated tumors the loss of cellular differentiation could 
be responsible for an increased reduction of the OPN expression (129). However, to draw 
statistically safe conclusions, more patient’s data per group must be collected and analyzed. 
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4.3.4. Analysis of expression levels in carcinomas according to the tumor 
staging 
The staging of the tumor was based on TNM system, where T specifies the extent of the 
tumor, N the extent of spread to the lymph nodes, and M shows the presence of metastasis. 
This TNM combination correspond to one of 5 stages, as stage 0 (S0) is carcinoma in situ 
(early cancer that is present only in the layer of cells in which it began) and stage 4 (S4) 
indicates that the cancer has spread to another organ. 
In the present study, the expression of DEFA 1-3 and DEFA 6 in tumor have been analyzed 
in 36 donors, but the expression of only 32 subjects were tested for stage-dependency (see 
page 52). 8 of them had S1 tumor, 7 were with S2, 11 with S3 and 6 with S4 pathologically 
staged tumors. For the rest of the investigated genes, only 26 patients with defined stage of 
cancer were tested, as 8 of them had S1 tumor, 6-S2, 9-S3 and only 3 presented cancer with 
stage 4 (S4). The lack of more data makes the indication of some tendency in the expression 
Figure 4-9  Tendency of increased OPN 
mRNA levels in G2 compared to G1. The 
graph shows the normalized level of OPN 
mRNA in samples from different tumor 
grades. The application of Spearman 
analysis, using each column of data, 
resulted in although not significant, but mild 
positive correlation coefficient of r=0.3, 
p=0.14. A r=1 gives a perfect correlation 
between the both data patterns analyzed. 
 
RESULTS 
53 
 
difficult. However, besides the Kruskal-Wallis test, linear regression analysis was 
performed. As the applied tests revealed, none of the genes investigated has shown any 
association between its expression and the stage of the cancer (data not shown). 
 
4.3.5. Gender and gene expression patterns in colorectal cancer 
All collected data in this study was divided into groups of males and females. Thus the 
mRNA expression differences between the two gender groups in normal as well as in tumor 
tissue obtained from patients who underwent colonoscopy was investigated by using non-
parametric Mann-Whitney test. The analysis revealed that the median expression of COX-2 
gene in normal tissue is significantly higher in males compared to females. Similar effect 
was observed regarding the median expression levels of OPN in tumor colon tissue (Table 
4-5 and Figure 4-10). For the rest of the genes, no specific tendency in the median 
expression between male and females was observed (data not shown). 
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Table 4-5 Comparison of the mRNA 
expression levels in males and females. 
mRNA expression levels of 12 GOI were 
analyzed. Mann-Whitney test was 
determining whether the expression 
differences between the both gender- groups 
were significant. Highlighted are the 
significant results. 
Mann-Whitney test, p-value Gene 
Normal tissue Tumor Tissue 
OPN 0,43 0,05 
COX-2 0,024 0,51 
DDX6 0,22 0,8 
DEFA 1-3 0,8 0,21 
DEFA 6 0,7 0,72 
eIF4E 0,3 0,2 
HAT1 0,14 0,5 
HSP90ß 0,23 0,28 
PKM2 0,7 0,18 
PLK1 0,46 0,35 
USP28 0,74 0,51 
Figure 4-10  Gender-dependent differences in the expression pattern of (A.) COX-2 mRNA in normal colon 
tissue and (B.) OPN mRNA in tumor colon tissue. The black horizontal lines in the boxes represent the median 
expression in the different gender groups. The outcome of the statistical analysis is presented in Table 4-5 
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4.4. Interplay of 12 target genes in individual patients. “Bar code” 
representation 
In the previous chapter the fluctuation in the expression profile of single target genes across 
all patients analyzed was investigated and it could be shown that at least some genes might 
be used to distinguish normal from tumor tissue. The predictive power was, however, not 
good enough for use in clinical applications. Therefore, in the present chapter, an attempt is 
made to use all 12 genes simultaneously for distinguishing normal from tumor tissues. Such 
genetic discrimination might support histological approaches as they are performed in the 
clinical routine. To facilitate such an analysis, for every individual donor, the combination 
of the expression patterns for the entire set of targets was visualized as a “bar code”.  
In order to present the meaning of the term “bar code”, the expression of 12 selected genes 
in 16 paired normal and tumor tissue samples, derived from randomly selected 8 patients, 
was evaluated. The outcome of the analysis is shown in Figure 4-11, page 55. Each column 
gives the sum of the expression of 12 genes in one individual donor for normal and tumor 
tissue, respectively. Each slice of the columns represents the contribution of a given single 
gene. Furthermore, the last column from each group represents the averaged expression 
among the 8 analyzed donors.  
The analysis shows that in normal tissue, the height of the columns, respectively the single 
gene’s contribution in this combination of genes was almost similar (Figure 4-11, A). This 
observation reflects a distinct similarity in the expression pattern of the 12 genes in normal 
colon tissues. Figure 4-11, B. shows the same data as Figure 4-11, A., but presented as 
relative value of each gene in percentage. As in Figure 4-11 A., the values in normal tissue 
were rather similar. In contrast, the tumor colon tissues showed extensive variability in the 
expression patterns. Apart from the stable slight up-regulation of HSP90ß and PKM2 genes, 
the expression variability appeared particularly due to the expression of OPN and DEFA 6 
and to a lesser extent, to the role of COX-2 which essentially did not contribute to the 
columns of the respective normal tissues, but it is clearly seen in a relatively moderate 
percentage of the tumor tissues analyzed (Figure 4-11, B). 
The expression variability in tumor is not a surprising observation since it is well known 
that neoplasms are predominantly heterogeneous and contain a variety of subpopulations of 
different cell types, with different metastatic potential (130). In addition to that, a recent 
study reported that for the case of colon cancer this inter-tumor heterogeneity is bigger than 
the intra-tumor heterogeneity (131). 
Indeed, in an empirical approach (using the expression data derived from randomly selected 
8 individuals, presented in Figure 4-11), by trial and error, the genes PKM2, HSP90ß, OPN 
and COX-2 were found to be those with the major impact for the discrimination between 
non-malignant and malignant tissues. Later on it came out that this result was verified by the 
performed in addition Principal Component Analysis (PCA), (section 4.6, page 61), where 
the same set of genes was found to be the “driving force” for achieving discrimination 
between the non-malignant, “N” and malignant, “T” colon tissues and/or vise versa.  
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Concluding remarks: 
The presentation of the gene expression data as a “bar code” can be a useful strategy to 
perform preliminary selection of gene targets, which can take a part in a further 
computational analysis in order to test whether efficient discrimination between blinded 
paired normal and tumor colon tissue can be performed.  
Figure 4-11  (A.) Cumulated gene expression of 12 targets in paired normal (N) and Tumor (T) tissue 
samples, derived from 8 subjects. The left group of columns shows the gene expression in normal tissue (N). 
The right group of columns shows the same set of data for tumor tissue (T). Every single patient is denoted 
with capital letter corresponding to the tissue type analyzed and number, designating the age of the 
investigated patient. In addition, the small types (letters) denote different patients with the same age. The last 
columns from each separated group illustrate the averaged expression across the subjects in the defined 
group. In contrast to the similar expression patterns in normal tissue, the columns showing the expression 
profiles of tumor tissues are markedly different in composition and in height; (B.) Percentage of contribution 
of the genes whose absolute expressions are shown in (A.).  
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4.4.1. Discrimination of normal and cancer tissue in 18 patients with 78% 
accuracy and no false negatives 
In order to verify the prominent role of PKM2, HSP90ß, OPN and COX-2 genes for their 
ability to distinguish non-malignant from malignant tissue, an independent set of 36 blinded 
samples, corresponding to paired normal and tumor tissues, derived from 18 patients was 
tested. 
To carry out the blinded study, a separate criterion (EgC), corresponding to any of the 
selected genes was designed. The EgC for certain gene (g) was computed by summing up its 
average expression ( E ), obtained from the normal tissue of the initial (learning) set of 8 
patients and the corresponding standard deviation (SD). The combined gene expression data 
for the learning set of 8 patients was already presented in Figure 4-11, page 55.  
 
SDEEgC +=    (1) 
 
where E  and SD are calculated by equations 2 and 3 as follows 
∑
=
=
N
i
iEN
E
1
1     (2) 
( )∑
=
−=
N
Ni
i EEN
SD 1    (3) 
 
where Ei is the relative expression of selected gene in sample i and N corresponds to the 
number of patients used for computation of the criterion. In our calculations N is equal to 8. 
The above performed calculation steps were applied to compute criteria for all four selected 
genes.  
Next, the ratio between the relative expression (Eg) of the selected genes for defined, 
unknown tissue sample and the computed criterion (EgC) of the corresponding gene (g) was 
calculated, see equation 4  
 
Rg = Eg / EgC    (4) 
 
where Rg is the ratio generated for a selected gene in single/defined tissue sample. 
 
In order to have comparable values, the estimated gene expression ratio (Rg) was converted 
to the fold-change (Fg) by using reciprocal transformation. Thus,  
 
if Rg ≥ 1, then Fg = Rg, while 
if Rg < 1, then Fg = -1/ Rg 
 
By this way, Fg adopts a positive value, when the expression of the selected gene in the 
defined tissue sample is higher compared to the corresponding criterion. Since the criterions 
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are based on the expressions of the genes in normal tissue, it is assumed that each positive 
value corresponds to a sample which revealed elevated gene expressions compared to that in 
normal tissue. This sample can be classified as a tumor. Correspondingly, Fg adopts a 
negative value, when the respective gene has a lower expression compared to the criterion. 
This would reflect the situation in the normal tissue. 
Next, in order to summarize the total expression impact of all selected genes in one 
unknown sample, the corresponding reciprocal values were summed up. 
 
SUM = FPKM2 + FHSP90ß + FOPN + FCOX-2    (5)  
 
where the index of each F indicates the gene for which this value was created.  
 
According to equation 5, a sample with a positive sum will be taken as cancerous 
(malignant) tissue, and respectively, sample with negative sum will be regarded as normal 
tissue. This procedure was applied to 36 blinded samples, derived from 18 patients. The 
outcome from the computational analysis is shown in Table 4-6, page 58. It demonstrated 
that 28 out of 36 samples, i.e 77.78% were correctly predicted with no reservation regarding 
the final outcome, and 8 samples, i.e 22.22% were incorrectly predicted (Table 4-6), marked 
in grey). Interestingly, they were all false positive, which means that they were estimated as 
tumor, although originally were derived from normal tissue. This fact can be counted as a 
distinct advantage of the analysis. It is for the sake of the false positive patient to undergo 
additional examinations and thus indeed to be verified that the examined tissue is normal 
and not tumor than to predict tumor as a normal tissue and skip the further examination 
procedures. On the other hand, in this analysis, not a single tumor would have escaped 
detection. 
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Concluding remarks: 
By trial and error, four genes were found to have a major impact for discrimination 
between non-malignant and malignant tissues, namely PKM2, HSP90ß, OPN and COX-2. 
Based of their expression patterns, an empirical approach has been developed. The latter 
accomplished correct prediction for the type of tested tissue of about 78%. 
 
Table 4-6 Listed outcomes from blinded study where 36 randomly selected samples from paired normal (N) 
and tumor (T) colon tissues were predicted according the defined criterions. The computed fold changes for 
the set of the selected genes (Fg), the sum of them and the predicted answers are listed. The latter were 
compared with the correct answers. Blinded sample, which possesses positive value for the sum of Fg is 
charged as a tumor and the sum with negative value, regard the sample as a normal. The marked in grey cells 
depict the wrong predicted blinded samples (22.22%). 77.77% were correctly predicted. 
Sample FHSP90ß FCOX-2 FOPN FPKM2 SUM Predicted 
Answers 
Actual 
Answer 
1 2.88 9.69 23.95 1.56 38.10 T T 
2 1.31 1.33 -1.02 1.29 2.90 T T 
3 1.72 -1.68 2.32 1.13 3.49 T N 
4 1.03 -1.96 -5.25 1.06 -5.12 N N 
5 -1.69 1.79 -5.92 -1.78 -7.60 N N 
6 -1.83 3.59 30.35 -2.68 29.43 T T 
7 1.78 4.43 65.75 1.38 73.34 T T 
8 1.45 7.82 2.23 -1.11 10.39 T N 
9 -1.67 -1.06 -1.24 -2.09 -6.06 N N 
10 1.99 29.50 45.06 1.16 77.72 T T 
11 1.71 -1.53 1.49 1.79 3.46 T T 
12 1.88 1.96 37.24 1.22 42.30 T T 
13 2.06 11.06 176.5 1.82 191.5 T T 
14 -1.40 -16.4 -34.7 -1.72 -54.2 N N 
15 -1.60 -37.1 -3.33 -1.95 -44 N N 
16 2.84 7.88 34.98 1.59 47.29 T T 
17 -2.21 2.04 3.48 -1.05 2.25 T T 
18 1.08 -1.27 1.09 -1.39 -0.48 N N 
19 -2.11 -1.28 1.67 -1.84 -3.56 N N 
20 1.16 1.23 4.07 -1.03 5.42 T N 
21 1.18 9.45 25.09 -2.15 33.56 T T 
22 -1.09 10.43 31.10 -1.48 38.95 T T 
23 2.42 2.39 19.26 1.21 25.28 T T 
24 2.56 8.04 77.65 2.41 90.65 T T 
25 1.53 -3.86 1.50 -1.06 -1.88 N N 
26 2.07 2.07 2.36 1.41 7.91 T N 
27 -1.27 -1.88 8.63 -1.93 3.53 T T 
28 1.73 -1.05 1.49 1.14 3.31 T N 
29 1.18 1.08 2.41 -1.06 3.59 T N 
30 2.46 -7.71 -1.01 2.98 -3.26 N N 
31 -1.54 2.31 -1.58 -2.74 -3.50 N N 
32 1.19 1.32 1.31 -1.48 2.33 T N 
33 2.13 3.65 3.31 1.04 10.14 T T 
34 3.37 31.62 728.5 1.67 765.2 T T 
35 7.26 1.72 50.69 1.64 61.31 T T 
36 -1.19 1.98 3.25 1.03 5.09 T N 
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4.5. Combined gene expression analysis of 12 GOI in Normal, 
Normal near Tumor, Adenoma and Tumor colon tissue across 26 
analyzed donors. Application of the Relative Expression Software Tool 
(REST) 
 
By applying REST, group-wise comparison of the relative expression of 12 selected genes 
in 4 different types of colon tissue obtained from 26 donors in total was performed. Non-
malignant, normal (N) tissues and malignant, tumor (T) colon tissues were derived from all 
26 donors, with histologically confirmed stages of colon cancer development. 18 of those 
objects provided normal near tumor (NnrT) and 12 of them - adenoma (A) tissue samples.  
For more detailed information about how the software works, refer to 3.2.5.3, page 31. In 
brief, after gene expression normalization, the REST software determines the expression 
alterations in the “sample groups” compared to the respective expressions in the “control 
group”. As a consequence, the evaluated data for each individual donor was plotted as a 
“bar code” presentation. For better display, the data was log transformed with base 2. 
(Figure 4-12, page 60).  In this graph, each colored slice of the column represents the ratio 
between the expressions of certain gene in the “sample group” and the respective expression 
in the “control group”. The first column of data, plotted on x-axis, symbolizes the 
expression of the entire gene set in the normal tissue, the so–called “control group”. In fact, 
the expression in the “control group” is equal to one since it was taken as a baseline in order 
to compute the expression’s changes in the “sample groups”. Therefore, when is log-
transformed the expression in the normal tissue crosses the zero line. Further, in Figure 
4-12, page 60 the “bar code” columns for individual donors with “NnrT”, “A” and “T” 
tissues are consecutively shown. The distinct tissue’s groups are separated from each other 
by empty space. In addition, for simplicity and better overview Figure 4-12 B, page 60 
summarized the medians of the log-transformed expression ratio computed across the 
donors for each defined tissue’s group. The slices of the bars above the zero line correspond 
to the genes which demonstrated elevated expression, compared to the expression in the 
“control group”, namely the normal tissue. Conversely, the genes exhibiting down-
regulation in comparison to the expression in normal “N” tissue are presented as slices 
below the zero line. The slices close to the zero represent genes with no change in the 
expression. 
The outcome from the REST computation revealed that the “NnrT” tissues, surgically 
removed from location approximately 5 mm away from the tumor and which are 
macroscopically proven to be benign showed already alterations in their expression profiles 
compared to the “N” colon tissue, removed at a distance 20 to 50 cm from the tumor side. 
This is in consistence with several previous studies where the presence of genetic changes in 
morphologically normal tissues derived from cancer patients was already reported. Loss of 
heterozygosity or microsatelitte instability were some of the observed alterations. However, 
it is still unclear whether these genomic modifications represent early precursors of the 
cancer, markers of increased risk, or simply population based polymorphisms (132; 133). 
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Nevertheless, the presented preliminary data is very useful, since the careful 
characterization and examination of the observed genetic alterations is necessary to 
understand the molecular changes possibly leading up to colon cancer development. 
The analysis showed that apart from the substantial inter-individual variations in the 
expression patterns, relative elevation in the expression of DEFA 1-3, DEFA 6 and to some 
extend OPN and COX-2 genes can be detected in “NnrT” tissues. These targets remained 
up-regulated also in “A” tissues (Figure 4-12, A and B, page 60), where the expression of 
DEFA 6 seems to be the hallmark for this tissue type (see detailed description is section 4.3, 
page 43).  
Notable is that all analyzed “A” samples were benign, although over time they can become 
malignant. Due to that reason, the detailed examination of their expression patterns would 
be an additional, useful source for better understanding the biology of the cancer.  
Furthermore, the expression of DEFA 1-3, DEFA 6, OPN and COX-2 genes remained 
elevated also in “T” tissue. Particularly over all patients, OPN and DEFA 1-3 expressions 
were higher in the “T” when compared to the respective expression levels in the “A” tissue 
(Figure 4-12, B, page 60). The elevated expression of these 4 genes during the cancer 
progression is not surprising, since many reports already proved their specific role in 
promoting the cell migration and proliferation (29; 34; 40; 97). Those features are typical 
for any malignant cell or cells derived from fast growing tissue as the adenoma. 
In addition to the up-regulation of DEFA 1-3, DEFA 6, OPN and COX-2, the expression 
profile of the examined 12 adenoma samples showed, relatively low but stable increase in 
the expression of PKM2, PLK1 and HSP90ß, which stayed relatively unchanged in cancer, 
“T” colon tissue. This observation is expectable since some of the investigated genes take 
part in processes such as cell proliferation, like PLK1, which drives the cells into mitosis 
and/or PKM2, which is target involved in glycolysis or as HSP90ß molecule, which is 
maintaining the homeostasis of the malignant cells in the hostel environment. All of those 
processes support the development of cancer. 
 
Concluding remarks 
REST computational analysis, combined with “bar code” representation is promising tool 
for presentation and evaluation of the expression data. 
 
4.6. Tissue discrimination by using Principal Component Analysis 
(PCA). 
In addition to the empirical “bar code” representation, simultaneous examination of the 
selected genes was performed by using PCA, (for detailed description refers to 3.2.5.2, page 
25). This statistical technique provides a way to achieve one of the main goals of this study, 
namely to identify those expression patterns, which most efficiently discriminate non 
malignant tissue from tissue with a defined stage of cancer. As a result, PCA allows a safe 
identification of the genes with the highest diagnostic value.  The analysis was carried out 
using the raw, not normalized expression data from all analyzed genes (including also the 
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reference genes) across all types of investigated tissues (normal, normal near tumor, 
adenoma and cancer). The outcome computed from the PCA is displayed in Figure 4-13, 
page 63. The different colors correspond to different types of tissue. The two dimensional 
image represents the first 2 out of 13 Principal Components (PCs) obtained after 
implementing the assay. In principal, the number of the computed PCs is equal to the 
number of variables (genes) analyzed. In the present study, however, the number of the PCs 
did not reflect the number of analyzed genes. The reason for this discrepancy was the 
mentioned above fact that only one primer pair was used to assay the expression of 2 
different genes with almost identical nucleotide sequences (DEFA 1 and DEFA 3). As a 
consequence, one of the 13 variables accounted for two investigated genes (DEFA 1 and 
DEFA 3). Thus, PCA computed 13 PCs corresponding to 14 genes (12 GOI and 2 HKG). 
Nonetheless, among the entire set of PCs. only the first two PCs are the most important one, 
possessing the highest eigenvalues. The eigenvalue measures the variance in all the 
variables which is accounted for by that component. The higher the eigenvalue, the larger 
the importance of the corresponding principal component should be. Thus, in Table 4-7 are 
listed the variance percentage and the respective eigenvalue for the entire set of principal 
components computed.  
 
 
 
The first two principal components accounted for 74% of the total variance in the original 
data and therefore they had the greatest impact in finding differences among the populations 
of the four different tissue types. 
In addition, an analysis of the loading of the two most informative principal components 
was performed to test, as to what degree the different original variables (genes) contributed 
to these components. The analysis showed that DEFA 6, DEFA 1-3; COX-2, OPN and to a 
lesser extend HSP90ß and PLK1 were the ones with the highest predictive contribution for 
tissue discrimination. The rest of the genes can be regarded as less critical for the further 
analysis (Figure 4-14, page 64). 
 
Table 4-7 List of the eigenvalues and the corresponding 
percentage of total variance accounted for by each 
principal component (PC) computed from the PCA of 14* 
analyzed genes across normal, normal near tumor, 
adenoma and tumor colon tissue.  
The principal component is a suitable combination of all 
14 investigated genes with different weights (In Figure 
4-14, page 64, it is shown how the 14* investigated genes 
contribute to PC1 and PC2, the most important principal 
components).   
* Notice that one primer pair was designed for 
simultaneous detection of 2 genes (DEFA 1 and DEFA 
3), because of their almost identical nucleotide sequences. 
PC Eigenvalue % variance 
1 29.01 50.05 
2 13.95 24.06 
3 7.1 12.24 
4 3.39 5.84 
5 1.60 2.76 
6 0.94 1.63 
7 0.73 1.26 
8 0.41 0.71 
9 0.28 0.49 
10 0.24 0.42 
11 0.15 0.26 
12 0.09 0.15 
13 0.07 1.12 
 
RESULTS 
63 
 
 
DDX6HAT1
HSP90ß
COX2
OPN
PKM2
PLK1
USP28
eIF4E
DEFA1-3
HD6
ßactin
GUS
-12 -8 -4 4 8 12
Component 1
-12
-9
-6
-3
3
6
C
om
po
ne
nt
 2
C
om
po
ne
nt
 2
 
 
The outcome of the PCA revealed a clear tendency of separation between the “normal”/”non 
malignant” colon tissue population (colored in green) and the respective 
“tumor”/”malignant” tissue population (colored in red) since the overlapping region 
between these two populations was relatively small. In addition, the trend of the adenoma 
population (colored in violet) to move in direction similar to that of the “tumor” one was 
also observed. Nevertheless, reasonable/solid conclusions about the discrimination of the 
“normal near tumor“ (colored in light blue) and “adenoma” (colored in violet) populations 
either from “normal” or from “tumor” populations was not worth to be built up. Therefore, 
these tissue populations were excluded from additional examinations. 
 
Figure 4-13. The Scatter Plot of the first Principal Component (PC1) versus the second most important 
Principal Component (PC2). Evaluated was the data from four different types of tissue. The green represents 
the “normal”, non-malignant population; blue – the “normal near tumor”; violet – the “adenoma” and the red 
color - the “tumor”, malignant group of colon tissues. A teaching version of this figure is given in the 
Material and Methods section, 3.2.5.2, page 25. 
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COX-2, OPN, HSP90ß and PKM2 safely distinguished normal from tumor tissue! 
 
The further efforts using PCA, focused on finding a set of genes by which the best 
discrimination between “normal/non-malignant” and “tumor/malignant” tissue population 
can be achieved. In order to do so, various sets of different combinations were assayed by 
PCA. Indeed, the best separation between those two populations was obtained when the 
expression of COX-2, OPN, PKM2 and HSP90ß were simultaneously analyzed. The PCA 
result is reported in Figure 4-15, page 65 together with the eigenvalues and variance 
percentages of the first two PCs which account for by 92% of the total variance of the 
original data. 
 
Figure 4-14 Combination of the 14* 
examined genes to PC1 and PC2, i.e. 
loading profiles. The higher the 
loading of the variables, the more 
this variable contributes to the 
variation accounted for by the 
principal component. The red arrows 
indicate the genes with highest 
weight.  
* DEFA 1-3 corresponds to two 
genes 
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One can immediately recognize that even in this two dimensional representation the large 
majority of data points is either in the red field (for cancer tissue) or the green field (for 
normal tissue). In a multidimensional representation, the discrimination power is even 
better. This result validates previous observations in this study, where by applying empirical 
approach, with trial and error, completely the same (identical) set of genes was selected as 
the most prominent one, achieving the best discrimination between malignant and non-
malignant colon tissue 4.4.1, page 56. 
 
Figure 4-15  Scatter Plot of the two most prominent principal components (PC). For performance of the 
computational anlysis, gene expression data of 4 genes, namely COX-2, OPN, PKM2 and HSP90ß across 
“normal” and “tumor” populations of colon tissue have been applied. The green block represents the 
“normal” population, the red – the “tumor” population. In addition, eigenvalues and the corresponding 
percentage of total variance accounted for by the first two most prominent PC are listed. 
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Concluding remarks: 
PCA was applied as a tool to analyze the multivariate gene expression data derived from 
normal, normal near tumor, adenoma and tumor colon tissues. The analysis verified that the 
selected combination of genes, namely HSP90ß, OPN, COX-2 and PKM2, is sufficient to 
significantly distinguish “normal/non-malignant” from “tumor/malignant” colon tissue 
populations. This finding is in consistence with an observation, previously reported in the 
present study, where empirical approach, with trial and error, achieved the same outcome. 
 
4.7. Direct comparison of gene expression data generated by qRT-
PCR with the data derived from NIH’s data base dbEST. 
 
The present investigation aims to test the predictive power of gene expression data derived 
from NIH’s data base dbEST, which collects expression results from a large number and 
variety of DNA microarray experiments. Therefore, a comparative analysis was performed 
between the gene expression data generated by qRT-PCR, across 26 paired/matched normal 
and tumor colon tissues, and the data obtained from the dbEST data base. Presently, dbEST 
provides information only for normal and tumor colon tissue. Unfortunately, data from 
intermediate tissues, such as normal near tumor and adenoma is not available and therefore 
they were not included into the analysis. Under investigation was the entire set of analyzed 
genes, except DEFA 1-3 and DEFA 6. No information about their expressions was found in 
the data base, neither for normal nor for tumor colon tissues.  
In order to carry out the comparative analysis, normalization of the data had to be 
implemented. According to the observations earlier discussed in this work (see section 4.1, 
page 35), ß-actin was used for calibration of the data obtained either by dbEST data or 
derived by qRT-PCR. The quantification of the relative expression was based on the 
expression ratio of the target gene versus the selected reference gene. Once the matter of 
normalization was clarified, the data for other genes can be taken without further 
precautions, except that they have to be obtained with the identical procedure as the ß-actin 
values. Therefore, a direct comparison of patient data, generated by qRT-PCR with the data 
base values could be performed. Generally, one can expect that normalized expression 
values for different genes are vastly diverse among patients. This is shown in Figure 4-16, 
page 67, where as an example, the variety in the HSP90ß expression pattern (derived by 
qRT-PCR) across 26 patients is presented in combination with the averaged expression 
obtained from dbEST data base. 
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Apart from the inter-individual variability and in order to facilitate the comparison between 
the gene expressions derived from the qRT-PCR and the dbEST data base, averaged gene 
expressions from the both different sources were combined and plotted in Figure 4-17, page 
68. In addition to the presentation of the data on a linear scale, for better visualization, the 
data was introduced on a logarithmic scale as well. This additional way for data description 
was necessary since, in fact the gene expression levels provided by qRT-PCR and dbEST 
data base, covered differences in the expression by more then 3 orders of magnitude. 
Therefore, by log transformation this wide range of values can be reduced and presented in 
a more manageable range. 
So far, the analysis revealed that dbEST database had no entries for the expression of 
DDX6, HAT1, USP28, OPN and COX-2 genes in normal tissue, while such data were 
available in regard to tumor colon tissue. Therefore, their expressions were counted as a 
zero. Thus, in Figure 4-17 A., page 68 the presented expression of these genes appeared on 
the zero line, while when the data was presented on logarithmic scale (Figure 4-17, B) these 
genes were not depicted at all. One plausible reason for the missing data in the database 
would be their relatively low transcriptional levels compared to the high expression level of 
well abundant genes. Therefore, their detection was impossible in terms of the applied DNA 
microarray approach, the source of the data in dbEST database. Such a low abundance (of 
the above mentioned genes) in normal tissue is in consensus with previous studies where, in 
the case of OPN and COX-2, the hardly measurable expression in normal tissue can be 
rapidly induced by tumor promoters, oncogenes, growth factors, cytokines and other stimuli 
(134-136).  
Figure 4-16  HSP90ß expression data generated by qRT-PCR and the averaged data provided from dbEST data 
base in normal and tumor tissue. Every rhomb symbol (♦) depicts the HSP90ß expression in one individual, 
obtained by qRT-PCR. For better visualization, the rhombs are connected. The left part of the graph illustrates 
the expression in normal tissue, the right - in tumor. The orange horizontal line represents the average values 
derived from dbEST database for hundreds to thousands of patients. 
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Similarly, the expression levels for those genes in normal tissue, measured by qRT-PCR 
were relatively low, when compared to the rest of the analyzed genes. This is more 
observable when the data were plotted on a linear scale (Figure 4-17, A., page 68). Thus, 
indeed the agreement between dbEST and qRT-PCR for those genes in normal tissue was 
quite reasonable. Moreover, the agreement in the case of HSP90ß, PKM2, PLK1 and eIF4E 
genes was excellent. The difference in the expression between the qRT-PCR and dbEST 
sources was relatively low (between 1 to 3 folds), which in term of the different approaches 
used for determination on the gene expression is already quite precise. 
Further, the predictive power of dbEST for cancer tissues is somewhat lower, but still good. 
One explanation, which could elucidate those disagreements, is that the database averages 
huge data over all subclasses of colon cancer, while the qRT-PCR data were generated from 
a cohort with a narrower spectrum of colon cancer stages. The estimated differences in the 
determined expressions between the qRT-PCR and the dbEST data base for tumor, in 
respect to PLK1, PKM2, OPN and DDX6 genes were from 5 to 8 fold. Nevertheless, these 
poor results are still useful, because although not considerable, for almost all genes the 
expression’s tendency between normal and tumor colon tissue remains the same, no matter 
which source has been used for evaluation. However, in respect to DDX6, general 
discrepancy in the expression profile, between normal and tumor tissue, was observed. In 
contrast to dbEST, where DDX6 was increased in malignant tissues, according to the qRT-
PCR approach, DDX6 showed to be down-regulated in cancer when compared to the normal 
tissue (among 26 donors). In spite of that fact, the agreement with the database for the rest 
of the analyzed genes (HAT1, HSP90ß, COX-2, USP28 and eIF4E) was very good, as the 
prediction was quite precise, in a range of 2 fold differences. 
 
4.8. Gene expression in cell lines 
In vitro cell models play an important role in understanding cellular events related to 
(patho)physiological conditions in humans. Therefore, they are widely used to address 
specific research questions, though their cellular metabolism alters drastically compared to 
physiological conditions (137). Furthermore, the cultured cells are relatively simple working 
models in comparison with the in vivo system, where the influence of different neighboring 
cells, neuro(endocrine) regulators and blood flow is present. So far, it is not clear whether 
cells in culture retain the gene expression profiles of their in vivo counterparts. A study 
analyzing the gene expression patterns in 60 human cell lines, including colon cancer cell 
lines, disclosed that the tissue, the cell lines are derived from, is the main factor accounting 
for the variation in the gene expression (138). Moreover, a recent report designed to 
compare protein expression profiles of two colorectal cancer cell models with their in vivo 
counterparts revealed that despite the consistence in the expression of several biologically 
significant proteins, many discrepancies appeared (137). Thus, care should be taken to 
prevent misinterpretation on in vitro obtained findings when translating them to the in vivo 
situation. 
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In the present study, gene expression analysis of all analyzed targets was performed in three 
colon cancer cell lines, representing different stages of carcinogenesis, namely one 
colorectal adenoma (LT97), and two carcinoma (HT29, SW480) cell lines (Table 3-1, page 
16). qRT-PCR was applied to three different extractions from the same cell line as the gene 
expression pattern of each extraction was measured in duplicate or triplicate. The expression 
of ß-actin gene was used for normalization. The outcome of the analysis is shown in Figure 
4-18. The fold changes in the expression among the lines as well as the estimated 
significance according to the performed One-way ANOVA test followed by Tukey post test 
are listed in Table 4-8, page 71. 
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According to the test, the highest significant expression differences were found in regard to 
COX-2 gene. SW480 cell line showed extremely low COX-2 expression compared to LT97 
and HT29 cell lines with almost 39 fold and 57 fold, respectively. Furthermore, a significant 
moderate increase of 6 fold was observed for USP28 and HAT1 in SW480 compared to 
HT29. USP28 was also 6 fold significantly elevated in SW480 in contrast to LT97. Another 
gene which showed extremely high expression alterations was OPN. Considerably high 
although not significant was the down regulation of OPN (with 66 fold) in SW480 
compared to HT29. On the other hand, HT29 exhibited 36 fold (insignificant) increases in 
OPN expression versus LT97. 
Apart from DEFA 1-3 and DEFA 6, which are separately described below, the rest of the 
genes showed relatively small alterations in their expression, and most of them were 
insignificant (Table 4-8, page 71).  
 
 
 
 
Figure 4-18  Cumulated averaged 
gene expression of 12 genes of 
interest in three cell lines, 
representing different stages of 
carcinogenesis.  
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*for the case of DEFA 1-3 only 2 groups had to be compared, therefore unpaired t-test was used 
 
 
DEFA 1-3 and DEFA 6 expression in cell lines 
Since HT29 lacked the expression of all defensins analyzed (DEFA 6 and DEFA 1-3) as 
well as DEFA 1-3 was missing in LT97 cells, the expression of those targets was screened 
in three additional colon cancer cell lines, namely - Caco 2, HCT116 and SW620 (Table 
3-1, page 16). 
 Comparison between two 
different cell lines 
Fold changes One way Anova, with Tukey post test 
 
PLK1 
HT29 vs LT97 
SW480 vs LT97  
SW480 vs HT29  
1.05 
1.54 
1.46 
P > 0.05 
P < 0.05 
P > 0.05 
 
COX-2 
HT29 vs LT97 
SW480 vs LT97  
SW480 vs HT29 
1,47 
-38,6 
-56,5 
P > 0.05 
P < 0.05 
P < 0.01 
 
PKM2 
HT29 vs LT97 
SW480 vs LT97  
SW480 vs HT29 
-2.44 
 1.23 
 3.00 
P > 0.05 
P > 0.05 
P > 0.05 
 
OPN 
HT29 vs LT97 
SW480 vs LT97  
SW480 vs HT29 
35.62 
-1.86 
-66.27 
P > 0.05 
P > 0.05 
P > 0.05 
 
HSP90ß 
HT29 vs LT97 
SW480 vs LT97  
SW480 vs HT29 
-1.37 
1.53 
2.1 
P > 0.05 
P < 0.01 
P < 0.001 
 
HAT1 
HT29 vs LT97 
SW480 vs LT97  
SW480 vs HT29 
-3.15 
 2.1 
6.55 
P > 0.05 
P < 0.05 
P < 0.01 
 
USP28 
HT29 vs LT97 
SW480 vs LT97  
SW480 vs HT29 
1.06 
6.02 
5.69 
P > 0.05 
P < 0.001 
P < 0.001 
 
eIF4E 
HT29 vs LT97 
SW480 vs LT97  
SW480 vs HT29 
-3,07373 
-2,11274  
1.45 
P < 0.01 
P < 0.05 
P > 0.05 
 
DDX6 
HT29 vs LT97 
SW480 vs LT97  
SW480 vs HT29 
-1,90 
-1,39 
 1.37 
P > 0.05 
P > 0.05 
P > 0.05 
 
DEFA 1-3* 
 
 
 
 
SW480 vs Caco 2  
 
N/A in HCT116 
N/A in LT97 
N/A in HT29 
N/A in SW620 
-1.1 
N/A 
N/A 
 
 
 
 
P > 0.05 
 
 
DEFA 6 
 
 
SW480 vs LT97   
Caco 2 vs LT97  
SW620 vs LT97 
SW480 vs Caco 2 
SW620 vs SW480 
SW620 vs Caco 2 
N/A in HCT116 
N/A in HT29 
-25.25801312 
-191.0804709 
-5222.838032 
-7.565142593 
-206.7794488 
-27.33318589 
 
 
P > 0.05 
P > 0.05 
P > 0.05 
P > 0.05 
P > 0.05 
P > 0.05 
Table 4-8  Listed are the fold changes in the gene expression when two different cell lines were compared as 
well as the outcomes of the performed One-Way ANOVA test followed by Tukey post test. Marked in grey are 
the differences computed as significant; N/A- not available data 
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Besides the lack of DEFA 1-3 in LT97 and HT29, the gene was also not detected in 
HCT116 and SW620 cell lines. In agreement with Zou et al. very low, but still measurable, 
was the DEFA 1-3 transcription in SW480 (92). However, the expression was several orders 
of magnitude lower than the one detected in peripheral blood mononuclear cells (PBMCs). 
Only in one out of three Caco 2 extractions, DEFA 1-3 was found. Furthermore, similar to 
the observations of several groups (97; 139), deviations in the levels of expression not only 
among the different cell lines, but also in extractions from different time periods within one 
cell line were detected. Still the reason for these alterations in the transcriptional regulation 
of DEFA 1-3 is unknown. However, Agerberth et al. suggested that this could be explained 
by instability of an important transcription factor needed for alpha –defensin expression 
(139).  
In regard to DEFA 6, additional to its lack in HT29, the gene was not found in HCT116 and 
PBMC. The latter observation was also not surprising, because the Paneth cells and not the 
leukocytes are the main source of DEFA 6 expression (94). Among the rest of the analyzed 
cell lines, LT97 cell line, which possesses genetic alteration characteristics of early 
adenoma in vivo (Table 3-1, page 16), revealed higher DEFA 6 expression. In SW480, Caco 
2 and SW620 cell lines the defensin transcription was lower.  
Moreover, it was also observed a deviation in the relative mRNA expression, in the range of 
1.2 to 22 fold, between different extractions obtained from one cell line. In this regard, 
besides the above mentioned explanation, it has also been reported that, with time in culture, 
Caco 2 undergo spontaneous cell cycle arrests and simultaneous spontaneous differentiation, 
linked with down-regulation of Wnt/ß-catenin/Tcf signaling (140), which has been 
suggested to activate the transcription of DEFA 6 gene. Thus, with the time in culture, Caco 
2 can diminish the already low DEFA 6 expression to levels which are undetectable using 
this type of assay. A very low, but still detectable expression level was observed in SW620, 
as in one of the three cell extractions, DEFA 6 expression was below the detection limit. 
This result was in agreement with the report from Nam et al., 2005 where the expression of 
the Paneth specific defensin gene was confirmed in SW480 and SW620 cell lines (93). 
Furthermore, since the relative expression of all 12 investigated genes in cell lines as well as 
in colon tissues was calculated in the same way, using the same normalization control, 
direct comparison between the gene expression patterns in colon tissues and cell lines was 
performed. Gene expressions in adenoma and tumor tissue (derived from patients with 
colorectal cancer) were compared with the respective expressions in LT97 (adenoma), 
HT29 and SW480 colorectal cancer cell lines. HT29 and SW480 cell lines represent 
different grades of colorectal cancer and therefore their expression for a defined gene was 
averaged, in order to be compared, with the evaluated expression in human tumor tissue, 
which indeed collects cancers with different stages as well. Thus, bar code representation 
was used to illustrate the combined expression patterns of all investigated genes in a certain 
type of tissue and/or cell line, see Figure 4-19, page 73. 
The analysis revealed big expression differences between the examined adenoma and tumor 
colon tissue on one hand and the corresponding colon cell lines on the other hand, in respect 
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to OPN, DEFA 1-3 and DEFA 6 genes. The relative OPN expression in adenoma and tumor 
tissue was more than 320 fold higher compared with the OPN expression in LT97 and the 
averaged expression in SW480 and HT29 cell lines. As mentioned above, DEFA 1-3 
expression was not detected in LT97, whereas the gene was amplified in adenoma tissue. 
The presence of DEFA 1-3 in tissue can be also a consequence of invading neutrophils (92; 
99). However, DEFA 1-3 was found in SW480 and HT29, but it was considerably low (47 
fold) compared to the respective expression in patient-derived tumor tissue.  
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In addition, the expression of DEFA 6 in adenoma and tumor tissue was much higher (>58 
fold) than the respective expression in LT97 and the averaged expression in SW480 and 
HT29 cell lines. 
Furthermore, the rest of the genes (PKM2, eIF4E, PLK1, DDX6, USP28, HAT1, HSP90ß, 
COX-2) showed comparably the same expression levels in LT97 cell line and adenoma 
tissue. The observed expression changes were in the range of 2 fold (note that 1 fold 
indicates no changes in the expression). Higher differences in the expression (of about 3.4 
fold) were found when colon cancer tissues were compared with the averaged expression of 
HT29 and SW480 colon cancer cell lines. This observation could be expected, since the 
expression data obtained from tumor tissue reflects the expression pattern of pool of cancers 
with different clinicopathological characteristics (stage, grade, gender of the patients). 
 
Concluding remarks  
The comparative analysis of gene expression data derived from human tissues and cell lines 
revealed that the expression levels of OPN, DEFA 1-3 and DEFA 6 genes in cultured cells 
differ drastically from those observed in colon tissue samples. Thus, the found discrepancies 
between the expression patterns have to be further considered if in vitro results are 
Figure 4-19  Combined relative expression of all investigated genes (see the legend of the figure) in colon 
tissues obtained from colorectal cancer patients (adenoma and tumor) and cell lines, representing different 
stages of colon cancer development. 
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evaluated. In contrast, the rest of the investigated genes showed relatively similar 
expression levels in cell lines as well as in tissue samples. 
 
 
4.9. Combined gene – and protein expression analysis of paired 
normal and tumor tissue, derived from patients with colorectal cancer. 
 
In order to examine whether during cancer development, mRNA abundance of a defined 
molecule correlates with the respective protein levels, mRNA and protein profiling 
approaches were applied in parallel. 
A number of proteins, namely HSP90ß, eIF4E, DDX6, PKM2 and COX-2, were analyzed 
for their expression profile in paired normal and tumor colon tissues. In total, 12 patients 
were included in the investigation. However, the computational analysis of DDX6 was 
performed based only of data derived from 6 out of the 12 tested donors. Representative 
Western blots are shown on Figure 4-20. 
 
ß-actin
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HSP90ß
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ß-actin
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ß-actin
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In order to calculate the expression level of the Western blot-analyzed protein in defined 
tissue samples, densitometric measurement of its band intensity and the corresponding ß-
actin (applied as a loading (normalization) control) was performed. Thus, Figure 4-21, page 
75, column B showed the computed relative protein expression for each individual patient, 
in the respective normal and tumor colon tissues. In addition to the relative protein 
expression, for better comparison, Figure 4-21, column A, also shows the relative gene 
expression, obtained by qRT-PCR, for paired normal and tumor colon tissues derived from 
the same patients, who were under Western blot investigation. 
 
Figure 4-20  Western blot analysis demonstrating the expression of (A.) eIF4E, HSP90ß, PKM2, (B.) DDX6 
and (C.) COX-2 in paired normal (N) and tumor (T) colon tissues derived from colorectal cancer patients. 
Equal protein loading was confirmed with a ß-actin antibody. 
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Normal Tumor
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0
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0
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0
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0.15
0.20
0.25 **
 
Figure 4-21   Relative gene– and protein–expression in paired normal and tumor colon tissue. Column A. 
Graphs, showing the relative mRNA expression of defined genes across individual patients, Column B. 
Graphs, showing relative protein expression levels, for each single donor, computed after performance of 
densitometric analysis of the Western blot. For all experiments, ß-actin expression serves as a normalization 
control. Each symbol represents the relative expression in individual patient as samples which belongs to 
different tissue groups, but were derived from the same donor are connected to each other. The significant 
expression differences in tumor with respect to expression in normal tissue are denoted (**, < 0.01; ***, 
<0.001); n indicates the number of donors included in the analysis.  
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The significance of the gene- and protein-expression differences between the two analyzed 
tissue’s groups was tested by Wilcoxon matched paired test. Table 4-9 summarizes the 
respective outcomes. 
 
 A. Fold changes in the relative GENE 
expression in tumor compared to normal tissue
B. Fold changes in the relative PROTEIN 
expression in tumor compared to normal tissue
DDX6 1.95, p= 0.56, n=6 1.2, p= 1, n=6 
HSP90ß 2.97, p= 0.001, ***, n=12 1.00, p= 0.91, n=12 
PKM2 1.81, p= 0.0034, **, n=12 1.11, p= 0.20, n=12 
eIF4E 1.08, p= 0.97, n=12 1.01, p= 0.73, n=12 
COX-2 26.4, p= 0.0005, ***, n=12 Densitometric measurements not performed 
 
 
Densitometric measurements of the Western blots and computation of the corresponding 
expression levels were performed for all proteins included in the comparative analysis, 
except for the case of COX-2. Only one of the tested 12 donors exhibited extremely high 
COX-2 expression in tumor tissue (Figure 4-20, C, page 74), the rest of the samples 
disclosed very weak or not detectable COX-2 signals, especially for samples obtained from 
normal tissues. Therefore, performance of accurate densitometric measurement was not 
achievable. As a consequence, the comparison between gene and protein expression levels 
of COX-2 molecule was not further carried out. However, general elevation of COX-2 
protein in tumor was monitored. Similar expression tendency was observed on gene 
expression level, where COX-2 mRNA, for the same 12 selected patients, was elevated in 
tumor (26 fold) compared to related normal tissue. According to the performed statistical 
test, the increase was significant, (Table 4-9).  
Besides the fact that the computed protein expression differences were not significant, the 
entire subset of investigated proteins did not show any expression alterations in tumor 
compared to normal tissue. In contrast, DDX6, HSP90ß and PKM2 genes revealed slight 
expression elevation in tumor, as for HSP90ß (2.97 fold) and PKM2 (1.81 fold), the 
detected expression changes were computed as statistically significant.  
Furthermore, the built up gene and protein expression ratios between tumor and normal 
tissue, for defined molecule of interest, were combined and plotted in a patients-resolved 
manner (Figure 4-22, page 77). The analysis disclosed that HSP90ß mRNA and protein 
expression ratios are relatively stable among all patients analyzed (except one patient) 
(Figure 4-22 A). However, it should be noticed that although stable the HSP90ß gene and 
proteins expression ratios were in different ranges. While the values for most of the gene 
expression ratios were above 2, the protein ratios were about 1, which indeed indicated that 
the protein expressions between normal and tumor tissue did not differ. In addition, the 
Table 4-9  Fold changes in the relative expression on gene (column A) and protein (column B) expression 
levels and the respective outcomes (p-values) from the performed non-parametric Wilcoxon matched pair 
test. The marked in grey fold changes are significant; n indicates the number of patients included in the 
computational analysis. 
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eIF4E expression ratio revealed considerable inter-individual variability on gene expression 
level, which was evened down on protein level (Figure 4-22, B). For the rest of the analyzed 
targets the data was too noisy to be interpretated (Figure 4-22, C and D). Therefore, more 
experiments and data points are needed in order to confirm and put on a more solid base the 
already found expression tendencies and/or to be able to make more clear assumptions 
regarding the molecules which  presently did not show any tendency in their gene- and 
protein- expression patterns. 
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Figure 4-22  Combined and plotted in a patients-resolved manner are the gene and protein expression ratios 
between normal and tumor tissue, for (A.) HSP90ß, (B.) eIF4E, (C.) PKM2 and (D.) DDX6 molecules. Each 
symbol denotes either gene (■) or protein (▲) expression ratio in individual patient (P). For better 
visualization, the gene expression ratios among the all analyzed patients are connected. Ratio equal to 1 
indicates no differences between the expression levels in tumor and normal tissue (broken horizontal line 
crosses the y-axis at 1); n indicates the number of analyzed patients. 
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Concluding remarks: 
The combined analysis of gene and protein expression data revealed that among all 12 
patients tested, the HSP90ß and PKM2 genes showed relatively low, but significant 
amplification in tumor tissues. On the protein side, however, no changes in the expression 
were found. Further, when the data were evaluated in a patient-wise manner, the HSP90ß 
mRNA and protein expression ratios, between normal and tumor tissue, showed to be 
relatively stable among all analyzed patients. However, the value of these expression ratios 
differed. In contrast, eIF4E disclosed higher inter-individual variability of the ratios on the 
mRNA level which was evened down on the protein level. All these observations can be a 
consequence of either a possible post-transcriptional/translational regulation and/or 
instability of the protein in the tumor cell or can be due to a smaller sensitivity of the 
protein assay to detect small expression differences. 
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5. DISCUSSION 
5.1. ß-actin and GUS as housekeeping genes are stably expressed in 
colon tissues. No need of multiple normalization strategy! 
 
Accurate normalization of the gene expression level is an absolute requirement for reliable 
results, especially when the biological significance of subtle gene-expression differences is 
studied. A number of reports have shown already that housekeeping gene expression can 
vary considerably not only among different types of tissue, but also among different disease 
states and/or different treatments (118-121). As a consequence, misinterpretation of the 
outcome can occur (123). Therefore, in order to find the most appropriate internal 
normalization control, many groups started to evaluate the gene expression variability of 
classically used housekeeping genes among various types of tissue and disease states (118; 
121; 141). Moreover, the application of multi-normalization strategy, where 2 or more 
housekeeping genes from different functional classes are used, becomes widely used (123). 
In the present study, apart from the normalization to the amount of total RNA added to each 
reaction, two widely used housekeeping genes, which are involved in different cellular 
processes, namely ß-actin and ß-Glucuronidase (GUS), were selected to serve as an internal 
reference control. Whereas GUS takes part in carbohydrate metabolism, the ß-actin gene 
corresponds to a molecule comprising part of the cytoskeleton network. This functional 
independency makes them suitable to be applied as endogenous controls for calibration, 
since it is likely that they are not co-regulated.  
The analysis, carried out in this study showed that apart from their different cellular 
abundance (Figure 4-1, page 36), ß-actin and GUS possessed minimal variance in their 
expression patterns across all patients analyzed, independent of the type of colon tissues 
investigated (Table 4-1, page 38 and Figure 4-2, page 37). This observation is in agreement 
with previously published data from Rubie et al., where relatively stable expression of ß-
actin and GUS in paired tissue derived from colon cancer patients has been demonstrated 
(118). Similar findings were described by Blanquicett et al. who reported that GUS is one of 
the least variable housekeeping genes among a set of others analyzed endogeneous controls, 
in paired normal and cancer colon tissues (119). Aerts et al. also demonstrated that apart 
from 18s rRNA, ß-actin and GUS have the best expression stability across 26 tumor cell 
lines tested, including colon cancer cell lines as well (142). Further, the performed Pearson 
correlation analysis displayed that both calibration genes disclosed correlation in their 
expression patterns among all colon tissue types, except the adenoma colon tissue, which 
probably can be explained by the small number of samples (n=12) included in the 
calculation (Figure 4-3, page 39). Moreover, the transcriptional levels of ß-actin and GUS 
were not significantly influenced by age or gender of the objects, which make them suitable 
to be used for further normalization of the gene expression data. 
When the transcription levels of the gene of interest were normalized to a single or to a 
combination of the two reference genes, only inconsiderable differences in the computed 
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outcomes occurred. This observation, together with the above described findings permit the 
usage of only one single gene for further normalization of the entire set of investigated 
genes. Thus, in an agreement with many other gene-expression reports (143-145), ß-actin 
was selected to be used as an internal control. This choice was supported by the fact that this 
HKG also serves as a loading control for protein expression analysis. 
 
Conclusions: 
Apart from the lack of 100% reliable internal control, many contradictory observations 
have been reported regarding the expression stability of one housekeeping gene among 
different tissue types. These findings emphasize the need to select and validate proper 
endogeneous control for each tissue under investigation as well as for each experimental 
condition prior the analysis. Thus, in the present study, the choice for such reliable 
normalization control was the ß-actin molecule, which was used for normalization of the 
protein expression data as well. 
 
5.2. A burst of alpha defensin 6 expression in adenoma stage of 
human colon carcinogenesis 
One of the main discoveries in this work was the unexpected extremely high increase of 
DEFA 6 gene expression in benign adenoma tissues over the normal tissues, obtained from 
patients with colorectal cancer. With almost 85 fold, DEFA 6 was shown to be 
overexpressed in adenoma tissue when compared to the respective normal tissue. In 
contrast, comparably low was the elevation in its expression in tumor over the normal tissue 
(5.8 fold), (Table 4-3, page 44). 
DEFA 6 as well as the other analyzed neutrophilic molecules (DEFA 1-3) belongs to the 
alpha defensin subfamily. All of these defensins are well known as antimicrobial peptides in 
the host defense of the gut and none of them was detected in healthy colon, but solely in 
chronically inflamed colon tissue (90; 94). Under chronic condition, constitutive activation 
of NF-ĸB occurs, which in turn can promote cancer development through enhanced cellular 
proliferation and inhibition of apoptosis (108). One of the many malignancies known to be 
initiated by this way is the inflammatory bowel disease (IBD)-associated colon cancer, 
though with low percentage, but with higher mortality than the sporadic forms (146).  
Alpha defensin expression was tested in different types of samples, derived from colorectal 
cancer patients, such as stool (92), serum, plasma (90; 91) and colon tissue (89; 92; 99). The 
latter sample type consists of a mix of different cell populations such as epithelial cells, a 
small percentage of fibroblasts and leukocytes.  
Widely spread is the knowledge that neutrophils are the main source of DEFA 1-3 and this 
was confirmed in the present study for leukocytes (PBMCs), obtained from healthy 
individuals, where an expression with several orders of magnitude higher than in all colon 
tissues and cell lines has been found (Figure 4-8, page 50). Therefore, the assumption that 
the elevated DEFA 1-3 expression in tumor tissues may be better explained with the 
invasion of neutrophil leukocytes rather than with the defensin production in the cancer cells 
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themselves seems reasonable (92; 99). In contrast to these reports, other research groups 
showed that although less pronounced than in neutrophils, DEFA 1-3 are also expressed in 
malignant colon cells (90; 101). However, it is still unclear how the malignant cells 
themselves influence the elevation of DEFA 1-3 expression in cancer tissues. It was 
reported, for example that DEFA 1-3 may stimulate bronchial epithelial cells to up-regulate 
interleukin-8 (IL-8) production, which then can modulate the transcriptional activation of 
DEFA 1-3. Therefore, it was speculated that DEFA 1-3 increase in tumors may primarily 
originate from invading immune cells, but initiated by DEFA 1-3 producing cancer cells 
(91; 147). 
Apart from the very high expression in leukocytes (PBMC), the results presented here 
showed a low, but significant DEFA 1-3 expression in premalignant, adenoma stage of 
colon cancer as compared to the corresponding normal tissues (4.01 fold). Increased DEFA 
1-3 transcription was found in tumor tissues as well (6.4 fold). However, our results verified 
the general observation of DEFA 1-3 elevation in colon tumors, see Table 4-3, page 44.  
In contrast to DEFA 1-3, DEFA 6 mRNA was not detected in PBMCs. This is not 
surprising, since it is well known that the main producers of DEFA 6 are the Paneth cells, 
which are also not found in healthy, but only in inflamed and malignant colon and stomach 
tissues (148; 149). In agreement with the present observations, DEFA 6 gene was reported 
to be elevated in colon cancer tissue and some of the cell lines (93). The authors also 
confirmed this finding on the protein expression level. However, the surprise was the 
detection of extremely high DEFA 6 expression in benign adenoma samples. In most 
patients the effect was reverted in tumor, where DEFA 6 expression was distinctly lower 
compared to adenoma, but still remained much higher than in normal tissue. Nonetheless, to 
our best knowledge this is the first study demonstrating a gene expression explosion of 
DEFA 6 in premalignant, benign adenoma. 
While the transcriptional activation of DEFA 1-3 mainly occurs via TLR (NOD2)/NFĸB 
signaling pathway the Wnt/ß-catenin/Tcf pathway is responsible for the transcriptional 
activation of DEFA 6. These two pathways regulate genes encoding proteins implicated in 
processes such as cellular proliferation, apoptosis, survival and motility, making them very 
essential for the development of cancer (1; 6; 25). Therefore, it is expectable that they will 
be hyperactive during the tumorogenesis. Particularly for colon cancer, it was demonstrated 
that the early key event in the initiation of the adenoma is the functional modification of 
components of the Wnt/ß-catenin/Tcf signaling, which also appears to control the intestinal 
homeostasis. Thus, in more than 80% of the early adenomas derived from sporadic colon 
cancer cases as well as in all cases of inherited form of colon cancer, familial adenomotous 
polyposis (FAP), a truncated mutation in the tumor suppressor gene APC was found (140). 
Some of the remaining cancer cases carried mutations in ß-catenin and/or Axin2, other 
components of the Wnt cascade (25). The immediate consequence of those mutations is 
hyper activation of the pathway leading not only to promotion of tumor development, but 
also to transcriptional activation of the DEFA 6 target gene (6). Therefore, it is reasonable to 
hypothesize that a DEFA 6 burst in an early pre-malignant stage of colon cancer 
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development is a consequence of hyperactive Wnt/ß-catenin/Tcf signaling in intestinal 
epithelium. However, this assumption does not exclude the possible influence of other 
signaling cascades on DEFA 6 transcriptional activation. Such cross-talk between the 
pathways may also be the reason for the reverted DEFA 6 expression in the latest stage of 
cancer development, where its transcription can be interfered by other signaling cascades 
that become modified in a later stage of tumorogenesis. Further examinations, aiming to 
address these questions, are necessary. 
 
Conclusions: 
To our knowledge this is the first study demonstrating a strong burst of the DEFA 6 gene in 
human adenoma tissue samples, which immediately indicates its potential to be used as a 
marker for early premalignant stages of colorectal cancer and not solely as a marker for 
colon cancer detection in general. 
 
5.3. Correlation between the gene expression pattern and clinico-
pathologic factors in colon cancer 
 
When working with individuals, it would be reasonable to evaluate the prognostic 
significance of the gene under investigation. This can be done by testing the correlation 
between the relative expression of the molecule examined and the clinico-pathological 
features of the donors such as age, gender, grade and stage of cancer.  
 
5.3.1. The expression of the investigated genes is not associated with the 
age of the patients 
The senescence of the gastrointestinal tract was reported to be associated with processes 
well known to be implicated in the development and progression of carcinogenesis, namely 
induced proliferation and apoptosis inhibition. Thus, it was suggested that ageing may 
predispose the gastrointestinal tract to neoplasia (150). 
If age-related transcriptional changes are a consequence of the ageing process, similar 
alterations might be expected among species, and certainly, organs of the same animal. 
However, it was demonstrated that many of the age-related transcriptional alterations are not 
shared between different species and also between different tissues obtained from one 
species, which underlines the apparent randomness of these changes (151).  
Although none of the molecules investigated showed to be significantly dependent on age, 
many studies already reported such correlation.  
 
COX-2 and ageing 
The COX-2 molecule was shown to be constitutively expressed in the colonic wall (39). As 
enzyme involved in prostaglandin synthesis, COX-2 is implicated in diverse physiological 
processes such as cell proliferation, survival, angiogenesis as well as inhibition of apoptosis. 
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Many of those processes are known to change with age. In addition, age-associated 
alterations in factors well known to induce the COX-2 gene expression, such as oxidative 
stress (152) and inflammation (153) can also be regarded to the senescence-induced COX-2 
transcriptional activation. In this line, several reports indicates altered COX-2 expression 
with increasing age not only in healthy (154-156), but in cancer tissues as well (128; 157). 
In contrast, Zhan et al. did not find any correlation between the age of colorectal cancer 
patients and the COX-2 expression level (158). This observation is in agreement with the 
data reported in the present study, where according to the Spearman correlation analysis, 
COX-2 was not significantly correlated with age: p=0.34 in normal and p=0.57 in tumor 
tissue, (Table 4-4, page 51).  
 
PLK1 and ageing 
A progressive decrease in the expression of the cell cycle regulator PLK1 has been reported 
in actively dividing human fibroblast with age (159), which might contribute to the loss of 
tissue regenerative capacity. However, in consistence with Macmillan et al. (160), the 
present study did not show any significant correlation between the expression of PLK1 and  
the age of the patients when normal colon tissues were examined (p=0.57 for normal tissue). 
It was speculated that the lack of any association between PLK1 expression and the age can 
be a consequence of the nature of the investigated tissue, namely intestinal epithelial cells 
which are characterized by high baseline proliferative activity. The colon tissues used in the 
present study contain of around 75% of epithelial cells (data derived from the PhD work of 
Julia Sauer, Department of Nutritional Toxicology, Institute for Nutrition, Friedrich-
Schiller-University Jena). Therefore, as a crucial regulator for cell division, the PLK1 
expression is probably maintained during ageing. Moreover, the Macmillan’s study reported 
an unexpected significant increase of PLK1 expression in tumor tissue with age, which can 
be caused by the hypothetical loss of common regulatory mechanism with the process of 
senescence. However, in the present work no correlation with the age has been found 
(p=0.44 for tumor, Table 4-4, page 51). 
 
HSP90ß and ageing 
Often, during the ageing process many proteins undergo different modifications, such as 
oxidation for instance. Those abnormal proteins can serve as stress signals for induction of 
Heat Shock Proteins (HSPs). The latter are highly inducible molecules which protect the 
modified proteins from denaturation. While Njemini et al. reported significant increase in 
HSP90 expression with age in blood cells (monocytes and lymphocytes) from healthy 
voluntaries, but not in patients with acute infections (161; 162), Boehm et al. as well as 
other research groups described decreases in HSP90ß mRNA and protein expression with 
age in numerous cell types. This leads to the hypothesis that diminishing HSP90 levels play 
a role in the multiple pathways and cellular dysfunctions that characterize senescence and 
result in the initiation of age-associated diseases (163). In the present work, no association 
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between HSP90ß expression and age was observed (Spearman analysis, p=0.43 in normal 
and p=0.33 in tumor tissues).  
 
eIF4E and ageing 
Further, in consistence with Berkel et al. the present study showed that age did not effect the 
expression of eIF4E along the adeno-carcinoma axis (54). According to the applied 
Spearman test, no correlation between gene expression and age was found. P-values higher 
than 0.05 were computed for normal (p=0.68) and tumor tissue (p=0.3), (Table 4-4, page 
51). However, a recent study showed that the depletion of eIF4E, specifically in somatic 
cells extends the lifespan in C. elegans (164). In contrast, Ruggero et al. presented that 
overexpression of eIF4E induces cellular senescence in mouse embryonic fibroblast (165). 
 
OPN and ageing 
Previous studies reported increased OPN expression with the age in neurons (166), mouse 
macrophages and human kidney proximal tubule epithelial cells (PTE) (167). OPN protein 
expression was significantly associated with age and grade of cancer in patients with gastric 
carcinoma (168). In contrast, no significant correlation between age and OPN in patients 
with non-small-cell lung cancer has been indicated (129). Nonetheless, the analysis 
illustrated significant correlation with gender of the objects and the grade of cancer.  
The above mentioned observations suggest that probably no common correlation between 
OPN expression and age among the different types of tissues exists. This speculation is 
reasonable, since OPN has been reported to be expressed in many different tissue types and 
cells and associated with various cellular processes. However, recently it has been published 
that ageing of the colonic mucosa is associated with the activation of Phosphatidylinositol 3-
kinase /Akt signaling (PI3K/Akt pathway), with resulting transcriptional activation of the 
downstream effector molecules such as OPN (150; 169). The latter observation leads to the 
assumption that OPN expression should be positively correlated with age in regard to 
colonic mucosal-ageing. However, the present study did not find any significant age-related 
alterations, possibly due to the narrow range of patient’s age analyzed (ranged from 58 to 
89) and the small sample size. 
 
DEFA 6 and ageing 
The present study revealed a slight tendency of positive correlation between the expression 
of the gene coding for the antimicrobial peptide DEFA 6 and the age of the patients (p=0.1 
in normal and p=0.15 in tumor tissue, see Table 4-4, page 51). In this respect, no other 
observations in the literature have been reported. However, it would be reasonable to 
speculate that the age-induced expression of this antimicrobial molecule could be partially a 
consequence of the paradoxical increase of inflammation (chronic inflammation), a feature 
commonly observed in ageing (153).  
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The literature data is in line with the outcomes of the present study, where no association 
has been found between the expression of DEFA 1-3, DDX6, USP28, HAT1 and PKM2 and 
the age of the patients, either in normal or in tumor colon tissues. 
 
5.3.2. The expression of the examined genes is not correlated with the 
grade and the stage of the cancer tissues obtained from individual patients. 
 
In order to develop an individual treatment plan for each analyzed donor, as well as to 
predict the patient’s prognosis, information regarding the grade and the stage of the cancer 
is necessary. 
Tumor grade is a system used to classify cancer cells in terms of how abnormal they look 
under a microscope and how quickly the tumor is growing and spreading. In contrast, the 
staging describes the extend or severity of an individual’s cancer based on the degree 
(extend) of the primary tumor and the level of spreading in the body (for more detailed 
information, refer to:http://www.cancer.gov/cancertopics/factsheet/detection/tumor-grade. 
Although many expression analyses revealed associations between those clinical parameters 
and the expression of certain molecules, the present study did not show the existence of any 
significant correlation, according to the performed Kruskal-Wallis and Spearman correlation 
analysis. 
  
COX-2, grade and stage of cancer 
Fujita et al. suggested that tumors with more COX-2 grow larger and in a more invasive 
manner (170). Further, it was shown that COX-2 expression was significantly associated 
with tumor size, depth of invasion, lymph node metastasis, vessels invasion, stage and 
recurrence (171). In contrast to these reports, Zhan et al. and others as well as the present 
study did not find such a correlation (158). No significant changes in the expression levels 
among the different grades and stages of cancer were detected. 
 
PLK1, grade and stage of cancer 
The expression of PLK1 as a cell cycle regulator has been reported to be significantly 
correlated with the histological grade and clinical stage of ovarian cancer (172). Moreover, 
Weichert et al. have shown that PLK1 expression was positively linked to the stage of colon 
cancer and nodal status (68). In contrast, Macmillan et al. found a lack of correlation 
between PLK1 expression and the stage of colorectal cancer, which however makes this 
molecule a potential independent prognostic marker (160). In consistence with this 
observation, the present study did not show any relationship between the PLK1 expression 
levels and the stage of colon cancer. 
 
HSP90ß, grade and stage of cancer 
HSP90 and its cochaperones have been shown to facilitate the neoplastic transformations 
via apoptosis inhibition (81). In this regard, HSP90 chaperon expression has been found to 
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be associated with a histologic grade of the patients (173) and its overexpression was 
reported to be connected with a poor patient prognosis. However, the present study did not 
find any correlations between the expression of HSP90ß gene and the grade or the stage of 
cancer. 
 
eIF4E, grade and stage of cancer 
Previous reports showed that eIF4E overexpression can result in malignant transformation 
in cell lines. Additionally, Berkel et al. demonstrated a highly significant correlation 
between the malignant potential of the premalignant colon lesions and the level of eIF4E 
expression. Highest level of it was detected in adenocarcinomas and the lowest levels were 
found in histologically normal mucosa (8; 54). However, the present study did not find any 
significant relationship between eIF4E transcriptional level and the various stages of 
carcinogenic process. 
 
DDX6, grade and stage of cancer 
As for the previously described targets, no relation between grade and stage of colon cancer 
and DDX6 expression was detected. This observation was in agreement with the data 
reported from Nakagawa et al. (174). 
  
OPN, grade and stage of cancer 
Induced OPN expression was found to be significantly correlated with the stage of cancer, 
but not with the tumor grade (175; 176). It was speculated that such correlation most likely 
reflects the effect of OPN on cell migration. OPN can support in vitro attachment for a 
variety of cell types and promotes migration of inflammatory and tumor cells. Moreover, by 
binding to various cell surface receptors, OPN can induce changes in tumor cell gene 
expression, including induction of proteolytic enzymes and activation of growth factor 
kinases, which in turn can lead to increased cell motility and invasion. In addition, in vivo 
experiments have demonstrated that OPN is preferably expressed by tumor cells with 
invasive and metastatic properties, suggesting that it may be a marker for cancer in a high 
stage (175). Nonetheless, our computational analysis revealed no correlation between the 
OPN expression level and the stage of cancer. 
 
PKM2, grade and stage of cancer 
In regard to PKM2, strong correlation have been found between the foecal tumor-PKM2 
and the stage of colon cancer as well as the grade of the tumor (74; 76; 77; 177). 
Immunohistological staining of tumor PKM2 in vast numbers of rat and human tumors 
revealed that increased amounts of the enzyme is a general metabolic alteration during 
tumorogenesis and correlates with malignancies of the tumor (76). Nonetheless, the present 
study did not find any significant relation between PKM2 transcriptional levels and the 
clinicopathological parameters. 
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Alpha-defensins, grade and stage of cancer 
The expression of DEFA 1-3 has been shown to be elevated in tumor colon tissue in all 
stages. However, DEFA 1-3 detected in plasma, was increased only in patients with Duke’s 
stage C and D (89). In addition, Holterman et al. observed that the percentage of alpha 
defensin positive cases increased with the grade of bladder tumors. The invasive cases of 
that tumor showed higher intensity levels compared to the noninvasive bladder cancer cells 
(101). In the present study, according to the performed statistical analysis, no significant 
correlation between alpha defensin transcriptional levels and the clinico-pathological 
parameters of the cancer was found.  
 
It is highly possible that the size of the available samples is too small in order to find any 
correlation between expression patterns and the clinicopathological parameters, such as 
stage and grade. 
 
5.3.3. COX-2 and OPN transcriptional levels are significantly correlated 
with the gender of the patients under investigation 
 
Several studies have reported that estrogen supplementation reduced the colorectal cancer 
risk (178; 179). Thus, since the females have a high estrogen background, it was proposed 
that they are less likely to develop colorectal cancer at all ages than males.  
In both genders the normal colon mucosa expresses the two estrogen receptor isoforms, 
namely ER-alpha and ER-beta. ER-beta is the predominant subtype in colon cells and its 
decreased levels were associated with colon tumor (180). In this respect, it was shown that 
re-expression of ER gene, by adding estrogens, can result in growth inhibition of CRC cell 
lines (181). As a consequence, the variations in the hormone levels between the genders 
lead to general gender-related expression diversity. 
The present study demonstrated a significant increase of OPN in colon cancer tissue 
obtained from male subjects (p=0.05). Similar significant increase in the expression of 
COX-2 gene in normal tissue, surgically removed from males compared to females, was 
detected as well (p=0.02). The rest of the analyzed molecules did not show any significant 
alterations with the gender of the objects under investigation (see Table 4-5, page 53).  
So far, the available data from the literature concerning estrogen-regulated expression of 
OPN and COX-2 is controversial. Consistent with the observation from the present study, it 
was shown that the female sex hormones decrease OPN expression in some renal damage 
states (182) and animal models of vascular injury (183). In contrast, Kayako found that 
estrogen stimulates the expression of extracellular matrix proteins, including OPN, in 
human alveolar bone-derived cells (184). 
In regard to COX-2, the results presented here can be easily explained by the already 
reported observations of COX-2 down-regulation in estrogen deficient animals when they 
have been treated with high concentrations of estrogen (185). The same outcome was 
observed by Zerkovski in breast cancer tissues (186). In contrast, COX-2 expression was 
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induced by estrogens in vascular tissues (187). The same inverse effect was shown by 
Tamura and co-workers in primary human uterine microvascular endothelial cells 
(HUMEC). They speculate that this effect can be specific since the estrogen was not 
affecting COX-2 expression in endometrial or endometriotic stromal or epithelial cells 
(188). 
 
Conclusions: 
The above presented data revealed that the gene expression pattern as well as its 
association with diverse clinicopathological features is specific and depends on the function 
the molecule has in special cell types and tissues environment. However, reasonable would 
be to speculate that the small sample size as well as the narrow ageing group available for 
computational analysis is the main problem for lacking statistically significant observations 
in such kind of examinations. 
 
5.4. COX-2, OPN, HSP90ß and PKM2 are the most prominent genes 
for discrimination between normal and tumor colon tissues 
Among the entire set of investigated genes, the combination of OPN, COX-2, HSP90ß and 
PKM2 genes was identified to perform the best tissue discrimination between non-malignant 
and malignant colon tissues. This was achieved by newly developed empirical analysis with 
determined diagnostic power of almost 78% (section 4.4.1, page 56) and widely applied 
Principal Component Analysis (PCA) where gene expression data collected from 28 non-
malignant and 26 malignant colon tissues was assessed (section 4.6, page 61).  
According to the published reports, all of the selected molecules revealed to be 
overexpressed in malignant colon tissue (section 1.4, page 7). However, in the current study 
not all of them showed a considerable increased expression in tumors. OPN was exhibiting 
the highest expression alteration in tumor tissue, with 13 fold over normal colon tissue, 
followed by moderately expressed genes such as DEFA 1-3 (6.4 fold), DEFA 6 (5.8 fold) 
and COX-2 (4 fold). Interestingly, PKM2 and HSP90ß with 1.6 fold and 2.13 fold, 
respectively, did not show a substantial increase in tumors, Table 4-3, page 44. Though low, 
their constant expression elevation in tumor cells as compared to their normal counterparts 
seems to be essential for cancer cell growth and/or survival, which has been speculated for 
the case of HSP90 by Isaacs et al., (124) and therefore, they might be important for further 
tissue discrimination. 
It should be noted that this empirical diagnostic strategy is in a preliminary stage of 
development. The number of patients involved in computation of the criteria used for 
diagnostic performance should be higher. Nevertheless, the outcomes of the assay revealed 
that this approach successfully discriminates normal from tumor tissue and therefore, in 
combination with other screening techniques, it can be a powerful tool for the diagnosis of 
colon cancer. In addition, it was demonstrated that the presentation of the gene expression 
data for each individual patient as a “bar code” depicts successfully the biological 
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characteristics of colon cancer and therefore it can be very valuable for a preliminary 
selection of gene targets with high diagnostic properties.  
 
5.5. Good prediction power of the dbEST data base concerning the 
gene expression data obtained by qRT-PCR 
 
Another aim of the present work was to test how valuable is the gene expression data 
derived from NIH’s data base dbEST. This database summarizes microarray expression 
data, so far published in the literature, for normal tissue and their corresponding malignant 
counterparts (derived from various organs) and makes available such pooled data in a 
statistically pre-evaluated form (113). In order to evaluate its prediction power, gene 
expression data derived from colon tissues and generated by qRT-PCR was directly 
compared with a huge amount of data obtained from NIH’s data base dbEST. The 
comparative analysis revealed that dbEST data base has a good prediction power in respect 
to paired normal and tumor colon tissues. The expression tendency, for almost all genes, in 
tumor compared to normal tissue remained the same, independent of the used data source 
(section 4.7, page 66). Therefore, it is reasonable to assume that the expression prediction 
for other tissue types, by data mining, might be useful as well. This will allow researchers, 
with a minimum effort, to check for instance, whether a gene acts as cancer-associated gene 
only in the experimentally investigated cell lines or tissues, or behaves similarly in a wide 
variety of tissues and organs. For example, earlier findings based solely on data mining 
revealed that the expressions of 42, termed “ubiquitous cancer genes”, were up-regulated in 
36 different types of cancer (113). Two of them, PKM2 and HSP90ß, which have shown 
overexpression in colon cancer, were also under present investigation. It was demonstrated 
that dbEST quite accurately predicts the expression of HSP90ß. Poorer was the agreement 
between prediction and experiment for PKM2 relative gene expression. Nevertheless, 
according to both dbEST and qRT-PCR sources PKM2 was increased in cancer compared to 
normal colon tissue. This places a number of interesting in silico investigations, solely based 
on dbEST data base, on significantly safer ground (189). 
One application of the present results for future studies would be to classify the gene 
expressions in different individuals despite the presence of a strong inter-individual 
variation. In this respect, a typical example is the HSP90ß gene (Figure 4-16, page 67). The 
normalized expression values for HSP90ß were vastly variable among the patients. Apart 
from the individuals, who revealed HSP90ß expression in malignant tissue closely in line 
with the dbEST prediction, there were patients whose tissue expression deviated 
significantly from the expression obtained from the data base. This is not surprising if the 
fact that the dbEST averages over hundreds of patients is taken into account. Therefore, the 
patients who disclosed expression profile which is in agreement with the dbEST are ”typical 
ones”, while those with a high deviation are “outliers”. The latter, for example, can be 
considered to undergo modified treatment of their cancer. 
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Conclusions: 
The present study showed that dbEST gives good predictions of gene expression for 
comparison with clinical data. This was shown in respect to non-malignant and malignant 
colon tissues derived from patients with colorectal cancer. Thus, the wealth of gene 
expression data buried in dbEST is more reliable than one might have expected so far. 
However, it has still to be verified, for few more tissue types, that the patient’s derived gene 
expression data obtained after performance of qRT-PCR indeed corresponds to the data 
obtained from dbEST data base or vise versa.  
The dbEST database can serve as a good “information source“, to perform 
advanced/preliminary screening for the gene expression pattern of one or a set of genes, 
involved in one particular or a net of cellular processes over all different types of non-
malignant and/or malignant tissues. This useful information could give researches valuable 
directions for future investigations. 
 
5.6. Messenger RNA (mRNA) expression does only moderately 
predict protein expression  
 
It is a well known fact that some mRNAs are transcribed, but not translated and therefore 
the number of mRNA copies does not necessarily reflect the number of functional protein 
molecules (190), which are mainly responsible for tumor phenotype (191). Moreover, the 
effects of environmental factors or processes such as nutrition or aging can not be evaluated 
simply just only by examination of gene expression pattern alone. Therefore, in addition to 
the valuable gene expression profiling, methods examining the protein profiling in the cells 
are required too. Such a protein analysis can adequately predict which proteins are 
expressed, to what quantity, and in what form and thus to complement the gene expression 
studies. Additionally, the combined gene and protein analytical techniques may define the 
complex relationship between transcription and translation, and consequently between 
mRNA and protein. In this regard, however, for humans only few reports are available so 
far (190; 192). All of them showed discrepancies in the relationship between mRNA and 
protein expression. Besides positive correlations between mRNA and protein expression 
levels, moderate and varied correlations were found as well. Therefore, it was speculated 
that no consistent mRNA-protein correlation exist. The analyses also showed that the 
correlation strength largely varies among different genes and different biological categories 
and only a subset of the studied mRNAs, with critical biological functions, had a significant 
positive correlation with the respective protein expression (190).  
Based on patient examinations it was also suggested that mRNA-protein expression 
correlation might vary in different individuals (190). This was confirmed also by the 
observation presented in this study where the gene and protein expression ratios, between 
tumor and normal tissue, were presented in patient-wise manner (Figure 4-22, page 77). 
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In addition, a precise parallel gene and protein examination can address the question 
whether the selected set of molecules can efficiently discriminate non – malignant from 
malignant stage not only on gene, but on protein expression level as well. 
The evaluated data, across all analyzed patients, showed that on the gene expression level 
the HSP90ß and PKM2 molecules exhibited relatively low, but significant up-regulation in 
cancer compared to the respective normal tissue. On the the protein level, however, no 
expression alterations were observed either for PKM2 or for HSP90ß molecule. The lack of 
such correlation between mRNA and protein expression can be caused by many factors. 
One factor can be the accuracy of the methods used for detection of mRNA and proteins. 
Another reason which can affect the relative quantities of mRNA and protein for defined 
molecule are the various complicated biological processes, such as transcriptional and/or 
post-transcriptional splicing, translational modifications, translational regulation, and 
protein complex formation. The degradation rates of mRNA and proteins also can affect the 
estimation of correlation between mRNA and the corresponding protein molecule (190).  
Furthermore, the present study showed that across all investigated donors no alterations 
were observed in regard to the eIF4E molecule on gene and protein expression levels. For 
such a stable expression correlation between mRNA and protein also the lack of any other 
known post translational modification of eIF4E, except its phosphorylation at S204, might 
contribute. This modification enhances the mRNA transport function of eIF4E and its 
transcription activation in cell culture, but it was not reported to influence the amount of 
protein in the cell (193). 
In respect to the DDX6 molecule only 6 donors were analyzed in parallel for their mRNA 
and protein expression patterns. When the relative expression in tumor tissue was compared 
with the respective expression in normal tissue, a moderate correlation between mRNA and 
protein expression levels was found among all analyzed donors. This observation was in 
agreement with the report of Akao et al., who showed that gastric mucosa produced a 
moderate amount of DDX6 protein consistent with the level of DDX6 mRNA (48). They 
also showed that some of the tissues, such as brain, lung and muscle, produce DDX6 
mRNA, but not the encoding protein, which leads to the conclusion that probably post 
transcriptional regulation of the DDX6 gene expression appears to operate in these tissues. 
Therefore one can conclude that the regulation of the DDX6 molecule is most likely tissue-
specific. 
Although in this work a direct comparison between COX-2 mRNA and protein expression 
levels was not performed (due to technical problems), published data indicate that COX-2 
expression is not only regulated on the transcriptional and post-transcriptional level but may 
also be regulated on the protein level (i.e. by the rate of protein synthesis and/or degradation 
(by ubiquitin-proteasome pathway)) (194). As a consequence the correlation between 
mRNA and protein can be affected.  
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Conclusions: 
In conclusion, the mRNA levels often can predict the protein levels, however, this might not 
to be true for all cases. 
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